


**CUMULATIVE
SUPPLEMENT 6**
June 2023



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**Cumulative Supplement 6
June 2023**

CONTENTS

	<i>PAGE</i>
Contents	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT	vi
1.3 APPLICANT NAME CHANGES.....	vii
1.4 LEVOTHYROXINE SODIUM	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**CUMULATIVE SUPPLEMENT 6
JUNE 2023**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
ALEOR DERMACEUTICALS LTD (ALEOR DERMACEUTICALS)	ALEMBIC PHARMACEUTICALS LTD (ALEMBIC)
ALLERGAN (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN HOLDINGS UNLTD CO (ALLERGAN HOLDINGS)	ABBVIE INC (ABBVIE)
ALLERGAN INC (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBIE (ABBVIE)

ALLERGAN SALES LLC (ALLERGAN)	ABBVIE INC (ABBVIE)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS LTD)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EPIC PHARMA INC (EPIC PHARMA)	EPIC PHARMA LLC (EPIC PHARMA LLC)
EPIC PHARMA INC (EPIC PHARMA INC)	EPIC PHARMA LLC (EPIC PHARMA LLC)
HERITAGE PHARMA LABS INC (HERITAGE PHARMA)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC (HERITAGE PHARMA AVET)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MAYNE PHARMA INC (MAYNE PHARMA INC)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA INTL)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA LLC (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2022</u>	<u>MAR 2023</u>	<u>JUN 2023</u>	<u>SEP 2023</u>	<u>DEC 2024</u>
DRUG PRODUCTS	21983	22398	22632		
LISTED SINGLE SOURCE	2718 (12.4%)	2759 (12.3%)	2779 (12.3%)		
MULTISOURCE	19265 (87.6%)	19639 (87.7%)	19853 (87.7%)		
THERAPEUTICALLY EQUIVALENT	19165 (87.2%)	19554 (87.3%)	19781 (87.4%)		
NOT THERAPEUTICALLY EQUIVALENT	100 (0.5%)	85 (0.4%)	72 (0.3%)		
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)	46 (0.2%)		
NEW MOLECULAR ENTITIES APPROVED	8	19	11		
NUMBER OF APPLICANTS	1211	1222	1217		

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET; ORAL						
<u>ABIRATERONE ACETATE</u>						
AB	FLORIDA	500MG	A215086	001	Mar 23, 2023	Mar NEWA
AB	TEVA PHARMS USA	500MG	A210726	001	Jan 26, 2023	Jan NEWA

ACARBOSE

TABLET; ORAL						
<u>ACARBOSE</u>						
@	DASH PHARMS	25MG	A091053	001	Jan 06, 2011	Feb CAHN
@		50MG	A091053	002	Jan 06, 2011	Feb CAHN
@		100MG	A091053	003	Jan 06, 2011	Feb CAHN

ACETAMINOPHEN

SOLUTION; INTRAVENOUS						
<u>ACETAMINOPHEN</u>						
AP	HQ SPCLT PHARMA	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Apr NEWA
AP	WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Apr NEWA
@	ZYDUS PHARMS	1GM/100ML (10MG/ML)	A216467	001	Oct 25, 2022	Mar DISC

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET; ORAL						
<u>APADAZ</u>						
>D>	+ @ KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Jun CAHN
	+ @	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Mar DISC
>D>	+ @	325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Jun CAHN
	+ @	325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Mar DISC
>D>	+ @	325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Jun CAHN
	+ @	325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Mar DISC
>A>	+ @ ZEVRA THERAP	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Jun CAHN
>A>	+ @	325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Jun CAHN
>A>	+ @	325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Jun CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL						
<u>BUTALBITAL AND ACETAMINOPHEN</u>						
AA	SENORES PHARMS	300MG;50MG	A214088	001	Apr 07, 2022	Jan CAHN
AA		325MG;25MG	A214088	002	Apr 07, 2022	Jan CAHN
AA		325MG;50MG	A214088	003	Apr 07, 2022	Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL						
<u>ACETAMINOPHEN AND CODEINE PHOSPHATE</u>						
@	NOSTRUM LABS INC	300MG;15MG	A088629	002	Mar 06, 1985	Apr DISC
@		300MG;30MG	A088629	003	Mar 06, 1985	Apr DISC
+	@	300MG;60MG	A088629	001	Mar 06, 1985	Apr DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL						
<u>HYDROCODONE BITARTRATE AND ACETAMINOPHEN</u>						
>D> AA	SUN PHARM INDNS INC	325MG;5MG	A090118	001	Dec 23, 2008	Jun DISC
>A>	@	325MG;5MG	A090118	001	Dec 23, 2008	Jun DISC
>D> AA		325MG;7.5MG	A090118	002	Dec 23, 2008	Jun DISC
>A>	@	325MG;7.5MG	A090118	002	Dec 23, 2008	Jun DISC
>D> AA		325MG;10MG	A090118	003	Dec 23, 2008	Jun DISC
>A>	@	325MG;10MG	A090118	003	Dec 23, 2008	Jun DISC

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL						
<u>COMBOGESIC</u>						
+!	AFM PHARMS LTD	325MG;97.5MG	N209471	001	Mar 01, 2023	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL						
<u>OXYCODONE AND ACETAMINOPHEN</u>						
@	DR REDDYS LABS SA	325MG;2.5MG	A090177	001	Oct 20, 2008	Apr CAHN
@		325MG;5MG	A090177	002	Oct 20, 2008	Apr CAHN
@		325MG;7.5MG	A090177	003	Oct 20, 2008	Apr CAHN
@		325MG;10MG	A090177	004	Oct 20, 2008	Apr CAHN
@		500MG;7.5MG	A090177	005	Oct 20, 2008	Apr CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

@	650MG;10MG	A090177	006	Oct 20,	2008	Apr CAHN
@ MAYNE PHARMA INC	325MG;2.5MG	A090177	001	Oct 20,	2008	Apr DISC
@	325MG;5MG	A090177	002	Oct 20,	2008	Apr DISC
@	325MG;7.5MG	A090177	003	Oct 20,	2008	Apr DISC
@	325MG;10MG	A090177	004	Oct 20,	2008	Apr DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDETABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	! AMNEAL PHARMS	325MG;37.5MG	A090485	001	Dec 09,	2009	Mar CHRS
	+ @ JANSSEN PHARMS	325MG;37.5MG	N021123	001	Aug 15,	2001	Mar DISC

ACETAZOLAMIDECAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB	INDICUS PHARMA	500MG	A090779	001	Jul 14,	2011	Feb CMFD
----	----------------	-------	---------	-----	---------	------	----------

TABLET;ORAL

ACETAZOLAMIDE

AB	AARKISH PHARMS NJ	125MG	A217197	001	May 09,	2023	Apr NEWA
AB		250MG	A217197	002	May 09,	2023	Apr NEWA
	@ BRECKENRIDGE	125MG	A207503	001	Apr 30,	2020	Jan DISC
	@	250MG	A207503	002	Apr 30,	2020	Jan DISC
AB	ZYDUS	125MG	A211069	001	Apr 04,	2023	Mar NEWA
AB		250MG	A211069	002	Apr 04,	2023	Mar NEWA

ACETIC ACID, GLACIALSOLUTION/DROPS;OTIC

ACETIC ACID

@ CHARTWELL RX 2%

A040166 001 Jul 26, 1996 Jan CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONESOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

>D> AT	COSETTE	2%;1%	A040609	001	Feb 06,	2006	Jun DISC
>A>	@	2%;1%	A040609	001	Feb 06,	2006	Jun DISC
>D> AT	TARO	2%;1%	A088759	001	Mar 04,	1985	Jun CHRS
>A> AT	+!	2%;1%	A088759	001	Mar 04,	1985	Jun CHRS

ACETYLCYSTEINEINJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP	STERISCIENCE	6GM/30ML (200MG/ML)	A217182	001	Apr 19,	2023	Apr NEWA
----	--------------	---------------------	---------	-----	---------	------	----------

ACYCLOVIRCAPSULE;ORAL

ACYCLOVIR

@ AUROBINDO PHARMA USA 200MG

A074727 001 Apr 22, 1997 May CAHN

CREAM;TOPICAL

ACYCLOVIR

AB	ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28,	2023	Feb NEWA
----	--------------------	----	---------	-----	---------	------	----------

SUSPENSION;ORAL

ACYCLOVIR

AB	MSN	200MG/5ML	A217393	001	Mar 09,	2023	Mar NEWA
----	-----	-----------	---------	-----	---------	------	----------

AB	! NOVITIUM PHARMA	200MG/5ML	A212252	001	Jul 10,	2020	May CHRS
----	-------------------	-----------	---------	-----	---------	------	----------

ZOVIRAX

+ @ MYLAN 200MG/5ML

N019909 001 Dec 22, 1989 May DISC

TABLET;ORAL

ACYCLOVIR

@ AUROBINDO PHARMA USA 400MG

A075211 001 Sep 28, 1998 Apr CAHN

@ 800MG

A075211 002 Sep 28, 1998 Apr CAHN

ADAPALENEGEL;TOPICAL

ADAPALENE

AB	ENCUBE ETHICALS	0.3%	A200298	001	Jun 14,	2012	Apr CMFD
----	-----------------	------	---------	-----	---------	------	----------

ALBENDAZOLE

TABLET;ORAL

ALBENDAZOLE

@ CHARTWELL RX

200MG

A211636 001 Jun 10, 2020 May CAHN

ALBUTEROL SULFATE

SOLUTION;INHALATION

ACCUNEB

>D>							
>D> AN	+!	MYLAN SPECIALITY LP	EQ 0.021% BASE	N020949	002	Apr 30, 2001	Jun DISC
>A>	+	@	EQ 0.021% BASE	N020949	002	Apr 30, 2001	Jun DISC
		ALBUTEROL SULFATE					
>D> AN		RITEDOSE CORP	EQ 0.021% BASE	A214531	001	Dec 28, 2021	Jun CHRS
>A> AN	!		EQ 0.021% BASE	A214531	001	Dec 28, 2021	Jun CHRS
		TABLET;ORAL					
		ALBUTEROL SULFATE					
AB		DASH PHARMS NATCO	EQ 2MG BASE	A072894	002	Jan 17, 1991	Feb CAHN
AB	!		EQ 4MG BASE	A072894	001	Jan 17, 1991	Feb CAHN

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED;INHALATION

AIRSUPRA

+! ASTRazeneca

EQ 90MCG BASE/INH;80MCG/INH

N214070 001 Jan 10, 2023 Feb CAHN

+! BOND

EQ 90MCG BASE/INH;80MCG/INH

N214070 001 Jan 10, 2023 Jan NEWA

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

AA	!	HIKMA	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	May CTEC
AA		NOVITIUM PHARMA	EQ 70MG BASE/75ML	A214512	001	May 11, 2023	May NEWA

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

AB		PAR PHARM	12MG	A216843	001	Jan 24, 2023	Jan NEWA
>D> AB		WATSON LABS TEVA	12MG	A208295	001	Dec 19, 2019	Jun CHRS
>A> AB	!		12MG	A208295	001	Dec 19, 2019	Jun CHRS
>D>		ENTEREG					
>D> AB	+!	CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Jun DISC
>A>	+	@	12MG	N021775	001	May 20, 2008	Jun DISC

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB		STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	Feb CTEC
		TABLET;ORAL					
		AMANTADINE HYDROCHLORIDE					
AB		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	Feb CTEC

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

!

HIKMA

EQ 50MG BASE/ML

A063313 001 Apr 11, 1994 Feb CTEC

AMINO ACIDS

INJECTABLE;INJECTION

FREAMINE HBC 6.9%

@ B BRAUN

6.9% (6.9GM/100ML)

N016822 006 May 17, 1983 Jan DISC

FREAMINE III 10%

@ B BRAUN

10% (10GM/100ML)

N016822 005

FREAMINE III 8.5%

@ B BRAUN

8.5% (8.5GM/100ML)

N016822 004

HEPATAMINE 8%

@ B BRAUN

8% (8GM/100ML)

N018676 001 Aug 03, 1982 Jan DISC

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PROCALAMINE

@ B BRAUN

3%;26MG/100ML;3GM/100ML;54MG/100ML
;41MG/100ML;150MG/100ML;200MG/100ML
L;120MG/100ML

N018582 001 May 08, 1982 Jan DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
 INJECTABLE; INJECTION
 FREAMEINE III 8.5% W/ ELECTROLYTES
 @ B BRAUN 8.5%;110MG/100ML;230MG/100ML;10MG/ N016822 007 Jul 01, 1988 Jan DISC
 100ML;440MG/100ML;690MG/100ML

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
 INJECTABLE; INJECTION
 FREAMEINE III 3% W/ ELECTROLYTES
 @ B BRAUN 3%;54MG/100ML;40MG/100ML;150MG/100 N016822 003 Jan DISC
 ML;200MG/100ML;120MG/100ML

AMINOCAPROIC ACID

SOLUTION; ORAL

AMINOCAPROIC ACID

AA	TARO	0.25GM/ML	A214458	001	Mar 24, 2023	May CAHN
AA	TARO PHARMS	0.25GM/ML	A214458	001	Mar 24, 2023	Mar NEWA
	@ VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Mar DISC

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

>A> AB	CHARTWELL RX	100MG	A077069	003	Oct 04, 2016	Jun CAHN
>A> AB		200MG	A077069	001	Apr 08, 2005	Jun CAHN
>A> AB		400MG	A077069	002	Apr 08, 2005	Jun CAHN
>D> AB	MURTY PHARMS	100MG	A077069	003	Oct 04, 2016	Jun CAHN
>D> AB		200MG	A077069	001	Apr 08, 2005	Jun CAHN
>D> AB		400MG	A077069	002	Apr 08, 2005	Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	GRAVITI PHARMS	10MG	A217411	001	May 19, 2023	May NEWA
AB		25MG	A217411	002	May 19, 2023	May NEWA
AB		50MG	A217411	003	May 19, 2023	May NEWA
AB		75MG	A217411	004	May 19, 2023	May NEWA
AB		100MG	A217411	005	May 19, 2023	May NEWA
AB		150MG	A217411	006	May 19, 2023	May NEWA
AB	RUBICON	10MG	A215376	001	May 01, 2023	Apr NEWA
AB		25MG	A215376	002	May 01, 2023	Apr NEWA
AB		50MG	A215376	003	May 01, 2023	Apr NEWA
AB		75MG	A215376	004	May 01, 2023	Apr NEWA
AB		100MG	A215376	005	May 01, 2023	Apr NEWA
AB		150MG	A215376	006	May 01, 2023	Apr NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

LIMBITROL

+ @ CHARTWELL RX	EQ 12.5MG BASE;5MG	N016949	001		Mar CAHN
+ @ CHARTWELL RX	EQ 25MG BASE;10MG	N016949	002		Mar CAHN

AMLODIPINE BENZOATE

SUSPENSION; ORAL

AMLODIPINE BENZOATE

>A>	@ AMNEAL	EQ 1MG BASE/ML	A215035	001	Jun 13, 2023	Jun DISC
KATERZIA						
>D>	+! AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	Jun CTEC

>A> +! EQ 1MG BASE/ML N211340 001 Jul 08, 2019 Jun CTEC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	COREPHARMA	EQ 2.5MG BASE	A076719	001	May 23, 2007	Feb CAHN
AB		EQ 5MG BASE	A076719	002	May 23, 2007	Feb CAHN
AB		EQ 10MG BASE	A076719	003	May 23, 2007	Feb CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

@ SOFIE

18.8mCi-188mCi/5ML (3.75-
37.5mCi/ML)

A204667 001 Apr 22, 2015 May DISC

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

@ CHARTWELL RX

125MG/5ML

A062059 001

Jan CAHN

@

250MG/5ML

A062059 002

Jan CAHN

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

>D>	+	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jun CFTG
>A> AB	+		EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jun CFTG
>D>	+		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jun CFTG
>A> AB	+		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jun CFTG
>D>	+		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jun CFTG
>A> AB	+		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jun CFTG
>D>	+		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jun CFTG
>A> AB	+		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jun CFTG
>D>	+		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jun CFTG
>A> AB	+		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jun CFTG
>D>	+!		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jun CFTG
>A> AB	+!		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jun CFTG
>A>	AMPHETAMINE						
>A> AB		ACTAVIS LABS FL INC	EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Jun NFTG
>A> AB			EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Jun NFTG
>A> AB			EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Jun NFTG
>A> AB			EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Jun NFTG
>A> AB			EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Jun NFTG
>A> AB			EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Jun NFTG

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Feb CMFD
AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Feb CTNA
AB		5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Feb CTNA
AB	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Feb CTNA
AB		1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Jan NEWA
AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Feb CTNA
AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Jan NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A217027	006	Jan 23, 2023	Jan NEWA
AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CMFD
	@	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CMFD
AB	@	2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CMFD
AB	@	3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CTNA
AB		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Feb CMFD
AB	@	5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Feb CMFD
AB	@	6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Feb CMFD
AB	@	7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Feb CTNA
	TABLET; ORAL					
		DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Feb CMFD
AB		1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Feb CMFD

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Feb CMFD
AB	3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Feb CMFD
AB	3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Feb CMFD
AB	5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Feb CMFD
AB	7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Feb CMFD

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

@ STERISCIENCE	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Jan CAHN
@	EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Jan CAHN
AP	EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Jan CAHN
AP	EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Jan CAHN
AP	EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Jan CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP	STERISCIENCE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Jan CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Jan CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Jan CAHN

APALUTAMIDE

TABLET;ORAL

ERLEADA

+	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb CHRS
+		240MG	N210951	002	Feb 17, 2023	Feb NEWA

APIXABAN

TABLET;ORAL

APIXABAN

>D> AB	AUROBINDO PHARMA LTD	2.5MG	A210026	001	May 26, 2023	Jun DISC
>A>	@	2.5MG	A210026	001	May 26, 2023	Jun DISC
AB		2.5MG	A210026	001	May 26, 2023	May NEWA
>D> AB		5MG	A210026	002	May 26, 2023	Jun DISC
>A>	@	5MG	A210026	002	May 26, 2023	Jun DISC
AB		5MG	A210026	002	May 26, 2023	May NEWA
AB	ZYDUS PHARMS	2.5MG	A210185	001	Feb 27, 2023	Feb NEWA
AB		5MG	A210185	002	Feb 27, 2023	Feb NEWA

APRACLONIDINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
IOPIDINE

AT	+! HARROW EYE	EQ 0.5% BASE	N020258	001	Jul 30, 1993	May CAHN
	+!	EQ 1% BASE	N019779	001	Dec 31, 1987	May CAHN

APREMILAST

TABLET;ORAL

APREMILAST

AB	SHILPA	10MG	A211774	001	Apr 07, 2023	Mar NEWA
AB		20MG	A211774	002	Apr 07, 2023	Mar NEWA
AB		30MG	A211774	003	Apr 07, 2023	Mar NEWA
	@ TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Feb DISC
	@	20MG	A211897	002	Aug 18, 2022	Feb DISC
	@	30MG	A211897	003	Aug 18, 2022	Feb DISC

ARFORMOTEROL TARTRATESOLUTION;INHALATION
ARFORMOTEROL TARTRATE

AN	RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb CMFD
----	---------------	---------------------	---------	-----	--------------	----------

ARGATROBANINJECTABLE;INJECTION
ARGATROBAN

AP	+! SANDOZ	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	May CAHN
----	-----------	------------------------	---------	-----	--------------	----------

ARIPIPRAZOLE

SOLUTION;ORAL

ARIPIPRAZOLE

AA	CHARTWELL RX	1MG/ML	A215595	001	Oct 25, 2022	May CAHN
	SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR					
	ABILITY ASIMTUFI					
+	OTSUKA	720MG/2.4ML (300MG/ML)	N217006	001	Apr 27, 2023	Apr NEWA
+		960MG/3.2ML (300MG/ML)	N217006	002	Apr 27, 2023	Apr NEWA

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

@	COREPHARMA	50MG	A201514	001	Mar 25, 2019	Feb CAHN
@		150MG	A201514	002	Mar 25, 2019	Feb CAHN
@		250MG	A201514	003	Mar 25, 2019	Feb CAHN

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

ARSENIC TRIOXIDE

AP	ORBICULAR	1MG/ML	A217413	001	Apr 20, 2023	Apr NEWA
AP		2MG/ML	A217413	002	Apr 20, 2023	Apr NEWA
AP	PENN LIFE	1MG/ML	A209873	001	May 06, 2019	May CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@ DR REDDYS LABS SA 325MG;50MG;40MG;30MG

A203335 001 Oct 30, 2015 Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

@ CHARTWELL RX 325MG;200MG

A089594 001 Mar 31, 1989 Mar CAHN

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

ROBAXISAL

+ @ ROBINS AH 325MG;400MG

N012281 001

Mar CRLD

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@ DR REDDYS LABS SA 325MG;4.8355MG

A091670 001 Mar 16, 2011 Apr CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

@ AUROBINDO PHARMA USA 50MG;25MG

A074203 001 Oct 31, 1993 Apr CAHN

@ 100MG;25MG

A074203 002 Oct 31, 1993 Apr CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	10MG	A079017	007	Apr 05, 2023	Mar NEWA
----	----------------------	------	---------	-----	--------------	----------

ATORVASTATIN CALCIUM

SUSPENSION;ORAL

ATORVALIQ

+! CMP DEV LLC 20MG/5ML

N213260 001 Feb 01, 2023 Feb NEWA

TABLET;ORAL

ATORVASTATIN CALCIUM

@ BIOCON PHARMA EQ 10MG BASE

A216436 001 Nov 23, 2022 May DISC

@ EQ 20MG BASE

A216436 002 Nov 23, 2022 May DISC

@ EQ 40MG BASE

A216436 003 Nov 23, 2022 May DISC

@ EQ 80MG BASE

A216436 004 Nov 23, 2022 May DISC

@ LEPU PHARM EQ 10MG BASE

A216848 001 Nov 03, 2022 Apr DISC

@ EQ 20MG BASE

A216848 002 Nov 03, 2022 Apr DISC

@ EQ 40MG BASE

A216848 003 Nov 03, 2022 Apr DISC

@ EQ 80MG BASE

A216848 004 Nov 03, 2022 Apr DISC

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROOPEN

+ @ MMT	EQ 0.25MG SULFATE/0.3ML	N017106 004	Sep 17, 2004	May DISC
+ @	EQ 0.5MG SULFATE/0.7ML	N017106 003	Jun 19, 2003	May DISC
+ @	EQ 1MG SULFATE/0.7ML	N017106 002	Jun 19, 2003	May DISC
+ @	EQ 2MG SULFATE/0.7ML	N017106 001		May DISC

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D> AA	UPSHER SMITH LABS	0.025MG;2.5MG	A210571 001	Aug 31, 2018	Jun DISC
>A>	@	0.025MG;2.5MG	A210571 001	Aug 31, 2018	Jun DISC

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

>A> AP	JIANGSU HANSOH PHARM	100MG/VIAL	A215905 001	Jun 28, 2023	Jun NEWA
--------	----------------------	------------	-------------	--------------	----------

AZELAIC ACID

AEROSOL, FOAM; TOPICAL

FINACEA

+! LEO PHARMA AS	15%	N207071 001	Jul 29, 2015	Feb CTEC
------------------	-----	-------------	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

>A> AB	BIONPHARMA	0.137MG/SPRAY	A090176 001	Jul 28, 2015	Jun CAHN
>D> AB	BRECKENRIDGE	0.137MG/SPRAY	A090176 001	Jul 28, 2015	Jun CAHN

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

@ ACI	EQ 250MG BASE	A215772 001	Jul 15, 2022	Jan DISC
@	EQ 500MG BASE	A215773 001	Jul 12, 2022	Jan DISC
@ AUROBINDO PHARMA USA	EQ 600MG BASE	A065360 001	Jan 08, 2007	May CAHN
AB ZYDUS PHARMS	EQ 250MG BASE	A213275 001	Apr 11, 2023	Mar NEWA
AB	EQ 500MG BASE	A213056 001	Apr 07, 2023	Mar NEWA

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

@ AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213 001	Jul 25, 2012	Jan DISC
! BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068 001	Oct 30, 1995	Jan CTEC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

@ AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088 001	Feb 06, 2004	Jan DISC
---------	--------------------------------------------------	-------------	--------------	----------

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

AP RUBICON	0.5MG/ML	A217324 001	Feb 22, 2023	Feb NEWA
AP	1MG/ML	A217324 002	Feb 22, 2023	Feb NEWA
AP	2MG/ML	A217324 003	Feb 22, 2023	Feb NEWA

SUSPENSION; ORAL

BACLOFEN

>A> SLAYBACK PHARMA LLC	25MG/5ML	A217252 001	Jun 08, 2023	Jun NFTG
FLEQSVY				

>D> +! AZURITY	25MG/5ML	N215602 001	Feb 04, 2022	Jun CFTG
>A> AB +!	25MG/5ML	N215602 001	Feb 04, 2022	Jun CFTG

TABLET; ORAL

BACLOFEN

AB UNICHEM	5MG	A212067 003	Mar 09, 2023	Mar NEWA
------------	-----	-------------	--------------	----------

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

>D>	+	GENENTECH INC	20MG	N 210854	001	Oct 24, 2018	Jun DISC
>A>	+	@	20MG	N 210854	001	Oct 24, 2018	Jun DISC
>D>	+	!	40MG	N 210854	002	Oct 24, 2018	Jun CHRS
>A>	+		40MG	N 210854	002	Oct 24, 2018	Jun CHRS
>D>	+		80MG	N 210854	003	Mar 18, 2021	Jun CHRS
>A>	+	!	80MG	N 210854	003	Mar 18, 2021	Jun CHRS

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

>A> AB	@	DASH PHARMS NATCO	750MG	A 077807	001	Dec 28, 2007	Feb CAHN
		ZYDUS	750MG	A 217592	001	Jun 08, 2023	Jun NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB	COREPHARMA	5MG	A 077128	001	Mar 08, 2006	Mar CAHN
AB		10MG	A 077128	002	Mar 08, 2006	Mar CAHN
AB		20MG	A 077128	003	Mar 08, 2006	Mar CAHN
AB		40MG	A 077128	004	Mar 08, 2006	Mar CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX	5MG;6.25MG	A 078794	001	Aug 21, 2014	May CMFD
AB		10MG;12.5MG	A 078794	002	Aug 21, 2014	May CMFD
AB		20MG;12.5MG	A 078794	003	Aug 21, 2014	May CMFD
AB		20MG;25MG	A 078794	004	Aug 21, 2014	May CMFD

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	APOTEX	25MG/VIAL	A 204230	001	Jun 05, 2023	May NEWA
AP		100MG/VIAL	A 204230	002	Jun 05, 2023	May NEWA
AP	BRECKENRIDGE	25MG/VIAL	A 205447	001	Feb 14, 2023	Feb NEWA
AP		100MG/VIAL	A 205447	002	Feb 14, 2023	Feb NEWA
AP	EUGIA PHARMA	25MG/VIAL	A 214739	001	Jun 05, 2023	May NEWA
AP		100MG/VIAL	A 214739	002	Jun 05, 2023	May NEWA
AP	KINDOS	25MG/VIAL	A 211001	001	Jun 05, 2023	May NEWA
AP		100MG/VIAL	A 211001	002	Jun 05, 2023	May NEWA
AP	MYLAN LABS LTD	25MG/VIAL	A 204104	001	Apr 28, 2023	May DISC
AP		25MG/VIAL	A 204104	001	Apr 28, 2023	Apr NEWA
AP	@	100MG/VIAL	A 204104	002	Apr 28, 2023	May DISC
AP		100MG/VIAL	A 204104	002	Apr 28, 2023	Apr NEWA
AP	NANG KUANG PHARM CO	25MG/VIAL	A 206554	001	Jun 07, 2023	May NEWA
AP		100MG/VIAL	A 206554	002	Jun 07, 2023	May NEWA

SOLUTION;INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

+ @	HOSPIRA	25MG/ML (25MG/ML)	N 211530	001	Dec 15, 2022	Jan DISC
+ @		100MG/4ML (25MG/ML)	N 211530	002	Dec 15, 2022	Jan DISC
+ @		200MG/8ML (25MG/ML)	N 211530	003	Dec 15, 2022	Jan DISC

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA	CHARTWELL RX	100MG	A 040682	001	Jul 30, 2007	Feb CAHN
AA		200MG	A 040682	002	Jul 30, 2007	Feb CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

+ @	BAUSCH	5%;EQ 1% BASE	N 050756	001	Dec 21, 2000	Feb DISC
		CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE				

AB	! GLENMARK PHARMS	5%;EQ 1% BASE	A 209252	001	Mar 14, 2019	Feb CHRS
----	-------------------	---------------	----------	-----	--------------	----------

<u>BEPOTASTINE BESILATE</u>			
SOLUTION/DROPS;OPHTHALMIC BEPOTASTINE BESILATE			
AT	ALEMBIC	1.5%	A214588 001 Apr 05, 2023 Mar NEWA
<u>BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE</u>			
INJECTABLE; INJECTION BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE			
AB	HIKMA	3MG/ML; EQ 3MG BASE/ML	A077838 001 Jan 17, 2023 Jan NEWA
<u>BETAMETHASONE DIPROPIONATE</u>			
LOTION, AUGMENTED;TOPICAL BETAMETHASONE DIPROPIONATE			
@ PAI HOLDINGS PHARM EQ 0.05% BASE			
OINTMENT, AUGMENTED;TOPICAL BETAMETHASONE DIPROPIONATE			
@ PAI HOLDINGS PHARM EQ 0.05% BASE			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE</u>			
AEROSOL, FOAM;TOPICAL CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE			
AB	GLENMARK PHARMS LTD	0.064%;0.005%	A214688 001 Mar 21, 2023 Mar NFTG
ENSTILAR			
AB	+! LEO PHARMA AS	0.064%;0.005%	N207589 001 Oct 16, 2015 Mar CFTG
OINTMENT;TOPICAL CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE			
@ TOLMAR 0.064%;0.005%			
SUSPENSION;TOPICAL CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE			
AB	COSETTE	0.064%;0.005%	A210765 001 May 11, 2020 Feb CAHN
<u>BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE</u>			
CREAM;TOPICAL CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE			
AB	! TARO	EQ 0.05% BASE;1%	A075673 001 May 29, 2001 May CHRS
LOTRISONE			
+ @ ORGANON		EQ 0.05% BASE;1%	N018827 001 Jul 10, 1984 May DISC
<u>BETAMETHASONE VALERATE</u>			
AEROSOL, FOAM;TOPICAL BETAMETHASONE VALERATE			
AB	XIROMED	0.12%	A210639 001 Apr 18, 2023 Apr NEWA
<u>BETAXOLOL HYDROCHLORIDE</u>			
SOLUTION/DROPS;OPHTHALMIC BETAXOLOL HYDROCHLORIDE			
@ AKORN EQ 0.5% BASE			
<u>BETHANECHOL CHLORIDE</u>			
TABLET;ORAL BETHANECHOL CHLORIDE			
AA	CHARTWELL RX	5MG	A040728 002 Oct 26, 2007 May CAHN
AA		10MG	A040728 003 Oct 26, 2007 May CAHN
AA		25MG	A040728 004 Oct 26, 2007 May CAHN
AA		50MG	A040728 001 Oct 26, 2007 May CAHN
<u>BEXAGLIFLOZIN</u>			
TABLET;ORAL BRENZAVVY			
+!	THERACOSBIO	20MG	N214373 001 Jan 20, 2023 Jan NEWA
<u>BICALUTAMIDE</u>			
TABLET;ORAL BICALUTAMIDE			
AB	PINNACLE LIFE SCI	50MG	A079089 001 Jul 06, 2009 Jan CAHN

BIMATOPROST

IMPLANT;OPHTHALMIC
DURYSTA
+! ABBVIE 10MCG N211911 001 Mar 04, 2020 Jan CAHN

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB	PAR PHARM	140MG;125MG;125MG	A205770	001	Mar 06, 2023	Feb NFTG
>A> AB	RICONPHARMA LLC	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Jun NEWA
	PYLERA					
AB	+! ABBVIE	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar CAHN
AB	+! ALLERGAN	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Feb CFTG

BISOPROLOL FUMARATE

TABLET;ORAL
BISOPROLOL FUMARATE

AB	ALEMBIC	5MG	A204891	001	Jan 11, 2017	Feb CAHN
AB		10MG	A204891	002	Jan 11, 2017	Feb CAHN
	@ DASH PHARMS NATCO	5MG	A075831	001	Dec 14, 2005	Feb CAHN
	@	10MG	A075831	002	Dec 14, 2005	Feb CAHN

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB

@ ACCORD HLTHCARE	3.5MG/VIAL	A204405	001	Jul 26, 2022	Feb DISC
POWDER;INTRAVENOUS BORTEZOMIB					
@ DR REDDYS	3.5MG/VIAL	N206927	001	Oct 04, 2019	May DISC
@ FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017	May DISC
SOLUTION;INTRAVENOUS BORTEZOMIB					
+ @ ACCORD HLTHCARE	2.5MG/ML (2.5MG/ML)	N215441	001	Jul 26, 2022	Feb DISC
+ @	3.5MG/1.4ML (2.5MG/ML)	N215441	002	Jul 26, 2022	Feb DISC

BOSENTAN

TABLET;ORAL
BOSENTAN

@ PAR PHARM INC	62.5MG	A205699	001	Apr 26, 2019	Apr DISC
@	125MG	A205699	002	Apr 26, 2019	Apr DISC

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION
BRETYLIUM TOSYLATE

@ BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018	Feb DISC
----------------	---------	---------	-----	--------------	----------

BREXPETIPRAZOLE

TABLET;ORAL
BREXPETIPRAZOLE

AB	AJANTA PHARMA LTD	0.25MG	A213718	001	Feb 03, 2023	Jan NEWA
AB		0.5MG	A213718	002	Feb 03, 2023	Jan NEWA
AB		1MG	A213718	003	Feb 03, 2023	Jan NEWA
AB		2MG	A213718	004	Feb 03, 2023	Jan NEWA
AB		3MG	A213718	005	Feb 03, 2023	Jan NEWA
AB		4MG	A213718	006	Feb 03, 2023	Jan NEWA
	@ AMNEAL	0.25MG	A213562	001	Jan 31, 2023	Mar DISC
AB		0.25MG	A213562	001	Jan 31, 2023	Jan NEWA
	@	0.5MG	A213562	002	Jan 31, 2023	Mar DISC
AB		0.5MG	A213562	002	Jan 31, 2023	Jan NEWA
	@	1MG	A213562	003	Jan 31, 2023	Mar DISC
AB		1MG	A213562	003	Jan 31, 2023	Jan NEWA
	@	2MG	A213562	004	Jan 31, 2023	Mar DISC
AB		2MG	A213562	004	Jan 31, 2023	Jan NEWA
	@	3MG	A213562	005	Jan 31, 2023	Mar DISC
AB		3MG	A213562	005	Jan 31, 2023	Jan NEWA
	@	4MG	A213562	006	Jan 31, 2023	Mar DISC
AB		4MG	A213562	006	Jan 31, 2023	Jan NEWA
	@ LUPIN LTD	0.25MG	A213512	001	Mar 17, 2023	May DISC
AB		0.25MG	A213512	001	Mar 17, 2023	Mar NEWA
	@	0.5MG	A213512	002	Mar 17, 2023	May DISC
AB		0.5MG	A213512	002	Mar 17, 2023	Mar NEWA

TABLET;ORAL
BREXPIPRAZOLE

	@	1MG	A213512	003	Mar 17, 2023	May DISC
AB		1MG	A213512	003	Mar 17, 2023	Mar NEWA
	@	2MG	A213512	004	Mar 17, 2023	May DISC
AB		2MG	A213512	004	Mar 17, 2023	Mar NEWA
	@	3MG	A213512	005	Mar 17, 2023	May DISC
AB		3MG	A213512	005	Mar 17, 2023	Mar NEWA
	@	4MG	A213512	006	Mar 17, 2023	May DISC
AB		4MG	A213512	006	Mar 17, 2023	Mar NEWA
	@ TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Feb DISC
	@	0.5MG	A213692	002	Aug 11, 2022	Feb DISC
	@	1MG	A213692	003	Aug 11, 2022	Feb DISC
	@	2MG	A213692	004	Aug 11, 2022	Feb DISC
	@	3MG	A213692	005	Aug 11, 2022	Feb DISC
	@	4MG	A213692	006	Aug 11, 2022	Feb DISC
>D> AB	ZYDUS PHARMS	0.25MG	A213660	001	Jan 10, 2023	Jun DISC
>A>	@	0.25MG	A213660	001	Jan 10, 2023	Jun DISC
>D> AB		0.5MG	A213660	002	Jan 10, 2023	Jun DISC
>A>	@	0.5MG	A213660	002	Jan 10, 2023	Jun DISC
>D> AB		1MG	A213660	003	Jan 10, 2023	Jun DISC
>A>	@	1MG	A213660	003	Jan 10, 2023	Jun DISC
>D> AB		2MG	A213660	004	Jan 10, 2023	Jun DISC
>A>	@	2MG	A213660	004	Jan 10, 2023	Jun DISC
>D> AB		3MG	A213660	005	Jan 10, 2023	Jun DISC
>A>	@	3MG	A213660	005	Jan 10, 2023	Jun DISC
>D> AB		4MG	A213660	006	Jan 10, 2023	Jun DISC
>A>	@	4MG	A213660	006	Jan 10, 2023	Jun DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE

AT	ALEMBIC	0.15%	A215225	001	Mar 29, 2023	Mar NEWA
----	---------	-------	---------	-----	--------------	----------

BRIVARACETAM

TABLET;ORAL
BRIVARACETAM

@ AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023	Mar DISC	
@	100MG	A214848	002	Jan 06, 2023	Mar DISC	
@ LUPIN LTD	10MG	A214918	001	Dec 20, 2022	Mar DISC	
@	25MG	A214918	002	Dec 20, 2022	Mar DISC	
@	50MG	A214918	003	Dec 20, 2022	Mar DISC	
@	75MG	A214918	004	Dec 20, 2022	Mar DISC	
@	100MG	A214918	005	Dec 20, 2022	Mar DISC	
BRIVIACT						
+ UCB INC	10MG	N205836	001	May 12, 2016	Mar CTEC	
+	25MG	N205836	002	May 12, 2016	Mar CTEC	
+	50MG	N205836	003	May 12, 2016	Mar CTEC	
+	75MG	N205836	004	May 12, 2016	Mar CTEC	
+!	100MG	N205836	005	May 12, 2016	Mar CTEC	

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

>D> AT2 ! AKORN	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jun CHRS
>A> AT2	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jun CHRS
>D> AT2 ALEMBIC	EQ 0.09% ACID	A210560	001	Jun 21, 2019	Jun CHRS
>A> AT2 !	EQ 0.09% ACID	A210560	001	Jun 21, 2019	Jun CHRS

BROMOCRIPTINE MESYLATE

TABLET;ORAL
BROMOCRIPTINE MESYLATE

@ AUROBINDO PHARMA USA	EQ 2.5MG BASE	A076962	001	Sep 24, 2004	Apr CAHN
------------------------	---------------	---------	-----	--------------	----------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL
BROMFED-DM

>D> AA ! WOCKHARDT BIO AG	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jun CHRS
>A> AA +	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jun CHRS
	BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE				
>A> @ BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jun CAHN
>D> @ BRECKENRIDGE	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jun CAHN
	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jan DISC

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>D> AA	PADAGIS US	2MG/5ML;10MG/5ML;30MG/5ML	A205292	001	Jul 15, 2014	Jun CHRS
>A> AA	!	2MG/5ML;10MG/5ML;30MG/5ML	A205292	001	Jul 15, 2014	Jun CHRS

BUDESONIDE

AEROSOL, FOAM;RECTAL

BUDESONIDE

AB	PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Mar NFTG
AB	+! SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Mar CFTG

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED;INHALATION

SYMBICORT AEROSPHERE

+! ASTRAZENECA	0.16MG/INH;0.0048MG/INH	N216579	001	Apr 28, 2023	Apr NEWA
----------------	-------------------------	---------	-----	--------------	----------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

>A> AP	KINDOS	0.25%	A216039	001	Jun 23, 2023	Jun NEWA
>A> AP		0.5%	A216039	002	Jun 23, 2023	Jun NEWA
>D>	@ STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Jun CMFD
>A> AP		0.25%	A091503	001	Oct 18, 2011	Jun CMFD
>D>	@	0.5%	A091503	002	Oct 18, 2011	Jun CMFD
>A> AP		0.5%	A091503	002	Oct 18, 2011	Jun CMFD
		BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE				
>D>	@ STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Jun CMFD
>A> AP		0.25%	A091487	002	Oct 18, 2011	Jun CMFD
>D>	@	0.5%	A091487	001	Oct 18, 2011	Jun CMFD
>A> AP		0.5%	A091487	001	Oct 18, 2011	Jun CMFD
>D>	@	0.75%	A091487	003	Oct 18, 2011	Jun CMFD
>A> AP		0.75%	A091487	003	Oct 18, 2011	Jun CMFD

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

AB	ALVOGEN	7.5MCG/HR	A207490	005	Mar 21, 2023	Mar NEWA
	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS					
	BRIXADI					
+!	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	May NEWA
+		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	May NEWA
+		24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	May NEWA
+		32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	May NEWA
+		64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	May NEWA
+		96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	May NEWA
+		128MG/0.36ML (356MG/ML)	N210136	007	May 23, 2023	May NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	DR REDDYS LABS SA	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Apr CAHN
	@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Apr CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	ANNORA PHARMA	100MG	A216800	001	May 31, 2023	May NEWA
AB1		150MG	A216800	002	May 31, 2023	May NEWA
AB1		200MG	A216800	003	May 31, 2023	May NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	GRAVITI PHARMS	5MG	A075413	001	Mar 19, 2002	Feb CAHN
	@	10MG	A075413	002	Mar 19, 2002	Feb CAHN
	@	15MG	A075413	003	Mar 19, 2002	Feb CAHN
AB	ZYDUS PHARMS	7.5MG	A078888	005	Mar 21, 2023	Mar NEWA

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

@ AM REGENT

6MG/ML

A202259 001 Dec 22, 2015

Jan DISC

@ ARTHUR GRP

6MG/ML

A205106 001 Sep 21, 2018

Mar DISC

CABAZITAXEL

SOLUTION; INTRAVENOUS

CABAZITAXEL

+! ACCORD HLTHCARE

60MG/3ML (20MG/ML)

N207949 001 Dec 29, 2021

Feb CMFD

AP APOTEX

60MG/1.5ML (40MG/ML)

A207736 001 Feb 10, 2023

Feb NEWA

AP DR REDDYS

60MG/1.5ML (40MG/ML)

A207718 001 Feb 10, 2023

Feb NEWA

>A> AP MYLAN LABS LTD

60MG/1.5ML (40MG/ML)

A207381 001 Jul 05, 2023

Jun NEWA

+! SANDOZ

45MG/4.5ML (10MG/ML)

N208715 001 Jan 05, 2023

Jan NEWA

+!

60MG/6ML (10MG/ML)

N208715 002 Jan 05, 2023

Jan NEWA

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

>D> +! EXELIXIS

EQ 20MG BASE

N203756 001 Nov 29, 2012

Jun CHRS

>A> +

EQ 20MG BASE

N203756 001 Nov 29, 2012

Jun CHRS

>D> +

EQ 80MG BASE

N203756 002 Nov 29, 2012

Jun CHRS

>A> +!

EQ 80MG BASE

N203756 002 Nov 29, 2012

Jun CHRS

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

@ TOLMAR

0.005%

A200935 001 May 30, 2012

Feb DISC

SOLUTION; TOPICAL

CALCIPOTRIENE

AT ! COSETTE

0.005%

A078468 001 Mar 24, 2011

Feb CHRS

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB ! STRIDES PHARMA

0.5MCG

A091356 002 Dec 12, 2014

May CHRS

AB + ROCALTROL

0.5MCG

N018044 002

May CHRS

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB SQUARE PHARMS

667MG

A217205 001 Mar 13, 2023

Mar NEWA

>D> SOLUTION; ORAL

PHOSLYRA

>D> +! FRESENIUS MEDCL

667MG/5ML

N022581 001 Apr 18, 2011

Jun DISC

>A> + @

667MG/5ML

N022581 001 Apr 18, 2011

Jun DISC

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

AB ZYDUS LIFESCIENCES

4MG

A091390 001 Aug 23, 2017

May CAHN

AB

8MG

A091390 002 Aug 23, 2017

May CAHN

AB

16MG

A091390 003 Aug 23, 2017

May CAHN

AB

32MG

A091390 004 Aug 23, 2017

May CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB ZYDUS LIFESCIENCES

16MG; 12.5MG

A203466 001 Nov 27, 2017

May CAHN

AB

32MG; 12.5MG

A203466 002 Nov 27, 2017

May CAHN

AB

32MG; 25MG

A203466 003 Nov 27, 2017

May CAHN

CAPECITABINE

TABLET; ORAL

XELODA

AB + CHEPLAPHARM

150MG

N020896 001 Apr 30, 1998

Apr CAHN

AB +!

500MG

N020896 002 Apr 30, 1998

Apr CAHN

CAPTOPRIL

TABLET;ORAL

Captopril

@	AUROBINDO PHARMA USA	12.5MG	A074434	001	Feb 13, 1996	May CAHN
@		25MG	A074434	002	Feb 13, 1996	May CAHN
@		50MG	A074434	003	Feb 13, 1996	May CAHN
@		100MG	A074434	004	Feb 13, 1996	May CAHN
AB	CHANGZHOU PHARM	12.5MG	A214442	001	Jan 27, 2023	Jan NEWA
AB		25MG	A214442	002	Jan 27, 2023	Jan NEWA
AB		50MG	A214442	003	Jan 27, 2023	Jan NEWA
AB		100MG	A214442	004	Jan 27, 2023	Jan NEWA
AB	COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Mar CAHN
AB		25MG	A074737	002	Oct 28, 1998	Mar CAHN
AB		50MG	A074737	003	Oct 28, 1998	Mar CAHN
AB		100MG	A074737	004	Oct 28, 1998	Mar CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

Captopril And Hydrochlorothiazide

RISING	25MG;15MG	A074896	001	Dec 29, 1997	May CMFD
!	25MG;25MG	A074896	002	Dec 29, 1997	May CMFD
!	50MG;15MG	A074896	004	Dec 29, 1997	May CMFD
	50MG;25MG	A074896	003	Dec 29, 1997	May CMFD

CARBAMAZEPINE

SUSPENSION;ORAL

Carbamazepine

AB	CHARTWELL RX	100MG/5ML	A075714	001	Jun 05, 2002	Jan CAHN
	TABLET;ORAL					
	CARBAMAZEPINE					
>A>	@ RK PHARMA	200MG	A214328	001	Aug 16, 2021	Jun CAHN
>D>	@ VGYAAN	200MG	A214328	001	Aug 16, 2021	Jun CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	CARBAMAZEPINE					
AB	AJANTA PHARMA LTD	100MG	A216193	001	Mar 24, 2023	Mar NEWA
AB		200MG	A216193	002	Mar 24, 2023	Mar NEWA
AB		400MG	A216193	003	Mar 24, 2023	Mar NEWA
>D>	@ RICONPHARMA LLC	100MG	A216404	001	Dec 02, 2022	Jun CMFD
>A> AB		100MG	A216404	001	Dec 02, 2022	Jun CMFD
>D>	@	200MG	A216404	002	Dec 02, 2022	Jun CMFD
>A> AB		200MG	A216404	002	Dec 02, 2022	Jun CMFD
>D>	@	400MG	A216404	003	Dec 02, 2022	Jun CMFD
>A> AB		400MG	A216404	003	Dec 02, 2022	Jun CMFD
AB	SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Feb NEWA
AB		200MG	A216235	002	Mar 02, 2023	Feb NEWA
AB		400MG	A216235	003	Mar 02, 2023	Feb NEWA

CARBIDOPA; LEVODOPA

TABLET;ORAL

Carbidopa And Levodopa

AB	ZYDUS PHARMS	10MG;100MG	A215999	001	Apr 04, 2023	Mar NEWA
AB		25MG;100MG	A215999	002	Apr 04, 2023	Mar NEWA
AB		25MG;250MG	A215999	003	Apr 04, 2023	Mar NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	CARBIDOPA AND LEVODOPA					
AB	! SCIEGEN PHARMS INC	50MG;200MG	A214091	002	Oct 05, 2021	May CHRS
AB	SUN PHARM INDs	50MG;200MG	A077828	002	Aug 23, 2007	May CHRS
	TABLET, ORALLY DISINTEGRATING;ORAL					
	CARBIDOPA AND LEVODOPA					
	SUN PHARM	10MG;100MG	A078690	001	Jul 31, 2009	Apr CTEC
		25MG;100MG	A078690	002	Jul 31, 2009	Apr CTEC

CARBOPLATIN

INJECTABLE;INTRAVENOUS

Carboplatin

AP	NOVAST LABS	450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May CMFD
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May CMFD

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

>A>	AP	ALEMBIC	EQ 0.25MG BASE/ML	A217198	001	Jun 15, 2023	Jun NEWA
	AP	CAPLIN	EQ 0.25MG BASE/ML	A21682	001	Feb 13, 2023	Feb NEWA
	AP	EUGIA PHARMA	EQ 0.25MG BASE/ML	A216939	001	May 25, 2023	May NEWA
>A>	AP	SOLA PHARMS	EQ 0.25MG BASE/ML	A216824	001	May 19, 2023	Jun CAHN
>D>	AP	WELDING	EQ 0.25MG BASE/ML	A216824	001	May 19, 2023	Jun CAHN
	AP		EQ 0.25MG BASE/ML	A216824	001	May 19, 2023	May NEWA

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

>A>	+	ONYX PHARMS AMGEN	10MG/VIAL	N202714	003	Jun 07, 2018	Jun CAHN
>A>	+		30MG/VIAL	N202714	002	Jun 03, 2016	Jun CAHN
>A>	AP	+!	60MG/VIAL	N202714	001	Jul 20, 2012	Jun CAHN
>D>	+	ONYX THERAP	10MG/VIAL	N202714	003	Jun 07, 2018	Jun CAHN
>D>	+		30MG/VIAL	N202714	002	Jun 03, 2016	Jun CAHN
>D>	AP	+!	60MG/VIAL	N202714	001	Jul 20, 2012	Jun CAHN

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

CARIPRAZINE HYDROCHLORIDE

@	ZYDUS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022	May CAHN
@		EQ 3MG BASE	A213984	002	Sep 09, 2022	May CAHN
@		EQ 4.5MG BASE	A213984	003	Sep 09, 2022	May CAHN
@		EQ 6MG BASE	A213984	004	Sep 09, 2022	May CAHN
	VRAYLAR					
+	ABBVIE	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan CAHN
+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan CAHN
+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan CAHN
+		EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan CAHN

CARMUSTINE

INJECTABLE; INJECTION

CARMUSTINE

AP	ACCORD HLTHCARE	100MG/VIAL	A214117	001	Dec 27, 2022	Mar CTNA
AP	MSN	100MG/VIAL	A214814	001	May 11, 2023	May NEWA
@	MYLAN LABS LTD	100MG/VIAL	A215368	001	Mar 03, 2023	Mar DISC
AP		100MG/VIAL	A215368	001	Mar 03, 2023	Feb NEWA
AP	PENN LIFE	100MG/VIAL	A209278	001	Apr 02, 2019	May CAHN

CEFAZOLIN SODIUM

POWDER; INTRAVENOUS

CEFAZOLIN SODIUM

+	! HQ SPCLT PHARMA	EQ 2GM BASE/VIAL	N211413	001	May 08, 2023	May NEWA
---	-------------------	------------------	---------	-----	--------------	----------

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

@	HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Mar DISC
@		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Mar DISC
@		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Mar DISC
@		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Mar DISC

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETAN

+	@ PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	May DISC
+	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	May DISC
	CEFOTETAN					
!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	May CTEC
!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	May CTEC

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS

TEFLARO

+	! ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010	May CAHN
+		600MG/VIAL	N200327	002	Oct 29, 2010	May CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AP	!	ACS DOBFAR	1GM/VIAL	A062640	002	Nov 20, 1985	May CHRS
AP	!		2GM/VIAL	A062640	003	Nov 20, 1985	May CHRS
AP	!		6GM/VIAL	A062640	004	Feb 03, 1992	May CHRS
		FORTAZ					
+ @	PAI HOLDINGS PHARM		500MG/VIAL	N050578	001	Jul 19, 1985	May DISC
+ @			1GM/VIAL	N050578	002	Jul 19, 1985	May DISC
+ @			2GM/VIAL	N050578	003	Jul 19, 1985	May DISC
+ @			6GM/VIAL	N050578	004	Jul 19, 1985	May DISC
	TAZICEF						
@ HOSPIRA			500MG/VIAL	A062662	001	Mar 06, 1986	May DISC
			500MG/VIAL	A062662	001	Mar 06, 1986	May CTEC

CEFUXOMINE SODIUM

INJECTABLE; INJECTION

>D>		CEFUXOMINE AND DEXTROSE IN DUPLEX CONTAINER					
>D>	+	B BRAUN	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001	Jun DISC
>A>	+	@	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001	Jun DISC
	+	!	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001	May CTEC
>D> AP	+	!	EQ 1.5GM BASE/VIAL	N050780	002	Feb 21, 2001	Jun DISC
>A>	+	@	EQ 1.5GM BASE/VIAL	N050780	002	Feb 21, 2001	Jun DISC
		CEFUXOMINE SODIUM					
>D> AP		ACS DOBFAR SPA	EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jun DISC
>A>		@	EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jun DISC
>A> AP	!	HIKMA	EQ 1.5GM BASE/VIAL	A065048	002	Jan 09, 2004	Jun CHRS
>A>		@	EQ 7.5GM BASE/VIAL	A065046	001	Jan 09, 2004	Jun DISC
>D> AP		HIKMA FARMACEUTICA	EQ 1.5GM BASE/VIAL	A065048	002	Jan 09, 2004	Jun CHRS
>D> AP			EQ 7.5GM BASE/VIAL	A065046	001	Jan 09, 2004	Jun DISC
>D>		ZINACEF					
>D> AP	+	PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun DISC
>A>	+	@	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun DISC
>D> AP	+	!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun DISC
>A>	+	@	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun DISC
		INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
		CEFUXOMINE SODIUM					
>A> AB	!	HIKMA	EQ 750MG BASE/VIAL	A065048	001	Jan 09, 2004	Jun CHRS
>D> AB		HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048	001	Jan 09, 2004	Jun CHRS
>D>		ZINACEF					
>D> AB	+	PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun DISC
>A>	+	@	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun DISC

CELECOXIB

CAPSULE; ORAL

CELECOXIB

>D> AB		MYLAN	50MG	A078857	001	May 30, 2014	Jun DISC
>A>		@	50MG	A078857	001	May 30, 2014	Jun DISC
		@	100MG	A078857	002	Feb 11, 2015	Mar DISC
>D> AB			200MG	A078857	003	Feb 11, 2015	Jun DISC
>A>		@	200MG	A078857	003	Feb 11, 2015	Jun DISC
>D> AB			400MG	A078857	004	Feb 11, 2015	Jun DISC
>A>		@	400MG	A078857	004	Feb 11, 2015	Jun DISC
AB		YABAO PHARM	100MG	A212564	001	Apr 10, 2023	Mar NEWA
AB			200MG	A212564	002	Apr 10, 2023	Mar NEWA
AB			400MG	A212564	003	Apr 10, 2023	Mar NEWA
		SOLUTION; ORAL					
		ELYXYB					
AB	+	SCILEX HLDG	25MG/ML	N212157	001	May 05, 2020	Feb CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>A> AA		BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	Jun CAHN
>D> AA		BRECKENRIDGE	5MG/5ML	A078488	001	Oct 06, 2008	Jun CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB	AUROBINDO PHARMA	30MG	A215056	001	Apr 18, 2023	Apr NEWA
AB	RUBICON	30MG	A216682	001	Apr 06, 2023	Mar NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT	CHARTWELL RX	0.12%	A075006	001	Mar 03, 2004	Jan CAHN
----	--------------	-------	---------	-----	--------------	----------

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A209755	001	Sep 10, 2018	Apr CTEC
AB		25MG	A209755	002	Sep 10, 2018	Apr CTEC
AB		50MG	A209755	003	Sep 10, 2018	Apr CTEC
AB		100MG	A209755	004	Sep 10, 2018	Apr CTEC
AB		200MG	A209755	005	Sep 10, 2018	Apr CTEC

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA	ACME LABS	500MG	A214365	001	Apr 27, 2023	Apr NEWA
AB	APPCO	375MG	A212047	001	Jan 27, 2023	Jan NEWA
AB		750MG	A212047	002	Jan 27, 2023	Jan NEWA
AA	BELCHER	250MG	A215540	001	Jan 24, 2023	Jan NEWA
AA	COREPHARMA	250MG	A214702	001	Apr 10, 2023	Mar NEWA

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

@ PAI HOLDINGS PHARM	1%	A209975	001	Apr 05, 2018	May DISC
SOLUTION;TOPICAL					
CICLOPIROX					
AT ! PADAGIS US	8%	A077623	001	Sep 18, 2007	Jan CHRS
PENLAC					
+ @ VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999	Jan DISC

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

@ AUROBINDO PHARMA USA	50MG	A077019	001	Nov 23, 2004	Apr CAHN
@	100MG	A077019	002	Nov 23, 2004	Apr CAHN
>D> @ EPIC PHARMA LLC	50MG	A077022	002	Mar 11, 2005	Jun CMFD
>A> AB	50MG	A077022	002	Mar 11, 2005	Jun CMFD
>D> @	100MG	A077022	001	Nov 23, 2004	Jun CMFD
>A> AB	100MG	A077022	001	Nov 23, 2004	Jun CMFD

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA	XTTRIUM LABS INC	EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997	Mar CAHN
----	------------------	-------------------	---------	-----	--------------	----------

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

>D> AB ACME LABS	EQ 30MG BASE	A213325	001	May 18, 2020	Jun CAHN
>D> AB	EQ 60MG BASE	A213325	002	May 18, 2020	Jun CAHN
>D> AB	EQ 90MG BASE	A213325	003	May 18, 2020	Jun CAHN
>A> AB CHARTWELL RX	EQ 30MG BASE	A213325	001	May 18, 2020	Jun CAHN
>A> AB	EQ 60MG BASE	A213325	002	May 18, 2020	Jun CAHN
>A> AB	EQ 90MG BASE	A213325	003	May 18, 2020	Jun CAHN

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPRO

AB + BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	May CTEC
AB +!	500MG/5ML	N020780	002	Sep 26, 1997	May CTEC

FOR SUSPENSION;ORAL

CIPROFLOXACIN

AB	CHARTWELL	250MG/5ML	A200563	001	Mar 05, 2014	May CMFD
AB		500MG/5ML	A200563	002	Mar 05, 2014	May CMFD
	INJECTABLE, SUSPENSION;OTIC					
	OTIPIRIO					

+ @ ALK ABELLO 6% (60MG/ML)

N207986 001 Dec 10, 2015 Jan DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

@ AKORN EQ 0.3% BASE

A076555 001 Dec 11, 2008 Feb DISC

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

>D>	@ AMNEAL	EQ 100MG BASE	A075939	001	Mar 03, 2005	Jun CMFD
>A> AB		EQ 100MG BASE	A075939	001	Mar 03, 2005	Jun CMFD
>D>	@	EQ 250MG BASE	A075939	002	Jun 09, 2004	Jun CMFD
>A> AB		EQ 250MG BASE	A075939	002	Jun 09, 2004	Jun CMFD
>D>	@	EQ 500MG BASE	A075939	003	Jun 09, 2004	Jun CMFD
>A> AB		EQ 500MG BASE	A075939	003	Jun 09, 2004	Jun CMFD
>D>	@	EQ 750MG BASE	A075939	004	Jun 09, 2004	Jun CMFD
>A> AB		EQ 750MG BASE	A075939	004	Jun 09, 2004	Jun CMFD

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

>D>	@ MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	Jun CAHN
>D>	@	425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	Jun CAHN
>A>	@ RISING	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	Jun CAHN
>A>	@	425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	Jun CAHN

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPROFLOXACIN AND DEXAMETHASONE

>A> AB	AKORN	0.3%;0.1%	A215768	001	Jun 09, 2023	Jun NEWA
--------	-------	-----------	---------	-----	--------------	----------

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

>A> AP	CAPLIN	EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Jun NEWA
>A> AP		EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Jun NEWA
AP	HIKMA	EQ 2MG BASE/ML	A203079	001	Apr 19, 2023	Apr NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+ ABBVIE	EQ 10MG BASE	N020822	001	Apr 27, 2000	Feb CAHN
AB	+	EQ 20MG BASE	N020822	002	Jul 17, 1998	Feb CAHN
AB	+!	EQ 40MG BASE	N020822	003	Jul 17, 1998	Feb CAHN
	@	EQ 60MG BASE	N020822	004	Jul 17, 1998	Feb CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

SANDOZ 125MG/5ML

!

250MG/5ML

A065283 002 Sep 04, 2007 May CTEC
A065283 003 Sep 04, 2007 May CTECCLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	EQ 75MG BASE	A216957	001	Mar 10, 2023	Mar NEWA
AB		EQ 150MG BASE	A216957	002	Mar 10, 2023	Mar NEWA
AB		EQ 300MG BASE	A216957	003	Mar 10, 2023	Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	CHARTWELL RX	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Feb CAHN
----	--------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL CLINDAMYCIN PHOSPHATE			
>D> AT	PADAGIS ISRAEL	1%	A090785 001 Mar 31, 2010 Jun CHRS
>A> AT	!	1%	A090785 001 Mar 31, 2010 Jun CHRS
>D>	EVOCLIN		
>D> AT	+! MYLAN	1%	N050801 001 Oct 22, 2004 Jun DISC
>A>	+ @	1%	N050801 001 Oct 22, 2004 Jun DISC
INJECTABLE;INJECTION CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%			
AP	HIKMA	EQ 6MG BASE/ML	A214401 001 Apr 05, 2023 Mar NEWA
AP		EQ 12MG BASE/ML	A214401 002 Apr 05, 2023 Mar NEWA
AP		EQ 18MG BASE/ML	A214401 003 Apr 05, 2023 Mar NEWA
SOLUTION;TOPICAL CLINDAMYCIN PHOSPHATE			
AT	CHARTWELL RX	EQ 1% BASE	A209846 001 Feb 08, 2018 May CAHN
	@ XTTRIUM LABS INC	EQ 1% BASE	A063304 001 Jul 15, 1997 Jan CAHN

CLOBAZAM

SUSPENSION;ORAL CLOBAZAM			
	@ ACCORD HLTHCARE	2.5MG/ML	A216008 001 Sep 06, 2022 Mar DISC
	@ UPSHER SMITH LABS	2.5MG/ML	A210569 001 Oct 22, 2018 Mar DISC

CLOBETASOL PROPIONATE

CREAM;TOPICAL CLOBETASOL PROPIONATE			
>D> AB1	@ CHARTWELL RX	0.05%	A211207 001 Mar 26, 2021 May CAHN
	ENCUBE	0.05%	A212982 001 Aug 28, 2020 Jun CHRS
>A> AB1	!	0.05%	A212982 001 Aug 28, 2020 Jun CHRS
	@ TORRENT	0.05%	A211836 001 Dec 30, 2019 Feb DISC
CLOBETASOL PROPIONATE (EMOLlient)			
	@ ANI PHARMS	0.05%	A075733 001 Aug 22, 2001 Apr DISC
CORMAX			
>D> AB1	! AKORN	0.05%	A074220 001 May 16, 1997 Jun CHRS
>A> AB1		0.05%	A074220 001 May 16, 1997 Jun CHRS

CLOFARABINE

SOLUTION;INTRAVENOUS CLOFARABINE			
	@ EUGIA PHARMA	20MG/20ML (1MG/ML)	A212457 001 Oct 03, 2022 Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL CLOMIPRAMINE HYDROCHLORIDE			
AB	AUROBINDO PHARMA	25MG	A216440 001 Mar 20, 2023 Mar NEWA
AB		50MG	A216440 002 Mar 20, 2023 Mar NEWA
AB		75MG	A216440 003 Mar 20, 2023 Mar NEWA
>A> AB	RK PHARMA	25MG	A213221 001 Jun 22, 2020 Jun CAHN
>A> AB		50MG	A213221 002 Jun 22, 2020 Jun CAHN
>A> AB		75MG	A213221 003 Jun 22, 2020 Jun CAHN
>D> AB	VGYAAN	25MG	A213221 001 Jun 22, 2020 Jun CAHN
>D> AB		50MG	A213221 002 Jun 22, 2020 Jun CAHN
>D> AB		75MG	A213221 003 Jun 22, 2020 Jun CAHN

CLONAZEPAM

TABLET;ORAL CLONAZEPAM			
AB	AUROBINDO PHARMA USA	0.5MG	A075150 001 Oct 05, 1998 Jan CMFD
AB		1MG	A075150 002 Oct 05, 1998 Jan CMFD
AB		2MG	A075150 003 Oct 05, 1998 Jan CMFD

CLOPIDOGREL BISULFATE

TABLET;ORAL CLOPIDOGREL BISULFATE			
>D>	@ CELLTRION	EQ 75MG BASE	A202266 001 Aug 14, 2012 Jun CAHN
>D>	@	EQ 300MG BASE	A202266 002 Nov 20, 2012 Jun CAHN
>A>	@ CHARTWELL RX	EQ 75MG BASE	A202266 001 Aug 14, 2012 Jun CAHN
>A>	@	EQ 300MG BASE	A202266 002 Nov 20, 2012 Jun CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@ DASH PHARMS	3.75MG
@	7.5MG
@	15MG

A071509	001	Oct 19, 1987	Feb CAHN
A071510	001	Oct 19, 1987	Feb CAHN
A071511	001	Oct 19, 1987	Feb CAHN

CLOZAPINE

TABLET;ORAL

CLOZAPINE

@ DR REDDYS LABS SA	25MG
@	50MG
@	100MG
@	200MG
@ MAYNE PHARMA	25MG
@	50MG
@	100MG
@	200MG

A203807	001	Sep 17, 2015	Apr CAHN
A203807	003	Aug 22, 2017	Apr CAHN
A203807	002	Sep 17, 2015	Apr CAHN
A203807	004	Aug 22, 2017	Apr CAHN
A203807	001	Sep 17, 2015	Apr DISC
A203807	003	Aug 22, 2017	Apr DISC
A203807	002	Sep 17, 2015	Apr DISC
A203807	004	Aug 22, 2017	Apr DISC

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

! ANIMA

10MG/5ML;30MG/5ML;1.25MG/5ML

A088704 001 Mar 22, 1985 Mar CAHN

COLCHICINE

CAPSULE;ORAL

COLCHICINE

>D>	@ PAR PHARM INC	0.6MG
>A> AB		0.6MG
	MITIGARE	
>D>	+! HIKMA INTL PHARMS	0.6MG
>A> AB	+!	0.6MG
	TABLET;ORAL	
>A>	LODOC	
>A>	+! AGEPHA PHARMA FZ	0.5MG

A208678	001	Nov 29, 2018	Jun CMFD
A208678	001	Nov 29, 2018	Jun CMFD
N204820	001	Sep 26, 2014	Jun CTEC
N204820	001	Sep 26, 2014	Jun CTEC
N215727	001	Jun 16, 2023	Jun NEWA

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB	IMPAX	3.75GM/PACKET
	TABLET;ORAL	
	COLESEVELAM HYDROCHLORIDE	
	@ CHARTWELL RX	625MG

A212886	001	Jan 18, 2023	Jan NEWA
A201354	001	Dec 17, 2020	May CAHN

COlestipol HYDROCHLORIDE

TABLET;ORAL

COlestipol HYDROCHLORIDE

AB	ANI PHARMS	1GM
AB	PRAXGEN	1GM

A216517	001	Mar 10, 2023	Apr CAHN
A216517	001	Mar 10, 2023	Mar NEWA

CROMOLYN SODIUM

SOLUTION;INHALATION

CROMOLYN SODIUM

AN	@ EUGIA PHARMA	10MG/ML
	VIRTUS	10MG/ML
	SOLUTION/DROPS;OPHTHALMIC	
	CROMOLYN SODIUM	
	@ AKORN	4%
AT	! SANDOZ	4%
AT	! SANDOZ INC	4%

A074209	001	Apr 26, 1994	May CAHN
A075437	001	Apr 21, 2000	Apr CAHN
A074706	001	Apr 29, 1998	Feb DISC
A075282	001	Jun 16, 1999	Feb CTEC
A075282	001	Jun 16, 1999	Feb CHRS

CYANOCOBALAMIN

SPRAY, METERED;NASAL

CYANOCOBALAMIN

>A> AB	LUPIN	0.5MG/SPRAY
	NASCOBAL	
>D>	+! ENDO PHARMS INC	0.5MG/SPRAY
>A> AB	+!	0.5MG/SPRAY

A210629	001	Jun 30, 2023	Jun NEWA
N021642	001	Jan 31, 2005	Jun CTEC
N021642	001	Jan 31, 2005	Jun CTEC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

@ APOTEX 15MG
@ 30MGA206703 001 Jul 24, 2018 Mar DISC
A206703 002 Jul 24, 2018 Mar DISC

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB CHARTWELL RX 5MG
AB 7.5MG
AB 10MGA078218 002 Jun 19, 2015 Feb CAHN
A078218 003 Nov 03, 2020 Feb CAHN
A078218 001 Apr 18, 2008 Feb CAHNCYCLOPENTOLATE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
CYCLOGYL+! ALCON LABS INC 0.5%
CYCLOPENTOLATE HYDROCHLORIDE
@ AKORN 0.5%A084109 001 Feb CTEC
A205937 001 Dec 09, 2015 Feb DISCCYCLOPHOSPHAMIDEINJECTABLE;INJECTION
CYCLOPHOSPHAMIDEAP XGEN PHARMS 500MG/VIAL
AP 1GM/VIAL
AP 2GM/VIALA211757 001 Oct 18, 2022 May CAHN
A211757 002 Oct 18, 2022 May CAHN
A211757 003 Oct 18, 2022 May CAHNSOLUTION;INTRAVENOUS
CYCLOPHOSPHAMIDE>A> +! DR REDDYS 500MG/ML (500MG/ML)
>A> +! 1GM/2ML (500MG/ML)
>A> +! 2GM/4ML (500MG/ML)
>A> +! NEVAKAR INJECTABLES 500MG/2.5ML (200MG/ML)
>A> +! 1GM/5ML (200MG/ML)N210852 001 Jun 07, 2023 Jun NEWA
N210852 002 Jun 07, 2023 Jun NEWA
N210852 003 Jun 07, 2023 Jun NEWA
N217651 001 Jun 28, 2023 Jun NEWA
N217651 002 Jun 28, 2023 Jun NEWACYCLOSPORINEEMULSION;OPHTHALMIC
CYCLOSPORINEAB APOTEX 0.05%
SOLUTION;OPHTHALMIC
VEVYE
+! NOVALIQ GMBH 0.1%
SOLUTION;ORAL
CYCLOSPORINE
AB2 XTTRIUM LABS INC 100MG/MLA207606 001 Jan 12, 2023 Jan NEWA
N217469 001 May 30, 2023 May NEWA
A065133 001 Sep 17, 2004 Jan CAHNCYPROHEPTADINE HYDROCHLORIDETABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDEAA CHARTWELL RX 4MG
@ RISING 4MGA088212 001 May 26, 1983 Mar CMFD
A207783 001 Dec 29, 2016 May DISCCYSTEINE HYDROCHLORIDEINJECTABLE;INJECTION
CYSTEINE HYDROCHLORIDE@ HIKMA 7.25%
@ NIVAGEN PHARMS INC 7.25%
7.25%A213073 001 Jan 26, 2023 Apr CAHN
A213073 001 Jan 26, 2023 Apr DISC
A213073 001 Jan 26, 2023 Jan NFTGDABRAFENIB MESYLATETABLET, FOR SUSPENSION;ORAL
TAFINLAR
+! NOVARTIS EQ 10MG BASE

N217514 001 Mar 16, 2023 Mar NEWA

DALBAVANCIN HYDROCHLORIDEPOWDER;INTRAVENOUS
DALVANCE>A> +! ABBVIE EQ 500MG BASE/VIAL
>D> +! ALLERGAN EQ 500MG BASE/VIALN021883 001 May 23, 2014 Jun CAHN
N021883 001 May 23, 2014 Jun CAHN

DAPRODUSTAT

TABLET;ORAL

JESDUVROQ

+	GLAXOSMITHKLINE	1MG	N 216951	001	Feb 01, 2023	Feb NEWA
+		2MG	N 216951	002	Feb 01, 2023	Feb NEWA
+		4MG	N 216951	003	Feb 01, 2023	Feb NEWA
+		6MG	N 216951	004	Feb 01, 2023	Feb NEWA
+!		8MG	N 216951	005	Feb 01, 2023	Feb NEWA

DAPSONE

GEL;TOPICAL

ACZONE

>A>	AB	+!	ABBVIE	5%	N 021794	001	Jul 07, 2005	Jun CAHN
>D>	AB	+!	ALLERGAN	5%	N 021794	001	Jul 07, 2005	Jun CAHN
			DAPSONE					
AB			ACRUX DDS	5%	A 213907	001	Jun 06, 2023	May NEWA
AB			AMNEAL	7.5%	A 212701	001	May 31, 2023	May NEWA
			TABLET;ORAL					
			DAPSONE					
>D>	AB	+!	EVEREST LIFE SCI	100MG	A 086842	001		Jun CHRS
>A>	AB	+		100MG	A 086842	001		Jun CHRS
>D>	AB		NOVITIUM PHARMA	100MG	A 206505	002	Dec 01, 2016	Jun CHRS
>A>	AB	!		100MG	A 206505	002	Dec 01, 2016	Jun CHRS

DAPTOMYCIN

POWDER;INTRAVENOUS

CUBICIN

		+ @	CUBIST PHARMS LLC	500MG/VIAL	N 021572	002	Sep 12, 2003	May DISC
		@	HAINAN POLY PHARM	500MG/VIAL	A 215890	001	Aug 18, 2022	Feb DISC
AP		!	QILU PHARM HAINAN	500MG/VIAL	A 215316	001	Aug 24, 2021	May CHRS
		+!	XELLIA PHARMS APS	350MG/VIAL	N 217415	001	Jan 30, 2023	Jan NEWA
		+!		500MG/VIAL	N 217415	002	Jan 30, 2023	Jan NEWA
			SOLUTION;INTRAVENOUS					
			DAPTOMYCIN IN 0.9% SODIUM CHLORIDE					
		+!	BAXTER HLTHCARE CORP	350MG/50ML (7MG/ML)	N 213645	002	Feb 27, 2023	Mar NEWA
		+!		500MG/50ML (10MG/ML)	N 213645	003	Feb 27, 2023	Mar NEWA
		+!		700MG/100ML (7MG/ML)	N 213645	004	Feb 27, 2023	Mar NEWA
		+!		1GM/100ML (10MG/ML)	N 213645	005	Feb 27, 2023	Mar NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

ENABLEX

+ @	ABBVIE	EQ 7.5MG BASE	N 021513	001	Dec 22, 2004	Apr CAHN
+ @		EQ 15MG BASE	N 021513	002	Dec 22, 2004	Apr CAHN

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

AB		ANNORA PHARMA	90MG	A 216229	003	Mar 16, 2023	Mar NEWA
		TABLET;ORAL					
		DEFERASIROX					
AB		CHARTWELL RX	90MG	A 212669	001	May 27, 2021	Mar CAHN
AB			180MG	A 212669	002	May 27, 2021	Mar CAHN
AB			360MG	A 212669	003	May 27, 2021	Mar CAHN
		@ CIPLA	90MG	A 211852	001	Feb 11, 2020	Mar DISC
		@	180MG	A 211852	003	Jun 15, 2020	Mar DISC
		@	360MG	A 211852	002	Feb 11, 2020	Mar DISC
		TABLET, FOR SUSPENSION;ORAL					
		DEFERASIROX					
		@ TEVA PHARMS USA	125MG	A 207124	001	Sep 23, 2022	Mar DISC
		@	250MG	A 207124	002	Sep 23, 2022	Mar DISC
		@	500MG	A 207124	003	Sep 23, 2022	Mar DISC

DEFERIPRONE

TABLET;ORAL

DEFERIPRONE

AB	!	HIKMA	1GM	A 213239	002	Feb 08, 2022	May CHRS
AB	+	FERRIPROX					
AB	+	CHIESI	1GM	N 021825	002	Jul 25, 2019	May CHRS

DESLOTRATADINE

TABLET;ORAL

DESLORATADINE

@ DASH PHARMS

5MG

A078351 001 Feb 10, 2012 Feb CAHN

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

AP GLAND 0.004MG/ML

A216904 001 Mar 20, 2023 Mar NEWA

DESONIDE

LOTION;TOPICAL

DESONIDE

@ PAI HOLDINGS PHARM 0.05%

A207855 001 Sep 28, 2017 May DISC

DEUTETETRABENAZINE

TABLET, EXTENDED RELEASE;ORAL

AUSTEDO XR

+ TEVA 6MG

+ 12MG

+! 24MG

N216354 001 Feb 17, 2023 Feb NEWA

N216354 002 Feb 17, 2023 Feb NEWA

N216354 003 Feb 17, 2023 Feb NEWA

DEXAMETHASONE

ELIXIR;ORAL

DEXAMETHASONE

+ @ XTRRIUM LABS INC 0.5MG/5ML

A088254 001 Jul 27, 1983 Jan CAHN

SUSPENSION/DROPS;OPHTHALMIC

MAXIDEX

+! HARROW EYE 0.1%

N013422 001 May CAHN

TABLET;ORAL

DEXAMETHASONE

AB ALVOGEN 4MG
AB 6MG
AB BIONPHARMA 2MG
AB 4MG
AB 6MG
AB NOVITIUM PHARMA 2MG
AB PRASCO 4MG
@ 4MG

A088481 004 Apr 28, 1983 Apr CTEC

A088481 001 Nov 28, 1983 Apr CTEC

A217538 001 Apr 26, 2023 Apr NEWA

A217001 001 Apr 19, 2023 Apr NEWA

A217001 002 Apr 19, 2023 Apr NEWA

A217696 001 May 09, 2023 Apr NEWA

A080399 002 Apr 20, 2022 Apr CMFD

A080399 002 Apr 20, 2022 Feb DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

>A> AP GENEYORK PHARMS EQ 10MG PHOSPHATE/ML

A214890 001 Jul 07, 2023 Jun NEWA

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC

MAXITROL

AT +! HARROW EYE 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

N050023 002 May CAHN

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRAMYCIN AND DEXAMETHASONE

>D> AB AMNEAL 0.1%;0.3%
>A> @ 0.1%;0.3%

A212991 001 Jul 15, 2021 Jun DISC

A212991 001 Jul 15, 2021 Jun DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP AMNEAL EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)
AP EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)
AP MILLA PHARMS EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)
AP EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)

A216604 001 May 15, 2023 May NEWA

A216604 002 May 15, 2023 May NEWA

A217308 001 Jun 07, 2023 May NEWA

A217308 002 Jun 07, 2023 May NEWA

DEXTROAMPHETAMINE SULFATE

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA	! PRASCO	5MG/5ML	A040776	001	Jan 29, 2008	Mar CAHN
	TABLET;ORAL					
	DEXTROAMPHETAMINE SULFATE					
AA	ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Jan CTEC
AA		7.5MG	A090533	003	Oct 25, 2011	Jan CTEC
AA		15MG	A090533	005	Oct 25, 2011	Jan CTEC
AA		20MG	A090533	006	Oct 25, 2011	Jan CTEC
AA		30MG	A090533	007	Oct 25, 2011	Jan CTEC
AA	WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	Jan CMFD
AA		5MG	A212160	002	Jun 07, 2021	Jan CMFD
AA		7.5MG	A212160	003	Jun 07, 2021	Jan CMFD
AA		10MG	A212160	004	Jun 07, 2021	Jan CMFD
AA		15MG	A212160	005	Jun 07, 2021	Jan CMFD
AA		20MG	A212160	006	Jun 07, 2021	Jan CMFD
AA		30MG	A212160	007	Jun 07, 2021	Jan CMFD

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Mar CMFD
AP	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Mar CMFD
AP	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Mar CMFD
AP	+! ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CHRS
AP	+!	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CTEC
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Mar CMFD
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Mar CMFD
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Mar CMFD
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Mar CMFD
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Mar CMFD

DIAZEPAM

GEL;RECTAL

DIASTAT ACUDIAL

AB	+! BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	May CFTG
AB	+!	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	May CFTG
	DIAZEPAM					
AB	NOVEL LABS INC	10MG/2ML (5MG/ML)	A091076	001	May 30, 2023	May NFTG
AB		20MG/4ML (5MG/ML)	A091076	002	May 30, 2023	May NFTG

DICLOFENAC POTASSIUM

TABLET;ORAL

DICLOFENAC POTASSIUM

AB	@ CHARTWELL RX	50MG	A075582	001	Feb 23, 2001	May CAHN
	SENORES PHARMS	50MG	A215787	001	Mar 15, 2023	Mar NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB	AMNEAL	3%	A200936	001	Oct 28, 2013	Feb CAHN
	SOLUTION;TOPICAL					

DICLOFENAC SODIUM

AB	AUROLIFE PHARMA LLC	2%	A213040	001	Feb 03, 2023	Jan NEWA
	TABLET, DELAYED RELEASE;ORAL					

DICLOFENAC SODIUM

AB	RUBICON	25MG	A216548	001	May 11, 2023	May NEWA
		50MG	A216548	002	May 11, 2023	May NEWA
AB		75MG	A216548	003	May 11, 2023	May NEWA

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB	@ AUROBINDO PHARMA USA	100MG	A076152	001	Dec 13, 2001	Apr CAHN
----	------------------------	-------	---------	-----	--------------	----------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

>A> AB	ZYDUS PHARMS	50MG;0.2MG
		75MG;0.2MG

A206771	001	Jun 12, 2023	Jun NEWA
A206771	002	Jun 12, 2023	Jun NEWA

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

AB	COREPHARMA	10MG	A216639	001	Mar 24, 2023	Mar NEWA
	INJECTABLE;INJECTION					
	BENTYL					
AP	+! ABBVIE	10MG/ML	N008370	001	Oct 15, 1984	Feb CAHN
	BENTYL PRESERVATIVE FREE					
AP	+! ABBVIE	10MG/ML	N008370	002	Oct 15, 1984	Feb CAHN
	TABLET;ORAL					
	DICYCLOMINE HYDROCHLORIDE					
AB	AUROBINDO PHARMA USA	20MG	A040317	001	Sep 07, 1999	Feb CMFD
AB	TWI PHARMS	20MG	A216782	001	Jun 01, 2023	May NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

! LANNETT CO INC 75MG

A091680 001 Oct 24, 2011 Feb CTEC

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

@ AVONDALE PHARMS 0.05%

A075187 001 Mar 30, 1998 May CAHN

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB	AVONDALE PHARMS	0.05%	A075374	001	Apr 27, 1999	May CAHN
----	-----------------	-------	---------	-----	--------------	----------

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL

DIHYDROERGOTAMINE MESYLATE

AB	AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Apr CMFD
>A> AB	RUBICON	0.5MG/SPRAY	A216881	001	Jun 22, 2023	Jun NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB1	TWI PHARMS	60MG	A217377	001	Mar 01, 2023	Feb NEWA
AB1		90MG	A217377	002	Mar 01, 2023	Feb NEWA
AB1		120MG	A217377	003	Mar 01, 2023	Feb NEWA

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP	EUGIA PHARMA	5MG/ML	A216552	001	Mar 29, 2023	Mar NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	DILTIAZEM HYDROCHLORIDE					
AB	AMTA	120MG	A216439	001	Mar 07, 2023	Feb NEWA
AB		180MG	A216439	002	Mar 07, 2023	Feb NEWA
AB		240MG	A216439	003	Mar 07, 2023	Feb NEWA
AB		300MG	A216439	004	Mar 07, 2023	Feb NEWA
AB		360MG	A216439	005	Mar 07, 2023	Feb NEWA
AB		420MG	A216439	006	Mar 07, 2023	Feb NEWA
AB	SCIEGEN PHARMS INC	120MG	A216327	001	Apr 06, 2023	Mar NEWA
AB		180MG	A216327	002	Apr 06, 2023	Mar NEWA
AB		240MG	A216327	003	Apr 06, 2023	Mar NEWA
AB		300MG	A216327	004	Apr 06, 2023	Mar NEWA
AB		360MG	A216327	005	Apr 06, 2023	Mar NEWA
AB		420MG	A216327	006	Apr 06, 2023	Mar NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

AB	SOLA PHARMS	120MG	A210436	001	Mar 26, 2021	Feb CMFD
AB		240MG	A210436	002	Mar 26, 2021	Feb CMFD

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+! PHARM ASSOC

12.5MG/5ML

A087513 001 Feb 10, 1982 Apr CRLD

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

>D>	AP	FRESENIUS KABI USA	5MG/ML	A074956	001	Sep 30, 1998	Jun DISC
>A>	@		5MG/ML	A074956	001	Sep 30, 1998	Jun DISC
		TABLET; ORAL					
		DIPYRIDAMOLE					
	@	ANI PHARMS	25MG	A086944	002	Apr 16, 1991	Apr DISC
	@		50MG	A086944	001	Feb 25, 1992	Apr DISC
	@		75MG	A086944	003	Feb 25, 1992	Apr DISC

DISULFIRAM

TABLET; ORAL

DISULFIRAM

@ DASH PHARMS

250MG

A203916 001 Mar 04, 2015 Feb CAHN

@

500MG

A203916 002 Mar 04, 2015 Feb CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

>D>	AB	CELLTRION	EQ 125MG VALPROIC ACID	A077296	001	Jul 31, 2008	Jun CAHN
>D>	AB		EQ 250MG VALPROIC ACID	A077296	002	Jul 31, 2008	Jun CAHN
>D>	AB		EQ 500MG VALPROIC ACID	A077296	003	Jul 31, 2008	Jun CAHN
>A>	AB	CHARTWELL RX	EQ 125MG VALPROIC ACID	A077296	001	Jul 31, 2008	Jun CAHN
>A>	AB		EQ 250MG VALPROIC ACID	A077296	002	Jul 31, 2008	Jun CAHN
>A>	AB		EQ 500MG VALPROIC ACID	A077296	003	Jul 31, 2008	Jun CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ALEMBIC	20MG/2ML (10MG/ML)	A215744	001	Feb 28, 2023	Feb NEWA
AP		80MG/8ML (10MG/ML)	A215744	002	Feb 28, 2023	Feb NEWA
AP		160MG/16ML (10MG/ML)	A215744	003	Feb 28, 2023	Feb NEWA
AP	MYLAN LABS LTD	20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Apr NEWA
AP		80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Apr NEWA

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

>A>	@ RK PHARMA	0.125MG	A215323	001	Apr 14, 2022	Jun CAHN
>A>	@	0.25MG	A215323	002	Apr 14, 2022	Jun CAHN
>A>	@	0.5MG	A215323	003	Apr 14, 2022	Jun CAHN
>D>	@ VGYAAN	0.125MG	A215323	001	Apr 14, 2022	Jun CAHN
>D>	@	0.25MG	A215323	002	Apr 14, 2022	Jun CAHN
>D>	@	0.5MG	A215323	003	Apr 14, 2022	Jun CAHN

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

>D>	@ EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004	Jun CRLD
>A>	+ @	5MG/5ML	N021719	001	Oct 18, 2004	Jun CRLD

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

+ @ B BRAUN		80MG/100ML	N019099	002	Oct 15, 1986	Apr DISC
+ @		320MG/100ML	N019099	004	Oct 15, 1986	Apr DISC
		DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER				
+ @ B BRAUN		40MG/100ML	N019099	001	Oct 15, 1986	Apr DISC
+ @		160MG/100ML	N019099	003	Oct 15, 1986	Apr DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

AT1	+! THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N020869	001	Apr 07, 1998	May CTEC
	COSOPT PF					
AT2	+! THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	May CTEC
	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE					
AT1	AKORN	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	May CTEC
AT1		EQ 2% BASE;EQ 0.5% BASE	A203058	001	Sep 22, 2014	May CTEC
AT1	ALEMBIC	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	May CTEC
AT1	BAUSCH AND LOMB	EQ 2% BASE;EQ 0.5% BASE	A090037	001	Jul 14, 2009	May CTEC
AT1	EUGIA PHARMA	EQ 2% BASE;EQ 0.5% BASE	A207629	001	May 14, 2021	May CTEC
AT2		EQ 2% BASE;EQ 0.5% BASE	A207630	001	Jul 24, 2018	May CTEC
AT1	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	May CTEC
AT1	GLAND PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE	A215520	001	Sep 19, 2022	May CTEC
AT1	INDOCO	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May CTEC
AT2	INGENUS PHARMS LLC	EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	May CTEC
AT		EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	Apr NEWA
AT1	MICRO LABS	EQ 2% BASE;EQ 0.5% BASE	A204777	001	May 28, 2020	May CTEC
AT2		EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	May CTEC
AT1	SANDOZ	EQ 2% BASE;EQ 0.5% BASE	A078749	001	Nov 06, 2008	May CTEC
AT1		EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	May CTEC
AT1	SOMERSET	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	May CTEC
AT1	TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009	May CTEC

DOXEPEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPEPIN HYDROCHLORIDE

>A> AB	MICRO LABS	EQ 10MG BASE	A217688	001	Jun 27, 2023	Jun NEWA
>A> AB		EQ 25MG BASE	A217688	002	Jun 27, 2023	Jun NEWA
>A> AB		EQ 50MG BASE	A217688	003	Jun 27, 2023	Jun NEWA
>A> AB		EQ 75MG BASE	A217688	004	Jun 27, 2023	Jun NEWA
>A> AB		EQ 100MG BASE	A217688	005	Jun 27, 2023	Jun NEWA
AB	ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CAHN
AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CAHN
AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CAHN
AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CAHN
AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CAHN
AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CAHN
AB	ZYDUS PHARMS	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar NEWA
AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar NEWA
AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar NEWA
AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar NEWA
AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar NEWA
AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar NEWA
CREAM;TOPICAL						
DOXEPEPIN HYDROCHLORIDE						
AB	TEVA PHARMS	5%	A215408	001	Feb 17, 2023	Feb NFTG
	ZONALON					
AB	+! MYLAN	5%	N020126	001	Apr 01, 1994	Feb CFTG
TABLET;ORAL						
DOXEPEPIN HYDROCHLORIDE						
AB	MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar NEWA
AB		EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

>A> AP	ALEMBIC	4MCG/2ML (2MCG/ML)	A215810	001	Jun 15, 2023	Jun NEWA
--------	---------	--------------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

AP	GLAND PHARMA LTD	EQ 100MG BASE/VIAL	A215583	001	Apr 12, 2023	Mar NEWA
>D> AP	PAR STERILE PRODUCTS	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022	Jun DISC
>A>	@	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022	Jun DISC
TABLET;ORAL						
DOXYCYCLINE HYCLATE						
@ ORYZA PHARMS SHENZHEN						
		EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb CAHN

**TABLET, DELAYED RELEASE;ORAL
DORYX**

>D>	AB	+ MAYNE PHARMA	EQ 50MG BASE	N 050795	006	Dec 19, 2014	Jun DISC
>A>		+ @	EQ 50MG BASE	N 050795	006	Dec 19, 2014	Jun DISC
>D>	AB	+ @	EQ 100MG BASE	N 050795	002	May 06, 2005	Jun DISC
>A>		DORYX MPC	EQ 100MG BASE	N 050795	002	May 06, 2005	Jun DISC
>D>		+! MAYNE PHARMA	EQ 120MG BASE	N 050795	008	May 20, 2016	Jun DISC
>A>		+ @	EQ 120MG BASE	N 050795	008	May 20, 2016	Jun DISC
		DOXYCYCLINE HYCLATE					
		@ AUROBINDO PHARMA USA	EQ 150MG BASE	A 091052	001	Feb 08, 2012	May CAHN

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

AP	HIKMA	2.5MG/ML	A 208197	001	Dec 14, 2017	May CAHN
----	-------	----------	----------	-----	--------------	----------

DROSPIRENONONE

TABLET, CHEWABLE;ORAL
DROSPIRENONONE

>D>		+! EXELTIS USA INC	3.5MG	N 216285	001	Jun 29, 2022	Jun DISC
>A>		+ @	3.5MG	N 216285	001	Jun 29, 2022	Jun DISC

DROXIDOPA

CAPSULE;ORAL
DROXIDOPA

	@ CHARTWELL RX	100MG	A 214217	001	May 05, 2022	May CAHN
	@	200MG	A 214217	002	May 05, 2022	May CAHN
	@	300MG	A 214217	003	May 05, 2022	May CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DRIZALMA SPRINKLE

	+ @ SUN PHARM	EQ 30MG BASE	N 212516	002	Jul 19, 2019	Mar DISC
	+ @	EQ 40MG BASE	N 212516	003	Jul 19, 2019	Jan DISC
	+ @	EQ 60MG BASE	N 212516	004	Jul 19, 2019	Mar DISC
	DULOXETINE HYDROCHLORIDE					
AB	ZYDUS HLTHCARE	EQ 40MG BASE	A 090739	004	Apr 18, 2023	Apr NEWA

DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

POWDER;INTRAVENOUS
XACDURO (COPACKAGED)

>D>		+! ENTASIS THERAP	EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL	N 216974	001	May 24, 2023	Jun CMS1
>A>		+!	EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL	N 216974	001	May 23, 2023	Jun CMS1
		+!	EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL	N 216974	001	May 24, 2023	May NEWA

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL
DYCLOPRO

!	SEPTODONT	0.5%	A 200480	001	Nov 20, 2018	May CAHN
!		1%	A 200480	002	Nov 20, 2018	May CAHN

ECONAZOLE NITRATE

CREAM;TOPICAL
ECONAZOLE NITRATE

@	AUROBINDO PHARMA USA	1%	A 210364	001	Apr 18, 2018	Apr CAHN
@	PAJ HOLDINGS PHARM	1%	A 076574	001	Dec 17, 2004	May DISC

EDETA TE CALCIUM DISODIUM

INJECTABLE;INJECTION
CALCIUM DISODIUM VERSENATE

+ @	BAUSCH	200MG/ML	N 008922	001		Mar DISC
	EDETA CALCIUM DISODIUM					
!	CASPER PHARMA LLC	200MG/ML	A 216435	001	May 03, 2023	Apr NFTG
		200MG/ML	A 216435	001	May 03, 2023	Apr NFTG

EFAVIRENZ

CAPSULE;ORAL					
EFAVIRENZ					
AUROBINDO PHARMA	50MG	A078064	001	Dec 15, 2017	Mar CTEC
!	200MG	A078064	003	Dec 15, 2017	Mar CHRS
	200MG	A078064	003	Dec 15, 2017	Mar CTEC
SUSTIVA					
+ @ BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998	Mar DISC
+ @	200MG	N020972	003	Sep 17, 1998	Mar DISC

ELACESTRANT DIHYDROCHLORIDE

TABLET;ORAL					
ORSERDU					
+ STEMLINE THERAP	EQ 86MG BASE	N217639	001	Jan 27, 2023	Jan NEWA
+!	EQ 345MG BASE	N217639	002	Jan 27, 2023	Jan NEWA

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

GRANULES;ORAL					
TRIKAFTA (COPACKAGED)					
+ VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG	N217660	001	Apr 26, 2023	Apr NEWA
+!	100MG, 75MG, 50MG;75MG	N217660	002	Apr 26, 2023	Apr NEWA

ELIGLUSTAT TARTRATE

CAPSULE;ORAL					
ELIGLUSTAT TARTRATE					
AB ZENARA	EQ 84MG BASE	A212420	001	May 02, 2023	Apr NEWA

EMPAGLIFLOZIN

TABLET;ORAL					
EMPAGLIFLOZIN					
@ ZYDUS PHARMS	10MG	A212138	001	Aug 03, 2022	Jan DISC
@	25MG	A212138	002	Aug 03, 2022	Jan DISC
JARDIANCE					
+ BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014	Jan CTEC
+!	25MG	N204629	002	Aug 01, 2014	Jan CTEC

EMTRICITABINE

CAPSULE;ORAL					
EMTRICITABINE					
AB AUROBINDO PHARMA LTD	200MG	A079188	001	Mar 15, 2023	Mar NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL					
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE					
@ APOTEX	200MG;300MG	A208740	001	Jun 16, 2021	Apr DISC
AB AUROBINDO PHARMA LTD	100MG;150MG	A211640	001	Mar 09, 2023	Mar NEWA
AB	133MG;200MG	A211640	002	Mar 09, 2023	Mar NEWA
AB	167MG;250MG	A211640	003	Mar 09, 2023	Mar NEWA

ENALAPRIL MALEATE

TABLET;ORAL					
ENALAPRIL MALEATE					
@ CHARTWELL RX	2.5MG	A075048	001	Aug 22, 2000	May CAHN
@	5MG	A075048	002	Aug 22, 2000	May CAHN
@	10MG	A075048	003	Aug 22, 2000	May CAHN
@	20MG	A075048	004	Aug 22, 2000	May CAHN

ENALAPRILAT

INJECTABLE;INJECTION					
ENALAPRILAT					
AP DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000	Apr CMFD

ENOXAPARIN SODIUM

INJECTABLE;SUBCUTANEOUS					
ENOXAPARIN SODIUM (PRESERVATIVE FREE)					
>D> AP APOTEX INC	30MG/0.3ML (100MG/ML)	A078990	001	Sep 28, 2018	Jun CAHN
>D> AP	40MG/0.4ML (100MG/ML)	A078990	002	Sep 28, 2018	Jun CAHN
>D> AP	60MG/0.6ML (100MG/ML)	A078990	003	Sep 28, 2018	Jun CAHN
>D> AP	80MG/0.8ML (100MG/ML)	A078990	004	Sep 28, 2018	Jun CAHN
>D> AP	100MG/ML (100MG/ML)	A078990	005	Sep 28, 2018	Jun CAHN
>D> AP	120MG/0.8ML (150MG/ML)	A078990	006	Sep 28, 2018	Jun CAHN

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

>D>	AP		150MG/ML (150MG/ML)	A078990	007	Sep 28, 2018	Jun CAHN
	AP	BE PHARMS	30MG/0.3ML (100MG/ML)	A214646	001	Jun 06, 2023	May NEWA
	AP		40MG/0.4ML (100MG/ML)	A214646	002	Jun 06, 2023	May NEWA
	AP		60MG/0.6ML (100MG/ML)	A214646	003	Jun 06, 2023	May NEWA
	AP		80MG/0.8ML (100MG/ML)	A214646	004	Jun 06, 2023	May NEWA
	AP		100MG/ML (100MG/ML)	A214646	005	Jun 06, 2023	May NEWA
	AP		120MG/0.8ML (150MG/ML)	A214646	006	Jun 06, 2023	May NEWA
	AP		150MG/ML (150MG/ML)	A214646	007	Jun 06, 2023	May NEWA
>A>	AP	GLAND	30MG/0.3ML (100MG/ML)	A078990	001	Sep 28, 2018	Jun CAHN
>A>	AP		40MG/0.4ML (100MG/ML)	A078990	002	Sep 28, 2018	Jun CAHN
>A>	AP		60MG/0.6ML (100MG/ML)	A078990	003	Sep 28, 2018	Jun CAHN
>A>	AP		80MG/0.8ML (100MG/ML)	A078990	004	Sep 28, 2018	Jun CAHN
>A>	AP		100MG/ML (100MG/ML)	A078990	005	Sep 28, 2018	Jun CAHN
>A>	AP		120MG/0.8ML (150MG/ML)	A078990	006	Sep 28, 2018	Jun CAHN
>A>	AP		150MG/ML (150MG/ML)	A078990	007	Sep 28, 2018	Jun CAHN
	AP	SHENZHEN TECHDOW	30MG/0.3ML (100MG/ML)	A205660	001	Mar 15, 2023	Mar NEWA
	AP		40MG/0.4ML (100MG/ML)	A205660	002	Mar 15, 2023	Mar NEWA
	AP		60MG/0.6ML (100MG/ML)	A205660	003	Mar 15, 2023	Mar NEWA
	AP		80MG/0.8ML (100MG/ML)	A205660	004	Mar 15, 2023	Mar NEWA
	AP		100MG/ML (100MG/ML)	A205660	005	Mar 15, 2023	Mar NEWA
	AP		120MG/0.8ML (150MG/ML)	A205660	006	Mar 15, 2023	Mar NEWA
	AP		150MG/ML (150MG/ML)	A205660	007	Mar 15, 2023	Mar NEWA

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

EMERPHED

	+!	NEXUS PHARMS	25MG/5ML (5MG/ML)	N213407	002	Feb 28, 2023	Mar NEWA
		EPHEDRINE SULFATE					
>D>	+!	ENDO VENTURES	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Jun CAHN
>D>	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Jun CAHN
>A>	+!	OPERAND PHARMS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Jun CAHN
>A>	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Jun CAHN
AP	SAGENT PHARMS INC		50MG/ML (50MG/ML)	A214528	001	Mar 09, 2023	Feb NEWA
AP	ZYDUS PHARMS		50MG/ML (50MG/ML)	A217276	001	May 16, 2023	May NEWA

EPINEPHRINE

SOLUTION; INTRAVENOUS

EPINEPHRINE

>A>	+!	BPI LABS	1MG/ML (1MG/ML)	N205029	003	May 12, 2023	Jun NEWA
		EPINEPHRINE IN 0.9% SODIUM CHLORIDE					
	+!	PAR STERILE PRODUCTS	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	Apr NEWA
	+!		4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	Apr NEWA
	+!		5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	Apr NEWA
	+!		8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Apr NEWA
	+!		10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Apr NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

!	HOSPIRA	0.01MG/ML; 2%	A089646	001	Jun 21, 1988	Apr CTEC
	XYLOCAINE W/ EPINEPHRINE					
+!	FRESENIUS KABI USA	0.02MG/ML; 2%	N006488	005		May CTEC

EPLERENONE

TABLET; ORAL

EPLERENONE

AB	ANNORA PHARMA	25MG	A213812	001	Jun 02, 2023	May NEWA
AB		50MG	A213812	002	Jun 02, 2023	May NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

AP2	! SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb CHRS
AP2	+ ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CHRS

<u>ERGOCALCIFEROL</u>					
CAPSULE;ORAL DRISDOL					
AA	+ VALIDUS PHARMS	50,000 IU	N 003444	001	Feb CHRS
	ERGOCALCIFEROL				
AA	CHARTWELL RX	50,000 IU	A 040833	001	May 20, 2009
AA	! STRIDES PHARMA	50,000 IU	A 090455	001	Aug 03, 2010
<u>ERLOTINIB HYDROCHLORIDE</u>					
TABLET;ORAL ERLOTINIB HYDROCHLORIDE					
AB	! ZYDUS PHARMS	EQ 150MG BASE	A 213065	003	Apr 16, 2020
	TARCEVA				
+ @ OSI PHARMS	EQ 25MG BASE	N 021743	001	Nov 18, 2004	Apr DISC
+ @	EQ 100MG BASE	N 021743	002	Nov 18, 2004	Apr DISC
+ @	EQ 150MG BASE	N 021743	003	Nov 18, 2004	Apr DISC
<u>ERTAPENEM SODIUM</u>					
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS ERTAPENEM SODIUM					
AP	SUN PHARM	EQ 1GM BASE/VIAL	A 209145	001	May 02, 2023
<u>ERYTHROMYCIN</u>					
GEL;TOPICAL ERYTHROMYCIN					
	@ PAI HOLDINGS PHARM	2%	A 208154	001	Jul 19, 2017
TABLET;ORAL ERYTHROMYCIN					
AB	ARBOR PHARMS LLC	500MG	A 061621	002	Jan CHRS
AB	! CADILA PHARMS LTD	500MG	A 213628	002	Jun 28, 2021
AB	ZYDUS	250MG	A 212693	001	Mar 07, 2023
AB		500MG	A 212693	002	Mar 07, 2023
<u>ERYTHROMYCIN ETHYLSUCCINATE</u>					
TABLET;ORAL ERYTHROMYCIN ETHYLSUCCINATE					
	@ AUROBINDO PHARMA USA	EQ 400MG BASE	A 062847	001	Sep 14, 1988
<u>ERYTHROMYCIN LACTOBIONATE</u>					
INJECTABLE;INJECTION ERYTHROMYCIN LACTOBIONATE					
	@ EXELA PHARMA	EQ 500MG BASE/VIAL	A 211086	001	Sep 17, 2020
<u>ESCITALOPRAM OXALATE</u>					
SOLUTION;ORAL LEXAPRO					
+ @ ABBVIE	EQ 5MG BASE/5ML	N 021365	001	Nov 27, 2002	Jan CAHN
TABLET;ORAL ESCITALOPRAM OXALATE					
	@ DASH PHARMS	EQ 5MG BASE	A 077550	001	May 14, 2015
	@	EQ 10MG BASE	A 077550	002	May 14, 2015
	@	EQ 20MG BASE	A 077550	003	May 14, 2015
AB	JUBILANT CADISTA	EQ 5MG BASE	A 202280	001	Sep 12, 2012
AB		EQ 10MG BASE	A 202280	002	Sep 12, 2012
AB		EQ 20MG BASE	A 202280	003	Sep 12, 2012
LEXAPRO					
AB	+ ABBVIE	EQ 5MG BASE	N 021323	001	Aug 14, 2002
AB	+	EQ 10MG BASE	N 021323	002	Aug 14, 2002
AB	!+	EQ 20MG BASE	N 021323	003	Aug 14, 2002
<u>ESMOLOL HYDROCHLORIDE</u>					
INJECTABLE;INJECTION BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER					
AP	+! BAXTER HLTHCARE	2GM/100ML	N 019386	005	Jan 27, 2003
	BREVIBLOC IN PLASTIC CONTAINER				
AP	+! BAXTER HLTHCARE	1GM/100ML	N 019386	004	Feb 16, 2001
	ESMOLOL HYDROCHLORIDE				
AP	AMNEAL	1GM/100ML	A 216603	001	Dec 13, 2022
AP		2GM/100ML	A 216603	002	Dec 13, 2022
AP	EUGIA PHARMA	1GM/100ML	A 216244	001	Mar 21, 2022
AP		2GM/100ML	A 216244	002	Mar 21, 2022

INJECTABLE; INJECTION
ESMOLOL HYDROCHLORIDE

AP	HQ SPCLT PHARMA	1GM/100ML	A214172	001	Dec 02, 2022	Jan CPOT
AP		2GM/100ML	A214172	002	Dec 02, 2022	Jan CPOT
AP	MYLAN LABS LTD	1GM/100ML	A206608	001	Jun 08, 2018	Jan CPOT
AP		2GM/100ML	A206608	002	Jun 08, 2018	Jan CPOT
AP	SAGENT PHARMS INC	1GM/100ML	A207107	001	Jun 08, 2018	Jan CPOT
AP		2GM/100ML	A207107	002	Jun 08, 2018	Jan CPOT

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL
ESOMEPRAZOLE MAGNESIUM

AB	PRINSTON INC	EQ 20MG BASE	A214920	001	Mar 28, 2023	Mar NEWA
AB		EQ 40MG BASE	A214920	002	Mar 28, 2023	Mar NEWA
	FOR SUSPENSION, DELAYED RELEASE; ORAL					
	ESOMEPRAZOLE MAGNESIUM					
AB	ZYDUS PHARMS	EQ 20MG BASE/PACKET	A206055	001	Jun 07, 2023	May NEWA
AB		EQ 40MG BASE/PACKET	A206055	002	Jun 07, 2023	May NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
 @ ACTAVIS LABS FL INC EQ 20MG BASE;375MG
 @ EQ 20MG BASE;500MG

A204470	001	Aug 24, 2022	Feb DISC
A204470	002	Aug 24, 2022	Feb DISC

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jan CHRS
	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Apr CTEC

ESTRADIOL

CREAM; VAGINAL
 ESTRADIOL

>A> AB	PRASCO	0.01%	A212313	001	Jul 15, 2021	Jun CAHN
>D> AB	PRASCO LABS LLC	0.01%	A212313	001	Jul 15, 2021	Jun CAHN

FILM, EXTENDED RELEASE; TRANSDERMAL
 ESTRADIOL

AB2	ZYDUS NOVELTECH INC	0.025MG/24HR	A202985	001	Mar 29, 2023	Mar NEWA
AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Mar NEWA
AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Mar NEWA
AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Mar NEWA
AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Mar NEWA
AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Mar NEWA
AB2	ZYDUS PHARMS	0.025MG/24HR	A202985	001	Mar 29, 2023	Apr CAHN
AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Apr CAHN
AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Apr CAHN
AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Apr CAHN
AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Apr CAHN
AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Apr CAHN

INSERT; VAGINAL

IMVEXXY

+	MAYNE PHARMA	0.004MG	N208564	001	May 29, 2018	Jan CAHN
+		0.01MG	N208564	002	May 29, 2018	Jan CAHN

SYSTEM; TRANSDERMAL

ESTRADIOL

AB	ZYDUS NOVELTECH INC	0.014MG/24HR	A204379	001	Apr 17, 2023	Apr NFTG
AB	ZYDUS PHARMS	0.014MG/24HR	A204379	001	Apr 17, 2023	May CAHN
AB1		0.025MG/24HR	A206241	001	Dec 01, 2022	May CAHN
AB1		0.0375MG/24HR	A206241	002	Dec 01, 2022	May CAHN
AB1		0.05MG/24HR	A206241	003	Dec 01, 2022	May CAHN
AB1		0.075MG/24HR	A206241	004	Dec 01, 2022	May CAHN
AB1		0.1MG/24HR	A206241	005	Dec 01, 2022	May CAHN

MENOSTAR

AB	+! BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004	Apr CFTG
	VIVELLE					
	@ SANDOZ	0.025MG/24HR	N020323	005	Aug 16, 2000	May CAHN
	@	0.0375MG/24HR	N020323	001	Oct 28, 1994	May CAHN
	@	0.05MG/24HR	N020323	002	Oct 28, 1994	May CAHN
	@	0.075MG/24HR	N020323	003	Oct 28, 1994	May CAHN
	@	0.1MG/24HR	N020323	004	Oct 28, 1994	May CAHN

SYSTEM; TRANSDERMAL
VIVELLE-DOT

AB1	+	SANDOZ	0.025MG/24HR	N 020538	009	May 03, 2002	May CAHN
AB1	+		0.0375MG/24HR	N 020538	005	Jan 08, 1999	May CAHN
AB1	+		0.05MG/24HR	N 020538	006	Jan 08, 1999	May CAHN
AB1	+		0.075MG/24HR	N 020538	007	Jan 08, 1999	May CAHN
AB1	+!		0.1MG/24HR	N 020538	008	Jan 08, 1999	May CAHN

ESTRADIOL VALERATE

INJECTABLE; INJECTION
ESTRADIOL VALERATE

AO		XIROMED	10MG/ML	A 216656	001	Apr 28, 2023	Apr NEWA
AO			20MG/ML	A 216656	002	Apr 28, 2023	Apr NEWA
AO			40MG/ML	A 216656	003	Apr 28, 2023	Apr NEWA

ESTRADIOL; NORETHINDRONE ACETATE**TABLET; ORAL****ESTRADIOL AND NORETHINDRONE ACETATE**

>A>	AB	AUROBINDO PHARMA LTD	0.5MG; 0.1MG	A 214729	001	Jun 30, 2023	Jun NEWA
>A>	AB		1MG; 0.5MG	A 214729	002	Jun 30, 2023	Jun NEWA

ETHINYLMONISTEROLOL; ETONOGESTREL**RING; VAGINAL**

>A>		ENILLORING					
>A>	AB	XIROMED	0.015MG/24HR; 0.12MG/24HR	A 211157	001	Jun 29, 2023	Jun NEWA

ETHINYLMONISTEROLOL; LEVONORGESTREL**TABLET; ORAL-28****LEVONORGESTREL AND ETHINYLMONISTEROLOL**

@	AMNEAL PHARMS	0.02MG; 0.1MG	A 201108	001	Feb 05, 2014	Jan DISC
@		0.03MG; 0.15MG	A 201095	001	Dec 08, 2014	Jan DISC
AB1	HETERO LABS	0.02MG; 0.1MG	A 212298	001	Feb 13, 2023	Feb NEWA
AB	LUPIN LTD	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A 200248	001	Nov 19, 2015	Jan CTEC

ETHINYLMONISTEROLOL; NORETHINDRONE ACETATE**TABLET; ORAL-28****RHUZDAH**

@	AUROBINDO PHARMA	0.035MG; 0.4MG	A 207585	001	Oct 11, 2022	Apr DISC
---	------------------	----------------	----------	-----	--------------	----------

ETHINYLMONISTEROLOL; NORETHINDRONE ACETATE**TABLET; ORAL****HAILEY 24 FE**

AB	!	GLENMARK PHARMS LTD	0.02MG; 1MG	A 204847	001	Nov 17, 2017	Feb CTNA
	MINASTRIN 24 FE						
+ @	APIL	0.02MG; 1MG		N 203667	001	May 08, 2013	Apr DISC
		NORETHINDRONE ACETATE AND ETHINYLMONISTEROLOL AND FERROUS FUMARATE					
AB	!	GLENMARK PHARMS LTD	0.02MG; 1MG	A 210369	001	Dec 26, 2017	Apr CHRS

ETHINYLMONISTEROLOL; NORGESTIMATE**TABLET; ORAL-28****NORGESTIMATE AND ETHINYLMONISTEROLOL**

@	AMNEAL PHARMS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A 203870	001	Nov 12, 2015	Jan DISC	
>D>	AB		0.035MG; 0.25MG	A 203865	001	Oct 27, 2015	Jun DISC
>A>	@	0.035MG; 0.25MG	A 203865	001	Oct 27, 2015	Jun DISC	

ETHINYLMONISTEROLOL; SEGESTERONE ACETATE**RING; VAGINAL****ANNOVERA**

+	!	MAYNE PHARMA	0.013MG/24HR; 0.15MG/24HR	N 209627	001	Aug 10, 2018	Jan CAHN
---	---	--------------	---------------------------	----------	-----	--------------	----------

ETOPOSIDE**INJECTABLE; INJECTION****ETOPOSIDE**

@	DASH PHARMS	20MG/ML	A 204927	001	Oct 31, 2017	Mar CAHN
@	DASH PHARMS NATCO	20MG/ML	A 203507	001	Nov 20, 2017	Feb CAHN

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

AB TEVA PHARMS USA 10MG A210050 004 Dec 09, 2019 Apr CMFD

EXEMESTANE

TABLET;ORAL

EXEMESTANE

@ ALVOGEN

25MG

A200898 001 Jul 28, 2014 Feb DISC

EZETIMIBE

TABLET;ORAL

EZETIMIBE

@ ORIENT PHARMA

10MG

A215693 001 Sep 13, 2022 Mar DISC

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB	ALKEM LABS LTD	40MG/5ML	A216400	001	May 15, 2023	May NEWA
>A>	APPCO	40MG/5ML	A217655	001	Jun 16, 2023	Jun NEWA
>A>	CARNEGIE	40MG/5ML	A217137	001	Jul 07, 2023	Jun NEWA
>D>	! LUPIN LTD	40MG/5ML	A090440	001	Jun 29, 2010	Jun CHRS
>A>		40MG/5ML	A090440	001	Jun 29, 2010	Jun CHRS
>D>	NOVITIUM PHARMA	40MG/5ML	A215043	001	Apr 20, 2021	Jun CHRS
>A>	!	40MG/5ML	A215043	001	Apr 20, 2021	Jun CHRS

INJECTABLE;INJECTION

FAMOTIDINE

@ ZYDUS PHARMS

10MG/ML

A215828 001 Nov 22, 2022 Apr DISC

TABLET;ORAL

FAMOTIDINE

AB	ALKEM LABS LTD	20MG	A217375	001	Apr 24, 2023	Apr NEWA
AB		40MG	A217375	002	Apr 24, 2023	Apr NEWA
AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan CAHN
AB		40MG	A215630	002	Jan 07, 2022	Jan CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

AB ASCENT PHARMS INC 26.6MG;800MG A216814 001 Mar 15, 2023 Mar NEWA

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

>D>	AB MYLAN	80MG	A205385	002	Jul 01, 2019	Jun DISC
>A>	@	80MG	A205385	002	Jul 01, 2019	Jun DISC
AB	ZYDUS LIFESCIENCES	40MG	A205443	001	Jan 09, 2023	Jan CAHN
AB		80MG	A205443	002	Jan 09, 2023	Jan CAHN

FENFLURAMINE HYDROCHLORIDE

SOLUTION;ORAL

FINTEPLA

>A>	+! UCB INC	EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020	Jun CAHN
>D>	+! ZOGENIX INC	EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020	Jun CAHN

FENOPIRIBATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

>D>	+! LUPIN	90MG	N021695	005	Oct 18, 2013	Jun DISC
>A>	+ @	90MG	N021695	005	Oct 18, 2013	Jun DISC

TABLET;ORAL

FENOPIRIBATE

AB	CHARTWELL RX	54MG	A209660	001	Feb 11, 2019	Feb CAHN
AB		160MG	A209660	002	Feb 11, 2019	Feb CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

AB	MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	May NEWA
		EQ 300MG BASE	A215548	002	May 16, 2023	May NEWA
AB		EQ 400MG BASE	A215548	003	May 16, 2023	May NEWA

CAPSULE;ORAL

NALFON

AB + XSPIRE PHARMA EQ 200MG BASE N 017604 003 May CTEC

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB	ZYDUS NOVELTECH INC	100MCG/HR	A 209655	008	Jan 24, 2023	Jan NEWA
>D> AB	ZYDUS PHARMS	100MCG/HR	A 209655	008	Jan 24, 2023	Jun DISC
>A>	@	100MCG/HR	A 209655	008	Jan 24, 2023	Jun DISC
AB		100MCG/HR	A 209655	008	Jan 24, 2023	May CAHN

FENTANYL-12

AB	ZYDUS NOVELTECH INC	12.5MCG/HR	A 209655	001	Jan 24, 2023	Jan NEWA
>D> AB	ZYDUS PHARMS	12.5MCG/HR	A 209655	001	Jan 24, 2023	Jun DISC
>A>	@	12.5MCG/HR	A 209655	001	Jan 24, 2023	Jun DISC
AB		12.5MCG/HR	A 209655	001	Jan 24, 2023	May CAHN

FENTANYL-25

AB	ZYDUS NOVELTECH INC	25MCG/HR	A 209655	002	Jan 24, 2023	Jan NEWA
>D> AB	ZYDUS PHARMS	25MCG/HR	A 209655	002	Jan 24, 2023	Jun DISC
>A>	@	25MCG/HR	A 209655	002	Jan 24, 2023	Jun DISC
AB		25MCG/HR	A 209655	002	Jan 24, 2023	May CAHN

FENTANYL-37

AB	ZYDUS NOVELTECH INC	37.5MCG/HR	A 209655	003	Jan 24, 2023	Jan NEWA
>D> AB	ZYDUS PHARMS	37.5MCG/HR	A 209655	003	Jan 24, 2023	Jun DISC
>A>	@	37.5MCG/HR	A 209655	003	Jan 24, 2023	Jun DISC
AB		37.5MCG/HR	A 209655	003	Jan 24, 2023	May CAHN

FENTANYL-50

AB	ZYDUS NOVELTECH INC	50MCG/HR	A 209655	004	Jan 24, 2023	Jan NEWA
>D> AB	ZYDUS PHARMS	50MCG/HR	A 209655	004	Jan 24, 2023	Jun DISC
>A>	@	50MCG/HR	A 209655	004	Jan 24, 2023	Jun DISC
AB		50MCG/HR	A 209655	004	Jan 24, 2023	May CAHN

FENTANYL-62

AB	ZYDUS NOVELTECH INC	62.5MCG/HR	A 209655	005	Jan 24, 2023	Jan NEWA
>D> AB	ZYDUS PHARMS	62.5MCG/HR	A 209655	005	Jan 24, 2023	Jun DISC
>A>	@	62.5MCG/HR	A 209655	005	Jan 24, 2023	Jun DISC
AB		62.5MCG/HR	A 209655	005	Jan 24, 2023	May CAHN

FENTANYL-75

AB	ZYDUS NOVELTECH INC	75MCG/HR	A 209655	006	Jan 24, 2023	Jan NEWA
>D> AB	ZYDUS PHARMS	75MCG/HR	A 209655	006	Jan 24, 2023	Jun DISC
>A>	@	75MCG/HR	A 209655	006	Jan 24, 2023	Jun DISC
AB		75MCG/HR	A 209655	006	Jan 24, 2023	May CAHN

FENTANYL-87

>D> AB	MYLAN TECHNOLOGIES	87.5MCG/HR	A 076258	008	Dec 29, 2014	Jun CTEC
>A>		87.5MCG/HR	A 076258	008	Dec 29, 2014	Jun CTEC
AB		87.5MCG/HR	A 076258	008	Dec 29, 2014	Jan CTEC
AB	ZYDUS NOVELTECH INC	87.5MCG/HR	A 209655	007	Jan 24, 2023	Jan NEWA
>D> AB	ZYDUS PHARMS	87.5MCG/HR	A 209655	007	Jan 24, 2023	Jun DISC
>A>	@	87.5MCG/HR	A 209655	007	Jan 24, 2023	Jun DISC
AB		87.5MCG/HR	A 209655	007	Jan 24, 2023	May CAHN

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE

AP	+! HIKMA	EQ 0.025MG BASE/0.5ML	N 019101	002	Jan 20, 2023	Jan NEWA
	+!	EQ 0.05MG BASE/ML	N 019101	001	Jul 11, 1984	Jan CTNA

SOLUTION;INTRAVENOUS

FENTANYL CITRATE

+ @ EXELA PHARMA	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N 215870	001	Feb 08, 2023	May DISC
+!	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N 215870	001	Feb 08, 2023	Feb NEWA
+ @	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N 215870	002	Feb 08, 2023	May DISC
+!	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N 215870	002	Feb 08, 2023	Feb NEWA

TABLET;BUCCAL, SUBLINGUAL

FENTANYL CITRATE

@ DR REDDYS LABS SA	EQ 0.1MG BASE	A 206329	001	Aug 22, 2022	Apr CAHN
@	EQ 0.2MG BASE	A 206329	002	Aug 22, 2022	Apr CAHN
@	EQ 0.3MG BASE	A 206329	003	Aug 22, 2022	Apr CAHN
@	EQ 0.4MG BASE	A 206329	004	Aug 22, 2022	Apr CAHN
@	EQ 0.6MG BASE	A 206329	005	Aug 22, 2022	Apr CAHN
@	EQ 0.8MG BASE	A 206329	006	Aug 22, 2022	Apr CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

@ LUPIN LTD	4MG	A204983	001	Jan 05, 2023	Feb DISC
@	8MG	A204983	002	Jan 05, 2023	Feb DISC

FEZOLINETANT

TABLET;ORAL

VEOZAH

+! ASTELLAS	45MG
-------------	------

N216578 001 May 12, 2023 May NEWA

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

+ @ FONSECA BIOSCIENCES	0.3%
-------------------------	------

N206307 001 Dec 17, 2014 Jan CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Jan CMFD
AB BIONPHARMA	EQ 0.5MG BASE	A210252	001	May 24, 2023	May NEWA

FINGOLIMOD LAURYL SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

TASCENSO ODT

+ CYCLE	EQ 0.25MG BASE
+!	EQ 0.5MG BASE

N214962 001 Dec 23, 2021 Jan CAHN
N214962 002 Dec 09, 2022 Jan CAHNFLOTUFOLASTAT F-18 GALLIUM

SOLUTION;INTRAVENOUS

POSLUMA

+! BLUE EARTH	50ML (8-158mCi/ML)
---------------	--------------------

N216023 001 May 25, 2023 May NEWA

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

>D> AP2 ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Jun DISC
>A> @	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Jun DISC
AP2	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Jan CTEC
AP1 AREVA PHARMS	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	Jan CTEC
AP1 FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CTEC
AP	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CHRS
AP1 SAGENT PHARMS INC	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan CTEC
>D> AP2 +! SANDOZ	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jun DISC
>A> + @	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jun DISC
AP2 +!	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jan CTEC

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

@ HIKMA	0.1MG
---------	-------

A216013 001 Oct 27, 2022 Apr DISC

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

@ INVATECH	0.025%
------------	--------

A088045 001 Dec 16, 1982 Mar CAHN

IMPLANT;INTRAVITREAL

YUTIQ

>A> +! ALIMERA SCIENCES INC	0.18MG
>D> +! EYEPOINT PHARMS	0.18MG

N210331 001 Oct 12, 2018 Jun CAHN

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT CHARTWELL RX	0.01%
-----------------	-------

A209596 001 Dec 26, 2017 May CAHN

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB1 ! AMNEAL	0.05%	A210554	001	Aug 21, 2018	Feb CHRS
+ @ TARO	0.05%	N019117	001	Jun 26, 1984	Feb DISC

	GEL;TOPICAL FLUOCINONIDE @ PAI HOLDINGS PHARM	0.05%	A209030	001	Jun 19, 2018	May DISC
	OINTMENT;TOPICAL FLUOCINONIDE AB CHARTWELL RX	0.05%	A207538	001	Jul 31, 2017	Apr CAHN
	SOLUTION;TOPICAL FLUOCINONIDE AT CHARTWELL RX	0.05%	A209118	001	Apr 23, 2018	May CAHN
	@ PAI HOLDINGS PHARM	0.05%	A207554	001	Mar 18, 2019	May DISC
	FLUOROMETHOLONE					
	SUSPENSION/DROPS;OPHTHALMIC FML +! ABBVIE FML FORTE	0.1%	N016851	002	Jul 28, 1982	Jan CAHN
	+! ABBVIE	0.25%	N019216	001	Apr 23, 1986	Jan CAHN
	FLUOROURACIL					
	INJECTABLE;INJECTION FLUOROURACIL AP ALEMBIC	2.5GM/50ML (50MG/ML)	A217295	001	Mar 03, 2023	Feb NEWA
	FLUOXETINE HYDROCHLORIDE					
	SOLUTION;ORAL FLUOXETINE HYDROCHLORIDE AA NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Mar CMFD
	AA XTRIUM LABS INC	EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002	Jan CAHN
	TABLET;ORAL FLUOXETINE HYDROCHLORIDE @ PIRAMAL HLTHCARE UK	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar DISC
	@	EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar DISC
	FLUPHENAZINE DECANOATE					
	INJECTABLE;INJECTION FLUPHENAZINE DECANOATE AO GLAND PHARMA LTD	25MG/ML	A215509	001	Mar 30, 2023	Mar NEWA
	FLUPHENAZINE HYDROCHLORIDE					
	TABLET;ORAL FLUPHENAZINE HYDROCHLORIDE >D> AB AJANTA PHARMA LTD	1MG	A217410	001	Jan 05, 2023	Jun DISC
	>A> @	1MG	A217410	001	Jan 05, 2023	Jun DISC
	>D> AB	2.5MG	A217410	002	Jan 05, 2023	Jun DISC
	>A> @	2.5MG	A217410	002	Jan 05, 2023	Jun DISC
	>D> AB	5MG	A217410	003	Jan 05, 2023	Jun DISC
	>A> @	5MG	A217410	003	Jan 05, 2023	Jun DISC
	>D> AB	10MG	A217410	004	Jan 05, 2023	Jun DISC
	>A> @	10MG	A217410	004	Jan 05, 2023	Jun DISC
	@ PRASCO	1MG	A089804	002	Aug 12, 1988	Apr DISC
	@	2.5MG	A089804	003	Aug 12, 1988	Apr DISC
	@	5MG	A089804	004	Aug 12, 1988	Apr DISC
	@	10MG	A089804	001	Aug 12, 1988	Apr DISC
	FLURANDRENOLIDE					
	LOTION;TOPICAL CORDRAN + @ ALMIRALL FLURANDRENOLIDE	0.05%	N013790	001		May DISC
	! PADAGIS ISRAEL	0.05%	A207133	001	Aug 30, 2016	May CTEC
	AT !	0.05%	A207133	001	Aug 30, 2016	May CHRS
	OINTMENT;TOPICAL CORDRAN + @ ALMIRALL FLURANDRENOLIDE	0.05%	N012806	001		May DISC
	! TELIGENT	0.05%	A207851	001	Dec 30, 2016	May CTEC
	AT !	0.05%	A207851	001	Dec 30, 2016	May CHRS

FLUTICASONE FUROATE; VILANEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

+ GLAXO GRP LTD

0.05MG/INH; EQ 0.025MG BASE/INH

N204275 003 May 12, 2023 May NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

LUVOX

AB + ANI PHARMS

25MG

N021519 001 Dec 20, 2007 Jan CRLD

AB +

50MG

N021519 002 Dec 20, 2007 Jan CRLD

AB +

100MG

N021519 003 Dec 20, 2007 Jan CRLD

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

>A> AP GLAND PHARMA LTD

1.5GM/1.5ML (1GM/ML)

A216791 001 Jul 06, 2023 Jun NEWA

FORMOTEROL FUMARATE

SOLUTION; INHALATION

FORMOTEROL FUMARATE

AN MANKIND PHARMA

0.02MG/2ML

A215883 001 Mar 22, 2023 Mar NEWA

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

AP PIRAMAL CRITICAL

EQ 150MG BASE/VIAL

A214683 001 May 16, 2023 May NEWA

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

AP AVET LIFESCIENCES

2.4GM/100ML

A213807 001 Jun 05, 2023 May NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ MYLAN LABS LTD

EQ 50MG PHENYTOIN NA/ML

A078736 001 Jun 08, 2010 Apr DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

@ MYLAN

EQ 2.5MG BASE

A202931 001 Aug 28, 2014 Apr DISC

FULVESTRANT

SOLUTION; INTRAMUSCULAR

FULVESTRANT

>A> AO EUGIA PHARMA

250MG/5ML (50MG/ML)

A215169 001 Jun 30, 2023 Jun NEWA

FUROSEMIDE

SOLUTION; ORAL

FUROSEMIDE

@ XTRIUM LABS INC

10MG/ML

A070655 001 Oct 02, 1987 Jan CAHN

TABLET; ORAL

FUROSEMIDE

@ CHARTWELL RX

20MG

N018413 001 Nov 30, 1983 Mar CAHN

@

40MG

N018413 002 Nov 30, 1983 Mar CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB LAURUS

100MG

A217546 001 May 12, 2023 May NEWA

AB

300MG

A217546 002 May 12, 2023 May NEWA

AB

400MG

A217546 003 May 12, 2023 May NEWA

SOLUTION; ORAL

GABAPENTIN

AA RUBICON

250MG/5ML

A216492 001 Jan 18, 2023 Jan NEWA

TABLET; ORAL

GABAPENTIN

@ CHARTWELL RX

600MG

A076120 001 Jan 27, 2006 May CAHN

@

800MG

A076120 002 Jan 27, 2006 May CAHN

AB GRANULES

600MG

A217116 001 Mar 28, 2023 Mar NEWA

	TABLET;ORAL GABAPENTIN	800MG	A217116	002	Mar 28, 2023	Mar NEWA
AB	<u>GADOBUTROL</u> SOLUTION;INTRAVENOUS GADOBUTROL					
AP	HAINAN POLY PHARM	4.5354GM/7.5ML (604.72MG/ML)	A217480	001	Mar 15, 2023	Mar NEWA
AP		9.0708GM/15ML (604.72MG/ML)	A217480	002	Mar 15, 2023	Mar NEWA
	<u>GADOTERATE MEGLUMINE</u> SOLUTION;INTRAVENOUS GADOTERATE MEGLUMINE					
AP	HENGRUI PHARMA	37.69GM/100ML (376.9MG/ML)	A215304	005	Apr 15, 2022	Feb CMS1
	<u>GANIRELIX ACETATE</u> INJECTABLE;INJECTION GANIRELIX ACETATE					
AP	GLAND PHARMA LTD	250MCG/0.5ML	A215658	001	Feb 28, 2023	Feb NEWA
AP	+! ORGANON USA ORGANON	250MCG/0.5ML	N021057	001	Jul 29, 1999	May CAHN
	<u>GATIFLOXACIN</u> SOLUTION/DROPS;OPHTHALMIC ZYMAR					
	+ @ ALLERGAN ZYMAXID	0.3%	N021493	001	Mar 28, 2003	Mar DISC
AT	+! ABBVIE	0.5%	N022548	001	May 18, 2010	Jan CAHN
	<u>GEFITINIB</u> TABLET;ORAL GEFITINIB					
AB	ACTAVIS LABS FL INC	250MG	A208913	001	Apr 26, 2023	Apr NEWA
AB	NATCO	250MG	A212827	001	May 31, 2023	May NEWA
AB	QILU PHARM HAINAN	250MG	A211591	001	Feb 13, 2023	Feb NEWA
	<u>GEMCITABINE HYDROCHLORIDE</u> INJECTABLE;INJECTION GEMCITABINE HYDROCHLORIDE					
AP	HIKMA	200MG/5.26ML (38MG/ML)	A213175	001	Mar 07, 2023	Feb NEWA
AP		1GM/26.3ML (38MG/ML)	A213175	002	Mar 07, 2023	Feb NEWA
AP		2GM/52.6ML (38MG/ML)	A213175	003	Mar 07, 2023	Feb NEWA
>D>	@ NOVAST LABS	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Jun CMFD
>A> AP		200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Jun CMFD
>D>	@	1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Jun CMFD
>A> AP		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Jun CMFD
>D>	@	2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Jun CMFD
>A> AP		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Jun CMFD
	<u>GENTAMICIN SULFATE</u> OINTMENT;OPHTHALMIC GENTAMICIN SULFATE					
	@ AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995	Feb DISC
	! FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb CTEC
AT	!	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb CHRS
	OINTMENT;TOPICAL GENTAMICIN SULFATE					
	@ PAI HOLDINGS PHARM	EQ 0.1% BASE	A209233	001	Dec 31, 2018	May DISC
	SOLUTION/DROPS;OPHTHALMIC GENOPTIC					
	@ ALLERGAN GENTAK	EQ 0.3% BASE	A062452	001	Oct 10, 1984	Feb DISC
	@ AKORN GENTAMICIN SULFATE	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb DISC
AT	! SANDOZ	EQ 0.3% BASE	A062196	001		Feb CHRS
	<u>GENTAMICIN SULFATE; PREDNISOLONE ACETATE</u> OINTMENT;OPHTHALMIC PRED-G					
	+ @ ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989	Jan DISC

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS

COPAXONE

>D>	@ TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996	Jun CRLD
>A>	+ @	20MG/VIAL	N020622	001	Dec 20, 1996	Jun CRLD

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

@ DASH PHARMS	2.5MG;250MG	A078083	001	Apr 12, 2007	Feb CAHN
@	2.5MG;500MG	A078083	002	Apr 12, 2007	Feb CAHN
@	5MG;500MG	A078083	003	Apr 12, 2007	Feb CAHN

GLUCAGON

SOLUTION;SUBCUTANEOUS

GVOKE KIT

+! XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	005	Aug 20, 2021	May NEWA
+ @ XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019	Jan DISC

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

+! HORIZON THERAP US	1.1GM/ML	N203284	001	Feb 01, 2013	Jan CAHN
----------------------	----------	---------	-----	--------------	----------

GLCOPYRROLATE

INJECTABLE;INJECTION

GLCOPYRROLATE

AP	@ LUPIN LTD	0.2MG/ML	A213655	001	Feb 07, 2023	Apr DISC
AP	MANKIND PHARMA	0.2MG/ML	A213655	001	Feb 07, 2023	Jan NEWA
	TABLET;ORAL		A217354	001	Feb 27, 2023	Feb NEWA
	GLCOPYRROLATE					
AA	ALEMBIC	1MG	A203657	001	Nov 30, 2018	Feb CAHN
AA		2MG	A203657	002	Nov 30, 2018	Feb CAHN
AA	AUROBINDO PHARMA	1MG	A202675	001	Apr 15, 2013	Jan CAHN
AA		2MG	A202675	002	Oct 30, 2018	Jan CAHN
>D>	TABLET, ORALLY DISINTEGRATING;ORAL					
>D>	DARTISLA ODT					
>D>	+! EDENBRIDGE PHARMS	1.7MG	N215019	001	Dec 16, 2021	Jun DISC
>A>	+ @	1.7MG	N215019	001	Dec 16, 2021	Jun DISC

GLCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

PREVDUO

+! SLAYBACK PHARMA LLC	0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb NEWA
------------------------	------------------------------------------	---------	-----	--------------	----------

GRANISETRON HYDROCHLORIDE

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

AB	@ AUROBINDO PHARMA USA	EQ 1MG BASE	A078725	001	Jan 30, 2008	May CAHN
AB		EQ 2MG BASE				

HALCINONIDE

CREAM;TOPICAL

HALCINONIDE

AB	CHARTWELL RX	0.1%	A214723	001	Sep 08, 2021	May CAHN
----	--------------	------	---------	-----	--------------	----------

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

@ PAI HOLDINGS PHARM	0.05%	A209978	001	Mar 20, 2018	May DISC
----------------------	-------	---------	-----	--------------	----------

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

@ ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022	Jan DISC
@	1MG	A200854	002	Jul 01, 2022	Jan DISC
@	2MG	A200854	003	Jul 01, 2022	Jan DISC
@	5MG	A200854	004	Jul 01, 2022	Jan DISC
@	10MG	A200854	005	Jul 01, 2022	Jan DISC
@	20MG	A200854	006	Jul 01, 2022	Jan DISC
AB ZYDUS PHARMS USA	0.5MG	A077580	001	Jan 17, 2023	Jan NEWA
AB	1MG	A077580	002	Jan 17, 2023	Jan NEWA
AB	2MG	A077580	006	Jan 17, 2023	Jan NEWA

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

AO MANKIND PHARMA	EQ 50MG BASE/ML	A216730	001	May 23, 2023	May NEWA
AO	EQ 100MG BASE/ML	A216730	002	May 23, 2023	May NEWA

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020	Feb CMFD
AP NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Feb CMFD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP EUGIA PHARMA	20MG/ML	A215147	001	Feb 13, 2023	Feb NEWA
Q MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	May DISC
TABLET;ORAL					
HYDRALAZINE HYDROCHLORIDE					
AA HERITAGE PHARMS INC					
AA 10MG					
AA 25MG					
AA 50MG					
AA 100MG					

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB HERITAGE PHARMS	12.5MG	A085182	003	May 02, 2023	Apr NEWA
--------------------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

>D> AB INVAGEN PHARMS	12.5MG;20MG	A204058	002	May 23, 2017	Jun CHRS
>A> AB !	12.5MG;20MG	A204058	002	May 23, 2017	Jun CHRS
>D> AB	25MG;20MG	A204058	003	May 23, 2017	Jun CHRS
>A> AB !	25MG;20MG	A204058	003	May 23, 2017	Jun CHRS
ZESTORETIC					
>D> AB +! ALMATICA	12.5MG;20MG	N019888	001	Sep 20, 1990	Jun CHRS
>A> AB +	12.5MG;20MG	N019888	001	Sep 20, 1990	Jun CHRS
>D> AB +!	25MG;20MG	N019888	002	Jul 20, 1989	Jun CHRS
>A> AB +	25MG;20MG	N019888	002	Jul 20, 1989	Jun CHRS

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB MACLEODS PHARMS LTD	12.5MG;20MG	A204801	001	Jun 01, 2023	May NEWA
	12.5MG;40MG	A204801	002	Jun 01, 2023	May NEWA
	25MG;40MG	A204801	003	Jun 01, 2023	May NEWA
AB ZYDUS PHARMS	12.5MG;20MG	A206377	001	Feb 24, 2023	Feb NEWA
AB	12.5MG;40MG	A206377	002	Feb 24, 2023	Feb NEWA
AB	25MG;40MG	A206377	003	Feb 24, 2023	Feb NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX	12.5MG; EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan CAHN
AB		12.5MG; EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan CAHN
AB		25MG; EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan CAHN
@	CHARTWELL RX	12.5MG; EQ 10MG BASE	A076374	001	Mar 31, 2004	Apr CAHN
@		12.5MG; EQ 20MG BASE	A076374	002	Mar 31, 2004	Apr CAHN
@		25MG; EQ 20MG BASE	A076374	003	Mar 31, 2004	Apr CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

AP	HIKMA	2MG/ML	A202159	001	Apr 27, 2018	May CAHN
	HOSPIRA INC	0.25MG/0.5ML	N200403	005	Mar 03, 2023	Mar NEWA
		4MG/ML	N200403	003	Dec 01, 2011	Apr CTEC

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+ @ AKORN 1%; 0.25%

N019261 001 Jan 30, 1992 Feb DISC

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	CHARTWELL RX	200MG	A210543	001	Jul 06, 2018	May CAHN
----	--------------	-------	---------	-----	--------------	----------

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+! BAUSCH 5MG
+! BAUSCH AND LOMB INC 5MGN018771 001 Jan CAHN
N018771 001 Jan CAHNHYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

+! AM REGENT 25MG/ML
+! 50MG/MLA087408 001 Feb CRLD
A087408 002 Feb CRLD

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB	CHARTWELL RX	10MG	A040804	001	Jun 30, 2008	Jan CAHN
AB		25MG	A040804	002	Jun 30, 2008	Jan CAHN
AB		50MG	A040804	003	Jun 30, 2008	Jan CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar CTEC
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar CTEC

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

>D>	+ PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017	Jun CAHN
>D>	+!	140MG	N205552	001	Nov 13, 2013	Jun CAHN
>A>	+ PHARMACYCLICS LLC	70MG	N205552	002	Dec 20, 2017	Jun CAHN
>A>	+!	140MG	N205552	001	Nov 13, 2013	Jun CAHN

SUSPENSION; ORAL

IMBRUVICA

>D>	+! PHARMACYCLICS INC	70MG/ML	N217003	001	Aug 24, 2022	Jun CAHN
>A>	+! PHARMACYCLICS LLC	70MG/ML	N217003	001	Aug 24, 2022	Jun CAHN

TABLET; ORAL

IMBRUVICA

>D>	+ PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018	Jun CAHN
>D>	+	280MG	N210563	002	Feb 16, 2018	Jun CAHN
>D>	+	420MG	N210563	003	Feb 16, 2018	Jun CAHN
>D>	+!	560MG	N210563	004	Feb 16, 2018	Jun CAHN
>A>	+ PHARMACYCLICS LLC	140MG	N210563	001	Feb 16, 2018	Jun CAHN
>A>	+	280MG	N210563	002	Feb 16, 2018	Jun CAHN
>A>	+	420MG	N210563	003	Feb 16, 2018	Jun CAHN
>A>	+!	560MG	N210563	004	Feb 16, 2018	Jun CAHN

ICOSAPENT ETHYL

CAPSULE;ORAL	ICOSAPENT ETHYL						
AB	DR REDDYS	500MG		A209499	002	Mar 08, 2023	Feb NEWA
AB	HIKMA	500MG		A209457	002	Mar 08, 2023	Feb NEWA
AB	ZYDUS	500MG		A217656	001	Apr 20, 2023	Apr NEWA
AB		1GM		A217656	002	Apr 20, 2023	Apr NEWA

IMATINIB MESYLATE

TABLET;ORAL	IMATINIB MESYLATE						
>D> AB	@ BRECKENRIDGE	EQ 100MG BASE		A205990	001	Feb 08, 2019	Mar DISC
>A>		EQ 400MG BASE		A205990	002	Feb 08, 2019	Jun DISC
AB	@	EQ 400MG BASE		A205990	002	Feb 08, 2019	Jun DISC
AB	CHARTWELL RX	EQ 100MG BASE		A208429	001	Jan 17, 2019	Jan CAHN
AB		EQ 400MG BASE		A208429	002	Jan 17, 2019	Jan CAHN

IMIQUIMOD

CREAM;TOPICAL	IMIQUIMOD						
ALDARA							
+ @ BAUSCH	5%			N020723	001	Feb 27, 1997	Feb DISC
IMIQUIMOD							
AB	! GLENMARK GENERICS	5%		A201994	001	Mar 06, 2012	Feb CHRS

INDAPAMIDE

TABLET;ORAL	INDAPAMIDE						
@ AUROBINDO PHARMA USA	1.25MG			A075105	001	Jul 23, 1998	Apr CAHN
@	2.5MG			A075105	002	Jul 23, 1998	Apr CAHN

INDOMETHACIN

CAPSULE;ORAL	INDOMETHACIN						
AB	CHARTWELL MOLECULES	25MG		N018829	002	Aug 06, 1984	Feb CMFD
AB		50MG		N018829	001	Aug 06, 1984	Feb CMFD
SUSPENSION;ORAL							
INDOCIN							
>D>	+! EGALET	25MG/5ML		N018332	001	Oct 10, 1985	Jun CAHN
>A>	+! ZYLA	25MG/5ML		N018332	001	Oct 10, 1985	Jun CAHN

INFIGRATINIB PHOSPHATE

CAPSULE;ORAL	INFIGRATINIB PHOSPHATE						
TRUSELTIQ							
+ @ HELSINN HLTHCARE	25MG			N214622	001	May 28, 2021	Apr DISC
+ @	100MG			N214622	002	May 28, 2021	Apr DISC

IOPAMIDOL

INJECTABLE;INJECTION	IOPAMIDOL						
AP	HAINAN POLY	41%		A215382	001	Feb 27, 2023	Feb NEWA
AP		61%		A215382	002	Feb 27, 2023	Feb NEWA
>D>	ISOVUE-250						
>D>	+! BRACCO	51%		N020327	002	Oct 12, 1994	Jun DISC
>A>	+ @	51%		N020327	002	Oct 12, 1994	Jun DISC
	ISOVUE-M 200						
AP	+! BRACCO	41%		N018735	001	Dec 31, 1985	Feb CTEC
	ISOVUE-M 300						
AP	+! BRACCO	61%		N018735	004	Dec 31, 1985	Feb CTEC

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL	IPRATROPIUM BROMIDE						
@ AUROBINDO PHARMA USA	0.021MG/SPRAY			A075552	001	Mar 31, 2003	Apr CAHN
@	0.042MG/SPRAY			A075553	001	Mar 31, 2003	Apr CAHN

IRBESARTAN

TABLET;ORAL
IRBESARTAN

>D>	@ UNICHEM	75MG	A203020	001	Dec 07, 2015	Jun CMFD
>A> AB		75MG	A203020	001	Dec 07, 2015	Jun CMFD
>D>	@	150MG	A203020	002	Dec 07, 2015	Jun CMFD
>A> AB		150MG	A203020	002	Dec 07, 2015	Jun CMFD
>D>	@	300MG	A203020	003	Dec 07, 2015	Jun CMFD
>A> AB		300MG	A203020	003	Dec 07, 2015	Jun CMFD

ISONIAZID

TABLET;ORAL
LANIAZID

@ CHARTWELL MOLECULAR	50MG	A080140	001	Feb CAHN
@	100MG	A080140	002	Feb CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP	@ AM REGENT	0.2MG/ML	A214775	001	Oct 19, 2022	Apr DISC
>D> AP	HIKMA	0.2MG/ML	A211703	001	Apr 26, 2023	Apr NEWA
>A> AP	NEXUS PHARMS	0.2MG/ML	A206961	001	Aug 02, 2017	Jun CHRS
>A> AP	!	0.2MG/ML	A206961	001	Aug 02, 2017	Jun CHRS
AP	PENN LIFE	0.2MG/ML	A215542	001	Sep 20, 2022	May CAHN
AP	ZYDUS PHARMS	0.2MG/ML	A215557	001	Apr 14, 2023	Apr NEWA
	ISUPREL					
>D> AP	+! BAUSCH	0.2MG/ML	N010515	001		Jun DISC
>A>	+ @	0.2MG/ML	N010515	001		Jun DISC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL
ISOSORBIDE MONONITRATE

@ SHANDONG	120MG	A214115	001	Apr 29, 2022	May DISC
------------	-------	---------	-----	--------------	----------

ISOSULFAN BLUE

INJECTABLE; INJECTION
ISOSULFAN BLUE

AP	AM REGENT	1%	A210294	001	May 17, 2023	May NEWA
----	-----------	----	---------	-----	--------------	----------

ISOTRETINOIN

CAPSULE;ORAL
MYORISAN

AB1	UPSHER SMITH LABS	10MG	A076485	001	Jan 19, 2012	May CAHN
AB1		20MG	A076485	002	Jan 19, 2012	May CAHN
AB1		30MG	A076485	004	Aug 25, 2015	May CAHN
AB1		40MG	A076485	003	Jan 19, 2012	May CAHN

IVACAFTOR

GRANULE;ORAL
KALYDECO

+	VERTEX PHARMS INC	5.8MG/PACKET	N207925	004	May 03, 2023	May NEWA
+		13.4MG/PACKET	N207925	005	May 03, 2023	May NEWA

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETAMINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jan NEWA
AP		EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jan NEWA
AP	GLAND PHARMA LTD	EQ 50MG BASE/ML	A216809	002	Jan 24, 2023	Jan NEWA
AP		EQ 100MG BASE/ML	A216809	003	Jan 24, 2023	Jan NEWA

KETOCONAZOLE

TABLET;ORAL
KETOCONAZOLE

@ AUROBINDO PHARMA USA	200MG	A075597	001	Dec 23, 1999	May CAHN
------------------------	-------	---------	-----	--------------	----------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>A>	AP	ASPIRO	15MG/ML	A217166	001	Jun 20, 2023	Jun NEWA
>A>	AP		30MG/ML	A217166	002	Jun 20, 2023	Jun NEWA
	AP	CAPLIN	15MG/ML	A217789	001	May 10, 2023	Apr NEWA
	AP		30MG/ML	A217789	002	May 10, 2023	Apr NEWA
		SOLUTION/DROPS; OPHTHALMIC ACULAR					
AT	+!	ABBVIE KETOROLAC TROMETHAMINE	0.5%	N019700	001	Nov 09, 1992	Jan CAHN
	@	AKORN	0.5%	A078434	001	Nov 05, 2009	Jan DISC
		TABLET; ORAL					
		KETOROLAC TROMETHAMINE					
AB	BIONPHARMA	10MG		A216759	001	Feb 23, 2023	Feb NEWA
AB	LEADING	10MG		A215745	001	Feb 23, 2023	Feb NEWA

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS; OPHTHALMIC

ACUVUE THERAVISION WITH KETOTIFEN

+ @ JOHNSON JOHNSON VISN EQ 19MCG BASE

N022388 001 Feb 25, 2022 May DISC

LACOSAMIDECAPSULE, EXTENDED RELEASE; ORAL
MOTPOLY XR

+	AUCTA	100MG	N216185	001	May 04, 2023	May NEWA
+		150MG	N216185	002	May 04, 2023	May NEWA
+		200MG	N216185	003	May 04, 2023	May NEWA

SOLUTION; INTRAVENOUS
LACOSAMIDE

AP	MSN	200MG/20ML (10MG/ML)	A215979	001	Feb 09, 2023	Feb NEWA

SOLUTION; ORAL
LACOSAMIDE

AA	MEDLEY PHARMS	10MG/ML	A216461	001	Feb 06, 2023	Jan NEWA

LACTULOSESOLUTION; ORAL
LACTULOSE

AA	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Mar CMFD

SOLUTION; ORAL, RECTAL
LACTULOSE

AA	BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Feb CMFD
----	-------	-----------	---------	-----	--------------	----------

LAMIVUDINETABLET; ORAL
LAMIVUDINE

@ AUROBINDO PHARMA USA 100MG

A204002 001 Dec 31, 2014 May CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TEMIXYS

+ @ CHARTWELL RX 300MG; 300MG

N211284 001 Nov 16, 2018 Mar CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@	CHARTWELL MOLECULAR	25MG	A077783	001	Nov 01, 2010	Jan CAHN
@		100MG	A077783	002	Nov 01, 2010	Jan CAHN
@		150MG	A077783	003	Nov 01, 2010	Jan CAHN
@		200MG	A077783	004	Nov 01, 2010	Jan CAHN

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

AB	AUROBINDO PHARMA LTD	15MG	A207167	001	Mar 28, 2023	Mar NEWA
AB		30MG	A207167	002	Mar 28, 2023	Mar NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST
@ AKORN 0.005%

A090887 001 Jul 19, 2011 Jan DISC

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC
ROCKLATAN
+! ALCON LABS INC 0.005%;EQ 0.02% BASE

N208259 001 Mar 12, 2019 May CAHN

LENALIDOMIDE

CAPSULE;ORAL
LENALIDOMIDE

AB	APOTEX	2.5MG	A211022	005	Mar 07, 2023	Feb NEWA
AB		20MG	A211022	006	Mar 07, 2023	Feb NEWA
AB	ARROW INTL	2.5MG	A201452	005	Mar 06, 2023	Feb NEWA
AB		20MG	A201452	006	Mar 06, 2023	Feb NEWA
AB	CIPLA	2.5MG	A214618	001	Mar 06, 2023	Feb NEWA
AB		20MG	A210435	005	Mar 06, 2023	Feb NEWA
AB	EUGIA PHARMA	2.5MG	A213885	001	Mar 06, 2023	Feb NEWA
AB		5MG	A213885	002	Mar 06, 2023	Feb NEWA
AB		10MG	A213885	003	Mar 06, 2023	Feb NEWA
AB		15MG	A213885	004	Mar 06, 2023	Feb NEWA
AB		20MG	A213885	005	Mar 06, 2023	Feb NEWA
AB		25MG	A213885	006	Mar 06, 2023	Feb NEWA
AB	HETERO LABS LTD V	2.5MG	A212414	001	May 11, 2023	May NEWA
AB		5MG	A212414	002	May 11, 2023	May NEWA
AB		10MG	A212414	003	May 11, 2023	May NEWA
AB		15MG	A212414	004	May 11, 2023	May NEWA
AB		20MG	A212414	005	May 11, 2023	May NEWA
AB		25MG	A212414	006	May 11, 2023	May NEWA
AB	LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023	Feb NEWA
AB		20MG	A210480	006	Mar 06, 2023	Feb NEWA
AB	MYLAN	2.5MG	A213912	005	Mar 06, 2023	Feb NEWA
AB		20MG	A213912	006	Mar 06, 2023	Feb NEWA
AB	SUN PHARM	2.5MG	A211846	005	Mar 06, 2023	Feb NEWA
AB		5MG	A211846	001	Feb 08, 2023	Jan NEWA
AB		10MG	A211846	002	Feb 08, 2023	Jan NEWA
AB		15MG	A211846	003	Feb 08, 2023	Jan NEWA
AB		20MG	A211846	006	Mar 06, 2023	Feb NEWA
AB		25MG	A211846	004	Feb 08, 2023	Jan NEWA
AB	TORRENT	10MG	A213405	001	Feb 17, 2023	Feb NEWA
AB		25MG	A213405	002	Feb 17, 2023	Feb NEWA
AB	ZYDUS PHARMS	2.5MG	A210154	005	Mar 06, 2023	Feb NEWA
AB		20MG	A210154	006	Mar 06, 2023	Feb NEWA

LENIOLISIB PHOSPHATE

TABLET;ORAL
JOENJA
+! PHARMING EQ 70MG BASE

N217759 001 Mar 24, 2023 Mar NEWA

LETROZOLE

TABLET;ORAL
LETROZOLE
@ CHARTWELL RX 2.5MG

A202716 001 May 16, 2013 Feb CAHN

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr CHRS
!		EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr CTEC
!		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Apr CHRS
>A> AP	HAINAN POLY	EQ 50MG BASE/VIAL	A217021	001	Jul 10, 2023	Jun NEWA
>A> AP		EQ 100MG BASE/VIAL	A217021	002	Jul 10, 2023	Jun NEWA
>A> AP		EQ 200MG BASE/VIAL	A217021	003	Jul 10, 2023	Jun NEWA
>A> AP		EQ 500MG BASE/VIAL	A217021	004	Jul 10, 2023	Jun NEWA

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE
© HIKMA EQ 10MG BASE/ML

A040347 001 Apr 25, 2000 Apr DISC

LEUPROLIDE ACETATEINJECTABLE; INJECTION
LEUPROLIDE ACETATE

>A> AP	RK PHARMA	1MG/0.2ML	A213829	001	Aug 13, 2021	Jun CAHN
>D> AP	VGYAAN	1MG/0.2ML	A213829	001	Aug 13, 2021	Jun CAHN
	POWDER; INTRAMUSCULAR LUPRON DEPOT-PED KIT					
+! ABBVIE ENDOCRINE INC	45MG		N020263	009	Apr 14, 2023	Apr NEWA
	POWDER; SUBCUTANEOUS ELIGARD KIT					
+! TOLMAR	7.5MG		N021343	001	Jan 23, 2002	Feb CAHN
+!	22.5MG		N021379	001	Jul 24, 2002	Feb CAHN
+!	30MG		N021488	001	Feb 13, 2003	Feb CAHN
+!	45MG		N021731	001	Dec 14, 2004	Feb CAHN

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM IN SODIUM CHLORIDE

AP	FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Jan NEWA
AP		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Jan NEWA
	SOLUTION; ORAL LEVETIRACETAM					
AA	ALEMBIC	100MG/ML	A203067	001	May 09, 2013	Feb CAHN
>A> AA	BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	Jun CAHN
>D> AA	BRECKENRIDGE	100MG/ML	A079120	001	Jan 16, 2009	Jun CAHN
AA	QUAGEN	100MG/ML	A090079	001	Apr 11, 2012	Feb CAHN
	© XTTRIUM LABS INC	100MG/ML	A090028	001	Mar 03, 2010	Mar CAHN
	TABLET; ORAL LEVETIRACETAM					
>A> AB	GRANULES	250MG	A217878	001	Jun 13, 2023	Jun NEWA
>A> AB		500MG	A217878	002	Jun 13, 2023	Jun NEWA
>A> AB		750MG	A217878	003	Jun 13, 2023	Jun NEWA
>A> AB		1GM	A217878	004	Jun 13, 2023	Jun NEWA
	© MYLAN	250MG	A076919	001	Nov 04, 2008	Apr DISC
	TABLET, EXTENDED RELEASE; ORAL LEVETIRACETAM					
	© AUROBINDO PHARMA USA	500MG	A200475	001	Dec 19, 2011	Apr CAHN
	©	750MG	A200475	002	Dec 19, 2011	Apr CAHN
	©	1GM	A200475	003	Dec 07, 2015	Apr CAHN
AB	OVERSEAS	500MG	A212688	002	May 05, 2023	Apr NEWA

LEVOFLOXACINSOLUTION/DROPS; OPHTHALMIC
LEVOFLOXACIN

© AKORN	0.5%	A090268	001	Dec 20, 2010	Jan DISC
! RISING	0.5%	A077700	001	Dec 20, 2010	Jan CTEC

LEVOLEUCOVORIN CALCIUMSOLUTION; INTRAVENOUS
LEVOLEUCOVORIN CALCIUM

AP	! GLAND PHARMA LTD	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	May CTEC
AP	HAINAN POLY PHARM	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A217314	001	May 22, 2023	May NEWA
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A217314	002	May 22, 2023	May NEWA

LEVOMILNACIPRAN HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
FETZIMA

AB	+	ABBVIE	EQ 20MG BASE	N204168	001	Jul 25, 2013	Mar CTEC
	+		EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CAHN
	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Mar CTEC
AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CAHN
	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Mar CTEC
AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CAHN
	+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Mar CTEC
AB	+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CAHN

CAPSULE, EXTENDED RELEASE;ORAL

LEVOMILNACIPRAN HYDROCHLORIDE

@	AUROBINDO PHARMA LTD	EQ 20MG BASE	A210826	001	Jan 06, 2023	Mar DISC
@		EQ 40MG BASE	A210826	002	Jan 06, 2023	Mar DISC
@		EQ 80MG BASE	A210826	003	Jan 06, 2023	Mar DISC
@		EQ 120MG BASE	A210826	004	Jan 06, 2023	Mar DISC
AB	PRINSTON INC	EQ 20MG BASE	A210771	001	Mar 20, 2023	Mar NEWA
AB		EQ 40MG BASE	A210771	002	Mar 20, 2023	Mar NEWA
AB		EQ 80MG BASE	A210771	003	Mar 20, 2023	Mar NEWA
AB		EQ 120MG BASE	A210771	004	Mar 20, 2023	Mar NEWA

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

AB	HIKMA	2MG	A074278	001	Mar 31, 2000	Jan CMFD
AB	! NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Apr CTEC
AB	SUN PHARM INDs INC	3MG	A213906	002	Apr 25, 2023	Apr NEWA

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

AB	@ TEVA PHARMS USA INC	0.137MG	A211369	005	May 02, 2023	May DISC
	@	0.137MG	A211369	005	May 02, 2023	Apr NFTG
AB	@	0.175MG	A211369	006	May 02, 2023	May DISC
	@	0.175MG	A211369	006	May 02, 2023	Apr NFTG
	TIROSINT	0.2MG	A211369	004	Nov 09, 2022	May DISC
AB	+ INSTITUT BIOCHIMIQUE	0.137MG	N021924	009	Oct 02, 2009	May CTEC
AB	+	0.137MG	N021924	009	Oct 02, 2009	Apr CFTG
	+	0.175MG	N021924	011	Apr 25, 2017	May CTEC
AB	+	0.175MG	N021924	011	Apr 25, 2017	Apr CFTG
	+!	0.2MG	N021924	012	Apr 25, 2017	May CTEC
	POWDER; INTRAVENOUS					
	LEVOTHYROXINE SODIUM					
AP	ZYDUS PHARMS	100MCG/VIAL	A217066	001	Mar 24, 2023	Mar NEWA
AP		200MCG/VIAL	A217066	002	Mar 24, 2023	Mar NEWA
AP		500MCG/VIAL	A217066	003	Mar 24, 2023	Mar NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB4	ASCENT PHARMS INC	0.025MG	A215259	001	Jan 18, 2023	Jan NEWA
AB4		0.05MG	A215259	002	Jan 18, 2023	Jan NEWA
AB4		0.075MG	A215259	003	Jan 18, 2023	Jan NEWA
AB4		0.088MG	A215259	004	Jan 18, 2023	Jan NEWA
AB4		0.1MG	A215259	005	Jan 18, 2023	Jan NEWA
AB4		0.112MG	A215259	006	Jan 18, 2023	Jan NEWA
AB4		0.125MG	A215259	007	Jan 18, 2023	Jan NEWA
AB4		0.137MG	A215259	008	Jan 18, 2023	Jan NEWA
AB4		0.15MG	A215259	009	Jan 18, 2023	Jan NEWA
AB4		0.175MG	A215259	010	Jan 18, 2023	Jan NEWA
AB4		0.2MG	A215259	011	Jan 18, 2023	Jan NEWA
AB4		0.3MG	A215259	012	Jan 18, 2023	Jan NEWA
AB2	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Jan CTEC
AB2		0.05MG	A211417	002	Dec 21, 2022	Jan CTEC
AB2		0.075MG	A211417	003	Dec 21, 2022	Jan CTEC
AB2		0.088MG	A211417	004	Dec 21, 2022	Jan CTEC
AB2		0.1MG	A211417	005	Dec 21, 2022	Jan CTEC
AB2		0.112MG	A211417	006	Dec 21, 2022	Jan CTEC
AB2		0.125MG	A211417	007	Dec 21, 2022	Jan CTEC
AB2		0.137MG	A211417	008	Dec 21, 2022	Jan CTEC
AB2		0.15MG	A211417	009	Dec 21, 2022	Jan CTEC
AB2		0.175MG	A211417	010	Dec 21, 2022	Jan CTEC
AB2		0.2MG	A211417	011	Dec 21, 2022	Jan CTEC
AB2		0.3MG	A211417	012	Dec 21, 2022	Jan CTEC

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

@ PAI HOLDINGS PHARM 5%

A205318 001 Feb 01, 2016 May DISC

PATCH;TOPICAL

LIDOCAINE

AB INST BIOCHIMIQUE SA 5%

A209190 001 Apr 30, 2020 Apr CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

>A> AP HUONS 2%
>A> AP MANKIND PHARMA 1%
>A> AP 1%
>A> AP 2%
>A> AP 2%A212821 002 Jun 15, 2023 Jun NEWA
A217692 001 Jun 16, 2023 Jun NEWA
A217693 001 Jul 11, 2023 Jun NEWA
A217692 002 Jun 16, 2023 Jun NEWA
A217693 002 Jul 11, 2023 Jun NEWA

JELLY;TOPICAL

GLYDO

AT ! SAGENT PHARMS INC 2%
LIDOCAINE HYDROCHLORIDE

A201094 001 Apr 28, 2014 Apr CHRS

AT AKORN 2%

A040433 001 Feb 12, 2003 Apr CHRS

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE

AT RUBICON 2%

A216780 001 Mar 28, 2023 Mar NEWA

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

@ PAI HOLDINGS PHARM 2.5%;2.5%

A205887 001 Jun 29, 2018 May DISC

LINACLOTIDE

CAPSULE;ORAL

LINACLOTIDE

AB @ AUROBINDO PHARMA 145MCG
AB @ 145MCG
AB 290MCG
AB 290MCG
LINZESS
+! ABBVIE 145MCG
+ 290MCG
AB +! ALLERGAN 145MCG
AB + 290MCGA209611 001 Feb 07, 2023 Mar DISC
A209611 001 Feb 07, 2023 Jan NEWA
A209611 002 Feb 07, 2023 Mar DISC
A209611 002 Feb 07, 2023 Jan NEWA
N202811 001 Aug 30, 2012 Mar CTEC
N202811 002 Aug 30, 2012 Mar CTEC
N202811 001 Aug 30, 2012 Jan CTEC
N202811 002 Aug 30, 2012 Jan CTECLINAGLIPTIN

TABLET;ORAL

LINAGLIPTIN

AB ZYDUS PHARMS 5MG

A208448 001 Mar 30, 2023 Mar NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB ZYDUS PHARMS 2.5MG;500MG
AB 2.5MG;850MG
AB 2.5MG;1GMA208449 001 Mar 30, 2023 Mar NEWA
A208449 002 Mar 30, 2023 Mar NEWA
A208449 003 Mar 30, 2023 Mar NEWALINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

>D> AP HAINAN POLY EQ 300MG BASE/ML
>A> @ EQ 300MG BASE/MLA216662 001 Dec 21, 2022 Jun DISC
A216662 001 Dec 21, 2022 Jun DISCLINEZOLID

TABLET;ORAL

LINEZOLID

AB CHARTWELL RX 600MG

A210702 001 Apr 25, 2019 Mar CAHN

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION
LIOTHYRONINE SODIUM

>D>	AP	XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Jun CHRS	
>A>	!		EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Jun CHRS	
>D>		TRIOSTAT						
>D>	AP	+!	PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Jun DISC
>A>		+ @		EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Jun DISC

LISINOPRIL

TABLET; ORAL
LISINOPRIL

AB		HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Mar CMFD
AB			5MG	A075752	002	Jul 01, 2002	Mar CMFD
AB			10MG	A075752	003	Jul 01, 2002	Mar CMFD
AB			20MG	A075752	004	Jul 01, 2002	Mar CMFD
AB			30MG	A075752	005	Jul 01, 2002	Mar CMFD
AB			40MG	A075752	006	Jul 01, 2002	Mar CMFD

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
LOPERAMIDE HYDROCHLORIDE

>A>	AB	JUBILANT CADISTA	2MG	A217840	001	Jul 05, 2023	Jun NEWA
AB		RUBICON	2MG	A216876	001	Jan 26, 2023	Jan NEWA
AB		ZYDUS LIFESCIENCES	2MG	A217471	001	Mar 23, 2023	Apr CAHN
AB		ZYDUS PHARMS	2MG	A217471	001	Mar 23, 2023	Mar NEWA

LORAZEPAM

TABLET; ORAL
LORAZEPAM

@ AMNEAL PHARMS	0.5MG	A078826	001	Jun 23, 2010	May DISC
@	1MG	A078826	002	Jun 23, 2010	May DISC
@	2MG	A078826	003	Jun 23, 2010	May DISC

LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM

AB		GRANULES	25MG	A215959	001	Feb 23, 2023	Feb NEWA
AB			50MG	A215959	002	Feb 23, 2023	Feb NEWA
AB			100MG	A215959	003	Feb 23, 2023	Feb NEWA

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
ALREX

AB	+!	BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998	Mar CFTG
AB		LOTEPREDNOL ETABONATE					
AB		AKORN	0.2%	A215933	001	Apr 12, 2023	Mar NFTG

LOVASTATIN

TABLET; ORAL
LOVASTATIN

@ AUROBINDO PHARMA USA	10MG	A075451	001	Dec 17, 2001	May CAHN
@	10MG	A075935	001	Dec 17, 2001	Apr CAHN
@	20MG	A075451	002	Dec 17, 2001	May CAHN
@	20MG	A075935	002	Dec 17, 2001	Apr CAHN
@	40MG	A075451	003	Dec 17, 2001	May CAHN
@	40MG	A075935	003	Dec 17, 2001	Apr CAHN

LUBIPROSTONE

CAPSULE; ORAL
LUBIPROSTONE

AB		AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan CMFD
AB			24MCG	A209450	002	Nov 30, 2021	Jan CMFD
AB		ZYDUS PHARMS	8MCG	A214131	001	Mar 23, 2023	Mar NEWA
AB			24MCG	A214131	002	Mar 23, 2023	Mar NEWA

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208002	002	Jan 03, 2019	Feb CMFD
AB		60MG	A208002	003	Jan 03, 2019	Feb CMFD
AB		80MG	A208002	004	Jan 03, 2019	Feb CMFD
AB		120MG	A208002	005	Jan 03, 2019	Feb CMFD
AB	AUROBINDO PHARMA LTD	20MG	A208045	001	Mar 10, 2023	Mar NEWA
AB		40MG	A208045	002	Mar 10, 2023	Mar NEWA
AB		60MG	A208045	003	Mar 10, 2023	Mar NEWA
AB		80MG	A208045	004	Mar 10, 2023	Mar NEWA
AB		120MG	A208045	005	Mar 10, 2023	Mar NEWA
	@ AVET LIFESCIENCES	120MG	A208058	005	Feb 28, 2023	Mar DISC
AB		120MG	A208058	005	Feb 28, 2023	Feb NEWA
AB	LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208031	002	Jan 03, 2019	Feb CMFD
AB		60MG	A208031	003	Jan 03, 2019	Feb CMFD
AB		80MG	A208031	004	Jan 03, 2019	Feb CMFD
AB		120MG	A208031	005	Jan 03, 2019	Feb CMFD
>A> AB	MACLEODS PHARMS LTD	20MG	A212124	001	Jun 09, 2023	Jun NEWA
>A> AB		40MG	A212124	002	Jun 09, 2023	Jun NEWA
>A> AB		60MG	A212124	003	Jun 09, 2023	Jun NEWA
>A> AB		80MG	A212124	004	Jun 09, 2023	Jun NEWA
>A> AB		120MG	A212124	005	Jun 09, 2023	Jun NEWA
AB	PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Feb CMFD
AB		40MG	A212091	002	Dec 28, 2020	Feb CMFD
AB		60MG	A212091	003	Dec 28, 2020	Feb CMFD
AB		80MG	A212091	004	Dec 28, 2020	Feb CMFD
AB		120MG	A212091	005	Dec 28, 2020	Feb CMFD
AB	TORRENT	20MG	A208055	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208055	002	Jan 03, 2019	Feb CMFD
AB		80MG	A208055	003	Jan 03, 2019	Feb CMFD
AB		120MG	A208055	004	Jan 03, 2019	Feb CMFD

MACIMORELIN ACETATEFOR SOLUTION;ORAL
MACRILEN

+ @ NOVO

EQ 60MG BASE/POUCH

N205598 001 Dec 20, 2017 May DISC

MACITENTAN

TABLET;ORAL

MACITENTAN

AB	@ AUROBINDO PHARMA LTD	10MG	A211198	001	Apr 18, 2023	Apr DISC
	OPSUMIT	10MG	A211198	001	Apr 18, 2023	Apr NEWA
AB	+! ACTELION	10MG	N204410	001	Oct 18, 2013	Apr CTEC
AB	+!	10MG	N204410	001	Oct 18, 2013	Apr CFTG

MAFENIDE ACETATEFOR SOLUTION;TOPICAL
MAFENIDE ACETATE

@ NOVAST LABS

5%

A206716 001 Jul 31, 2017 May DISC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Mar CMFD
AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Mar CMFD

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4

AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Mar CMFD
AP	+! BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Mar CTEC

PLASMA-LYTE A IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	Mar CTEC
AP	+! BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	Mar CTEC

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	AMNEAL	2GM/50ML (40MG/ML)	A216597	001	Feb 15, 2023	Feb NEWA
AP		4GM/100ML (40MG/ML)	A216597	002	Feb 15, 2023	Feb NEWA

>A> MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE

>A> FOR SOLUTION; ORAL

>A> SUFLAVE

>A>	+! BRAINTREE LABS	0.9GM/BOT; 178.7GM/BOT; 1.12GM/BOT; 0.5GM/BOT; 7.3GM/BOT	N215344	001	Jun 15, 2023	Jun NEWA
-----	-------------------	----------------------------------------------------------	---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	WILSHIRE PHARMS INC	12.5MG	A205136	001	Feb 22, 2019	May CAHN
AA		25MG	A205136	002	Feb 22, 2019	May CAHN
AA		50MG	A205136	003	Feb 22, 2019	May CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@ CHARTWELL RX	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan CAHN
@	EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

AB	AMNEAL	150MG/ML	A215397	001	Jun 07, 2023	May NEWA
----	--------	----------	---------	-----	--------------	----------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

>A>	@ BIONPHARMA	125MG/ML	A204688	001	Dec 01, 2017	Jun CAHN
>D>	@ BRECKENRIDGE	125MG/ML	A204688	001	Dec 01, 2017	Jun CAHN
	@	125MG/ML	A204688	001	Dec 01, 2017	Jan DISC
AB	XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Jan CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	ASCENT PHARMS INC	7.5MG	A217579	001	Jun 07, 2023	May NEWA
AB		15MG	A217579	002	Jun 07, 2023	May NEWA
AB	COREPHARMA	7.5MG	A077882	001	Jul 20, 2006	Feb CAHN
AB		15MG	A077882	002	Jul 20, 2006	Feb CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

@ ANJ PHARMS	28MG	A205365	004	Feb 28, 2020	Feb DISC
@ XIAMEN LP PHARM CO	7MG	A213985	001	Oct 11, 2022	Apr DISC
@	14MG	A213985	002	Oct 11, 2022	Apr DISC
@	28MG	A213985	003	Oct 11, 2022	Apr DISC

NAMENDA XR

AB	+ ABBVIE	7MG	N022525	001	Jun 21, 2010	Feb CAHN
AB	+	14MG	N022525	002	Jun 21, 2010	Feb CAHN
AB	+	21MG	N022525	003	Jun 21, 2010	Feb CAHN
AB	+!	28MG	N022525	004	Jun 21, 2010	Feb CAHN

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

@ YILING	5MG	A212947	001	Apr 03, 2020	Mar CAHN
@	10MG	A212947	002	Apr 03, 2020	Mar CAHN
NAMENDA					

AB	+ ABBVIE	5MG	N021487	001	Oct 16, 2003	Feb CAHN
AB	+!	10MG	N021487	002	Oct 16, 2003	Feb CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST PLAIN

! DEPROCO

3%

A088387 001 Oct 10, 1984 May CTEC

MEROPENEM

INJECTABLE; INJECTION

MEROPELEM

@ BROOKS STERISCIENCE

500MG/VIAL

@

1GM/VIAL

A216154 001 Aug 18, 2022 Mar DISC

A216154 002 Aug 18, 2022 Mar DISC

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

AB +! ABBVIE 400MG

N204412 001 Feb 01, 2013 Feb CAHN

CAPSULE, EXTENDED RELEASE; ORAL

MESALAMINE

AB AMTA 375MG

A217533 001 Jun 06, 2023 May NEWA

AB AUROBINDO PHARMA LTD 375MG

A214477 001 Mar 31, 2023 Mar NEWA

ENEMA; RECTAL

MESALAMINE

AB ENCUBE 4GM/60ML

A216941 001 May 30, 2023 May NEWA

SUPPOSITORY; RECTAL

CANASA

@ ABBVIE 500MG

N021252 001 Jan 05, 2001 Feb CAHN

AB +! 1GM

N021252 002 Nov 05, 2004 Feb CAHN

TABLET, DELAYED RELEASE; ORAL

MESALAMINE

AB SINOTHERAPEUTICS INC 1.2GM

A217337 001 May 12, 2023 May NEWA

METAXALONE

TABLET; ORAL

METAXALONE

>D> +! PRIMUS PHARMS 640MG

N022503 001 Jun 01, 2015 Jun DISC

>A> + @ 640MG

N022503 001 Jun 01, 2015 Jun DISC

+! 640MG

N022503 001 Jun 01, 2015 Feb CMFD

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

>A> AB3 RK PHARMA 500MG

A215629 001 Jun 20, 2023 Jun CAHN

>A> AB3 1GM

A215629 002 Jun 20, 2023 Jun CAHN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

+ MSD SUB MERCK 500MG; EQ 50MG BASE

N022044 001 Mar 30, 2007 Mar CAHN

+! 1GM; EQ 50MG BASE

N022044 002 Mar 30, 2007 Mar CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB MACLEODS PHARMS LTD 5MG

A209827 001 May 24, 2023 May NEWA

AB 10MG

A209827 002 May 24, 2023 May NEWA

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

@ BAXTER HLTHCARE CORP 1GM/10ML (100MG/ML)

A215065 001 Jul 14, 2022 Feb DISC

TABLET; ORAL

METHOCARBAMOL

AA AUROBINDO PHARMA LTD 500MG

A213967 002 Feb 09, 2023 Feb NEWA

AA 750MG

A213967 001 Aug 12, 2020 Feb CMFD

>D> AA ! AUSTARPHARMA LLC 1GM

A200958 003 Dec 06, 2021 Jun CTEC

>A> AB ! 1GM

A200958 003 Dec 06, 2021 Jun CTEC

AA DBL PHARMS 500MG

A203550 001 Feb 08, 2017 Feb CAHN

AA 750MG

A203550 002 Feb 08, 2017 Feb CAHN

>A> AB MIKART 1GM

A212707 001 Jun 12, 2023 Jun NEWA

METHOTREXATE

SOLUTION;ORAL
JYLAMVO
+ @ THERAKIND 2MG/ML

N212479 001 Nov 29, 2022 May DISC

METHSUXIMIDE

CAPSULE;ORAL
CELONTIN
AB +! PARKE DAVIS 300MG
METHSUXIMIDE
AB NOVITIUM PHARMA 300MG

N010596 008 Apr CFTG
A217213 001 May 01, 2023 Apr NFTG>D> METHYLDOPA

>D> TABLET;ORAL
>D> METHYLDOPA
>D> CHARTWELL RX 250MG
>A> @ 250MG
250MG
>D> ! 500MG
>A> @ 500MG
!

N018934 001 Jun 29, 1984 Jun DISC
N018934 001 Jun 29, 1984 Jun DISC
N018934 001 Jun 29, 1984 May CMFD
N018934 002 Jun 29, 1984 Jun DISC
N018934 002 Jun 29, 1984 Jun DISC
N018934 002 Jun 29, 1984 May CMFD

METHYLERGONOVINE MALEATE

TABLET;ORAL
METHYLERGONOVINE MALEATE
>A> AB ! CHARTWELL RX 0.2MG
>D> AB ! NOVEL LABS INC 0.2MG

A091577 001 May 02, 2011 Jun CAHN
A091577 001 May 02, 2011 Jun CAHNMETHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB ALKEM LABS LTD 18MG
AB 27MG
AB 36MG
AB 54MG
>D> BX AMNEAL PHARMS 18MG
>A> @ 18MG
>D> BX 27MG
>A> @ 27MG
>D> BX 36MG
>A> @ 36MG
>D> BX 54MG
>A> @ 54MG

A214447 001 May 23, 2023 May NEWA
A214447 002 May 23, 2023 May NEWA
A214447 003 May 23, 2023 May NEWA
A214447 004 May 23, 2023 May NEWA
A207515 001 Feb 01, 2018 Jun DISC
A207515 001 Feb 01, 2018 Jun DISC
A207515 002 Feb 01, 2018 Jun DISC
A207515 002 Feb 01, 2018 Jun DISC
A207515 003 Feb 01, 2018 Jun DISC
A207515 003 Feb 01, 2018 Jun DISC
A207515 004 Feb 01, 2018 Jun DISC
A207515 004 Feb 01, 2018 Jun DISC

METHYLPREDNISOLONE

TABLET;ORAL
MEDROL
+ PFIZER 2MG
METHYLPREDNISOLONE
@ CHARTWELL RX 2MG
@ 4MG
@ 8MG
@ 16MG
@ 32MG

N011153 002 Apr CTEC
A209097 001 Feb 22, 2019 May CAHN
A209097 002 Feb 22, 2019 May CAHN
A209097 003 Feb 22, 2019 May CAHN
A209097 004 Feb 22, 2019 May CAHN
A209097 005 Feb 22, 2019 May CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE ACETATE
AB EUGIA PHARMA 40MG/ML
AB 80MG/ML
>D> @ PAR STERILE PRODUCTS 40MG/ML
>A> AB 40MG/ML
AB SLAYBACK PHARMA LLC 40MG/ML

A211930 001 Apr 13, 2023 Apr NEWA
A211930 002 Apr 13, 2023 Apr NEWA
A214297 001 Jan 21, 2022 Jun CMFD
A214297 001 Jan 21, 2022 Jun CMFD
A214870 002 May 10, 2023 Apr NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL
METOCLOPRAMIDE HYDROCHLORIDE
AA ! XTTRIUM LABS INC EQ 5MG BASE/5ML

A074703 001 Oct 31, 1997 Jan CAHN

METOLAZONE

TABLET;ORAL

METOLAZONE

@ AACE PHARMS	2.5MG
@	5MG
@	10MG

A216216	001	Oct 25, 2022	Apr DISC
A216216	002	Oct 25, 2022	Apr DISC
A216216	003	Oct 25, 2022	Apr DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

@ ACCORD HLTHCARE	EQ 25MG TARTRATE
@	EQ 50MG TARTRATE
@	EQ 100MG TARTRATE
@	EQ 200MG TARTRATE
>A> AB GRANULES	EQ 25MG TARTRATE
>A> AB	EQ 50MG TARTRATE
>A> AB	EQ 100MG TARTRATE
>A> AB	EQ 200MG TARTRATE

A215637	001	Oct 18, 2022	Apr DISC
A215637	002	Oct 18, 2022	Apr DISC
A215637	003	Oct 18, 2022	Apr DISC
A215637	004	Oct 18, 2022	Apr DISC
A216916	001	Jun 12, 2023	Jun NEWA
A216916	002	Jun 12, 2023	Jun NEWA
A216916	003	Jun 12, 2023	Jun NEWA
A216916	004	Jun 12, 2023	Jun NEWA

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

>D> AP HOSPIRA	1MG/ML
>A> @	1MG/ML

A075160	001	Jul 06, 1998	Jun DISC
A075160	001	Jul 06, 1998	Jun DISC

TABLET;ORAL

METOPROLOL TARTRATE

AB ZYDUS PHARMS	25MG
AB	50MG
AB	100MG

A212402	001	Apr 19, 2023	Apr NEWA
A212402	002	Apr 19, 2023	Apr NEWA
A212402	003	Apr 19, 2023	Apr NEWA

METRONIDAZOLE

CREAM;TOPICAL

METRONIDAZOLE

AB ZYDUS LIFESCIENCES	0.75%
GEL;TOPICAL METRONIDAZOLE	

A217128	001	Apr 21, 2023	Apr NEWA
---------	-----	--------------	----------

GEL;VAGINAL

METRONIDAZOLE

AB COSETTE	1%
------------	----

A216692	001	Jan 23, 2023	Jan NEWA
A090903	001	Jul 22, 2011	Feb DISC

@ TOLMAR

1%

>A> AB COSETTE	0.75%
>A> AB @ ENCUBE	0.75%
>A> AB	0.75%

A216323	001	Jul 12, 2023	Jun NEWA
A077264	001	Oct 31, 2006	Mar CAHN
A215610	001	Jun 16, 2023	Jun NEWA

INJECTABLE;INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

>A> AP AMNEAL	500MG/100ML
---------------	-------------

A217665	001	May 24, 2023	Jun CMS1
---------	-----	--------------	----------

TABLET;ORAL

METRONIDAZOLE

AB ALEMBIC	250MG
AB	500MG

A208681	001	Jun 20, 2017	Feb CAHN
A208681	002	Jun 20, 2017	Feb CAHN

METRONIDAZOLE IN PLASTIC CONTAINER

INJECTABLE;INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

>D> AP AMNEAL	500MG/100ML
AP	500MG/100ML

A217665	001	May 24, 2023	Jun CMS1
A217665	001	May 24, 2023	May NEWA

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

AB LEADING	150MG
AB	200MG
AB	250MG
AB ZENARA	150MG
AB	200MG
AB	250MG

A215876	001	Feb 27, 2023	Feb NEWA
A215876	002	Feb 27, 2023	Feb NEWA
A215876	003	Feb 27, 2023	Feb NEWA
A215315	001	Aug 26, 2022	Feb CAHN
A215315	002	Aug 26, 2022	Feb CAHN
A215315	003	Aug 26, 2022	Feb CAHN

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

@ ZYDUS PHARMS EQ 50MG BASE/VIAL
@ EQ 100MG BASE/VIALA215241 001 Oct 24, 2022 Mar DISC
A215241 002 Oct 24, 2022 Mar DISCMIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

AP HIKMA 50MG/50ML (1MG/ML)
AP 100MG/100ML (1MG/ML)
AP +! INFORLIFE 50MG/50ML (1MG/ML)
AP +! 100MG/100ML (1MG/ML)A216159 001 Apr 17, 2023 Apr NFTG
A216159 002 Apr 17, 2023 Apr NFTG
N211844 001 Mar 22, 2021 Apr CFTG
N211844 002 Mar 22, 2021 Apr CFTGMILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

+ ABBVIE 12.5MG
+ 25MG
+! 50MG
+ 100MGN022256 001 Jan 14, 2009 Jan CAHN
N022256 002 Jan 14, 2009 Jan CAHN
N022256 003 Jan 14, 2009 Jan CAHN
N022256 004 Jan 14, 2009 Jan CAHNMILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP SHANDONG EQ 1MG BASE/ML

A216373 001 Jan 23, 2023 Jan NEWA

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

MINOCIN

+! REMPEX EQ 100MG BASE/VIAL

N050444 001 May CTEC

TABLET, EXTENDED RELEASE; ORAL
MINOCYCLINE HYDROCHLORIDE>A> AB ZYDUS PHARMS EQ 55MG BASE
>A> AB EQ 65MG BASE
>A> AB EQ 115MG BASEA203553 002 Jun 16, 2023 Jun NEWA
A203553 003 Jun 16, 2023 Jun NEWA
A203553 007 Jun 16, 2023 Jun NEWAMIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MIRABEGRON

@ ZYDUS PHARMS 25MG
@ 50MGA209488 001 Sep 29, 2022 Mar DISC
A209488 002 Sep 29, 2022 Mar DISCMIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

AB PRASCO 7.5MG
AB 15MG
AB 30MG
AB 45MGA216751 001 Jan 18, 2023 Jan NEWA
A216751 002 Jan 18, 2023 Jan NEWA
A216751 003 Jan 18, 2023 Jan NEWA
A216751 004 Jan 18, 2023 Jan NEWA

REMERON

AB +! ORGANON 15MG
AB + 30MG
AB + 30MG
AB + @ 45MG
AB + @ 45MGN020415 001 Jun 14, 1996 Apr CAHN
N020415 002 Jun 14, 1996 Apr CAHN
N020415 002 Jun 14, 1996 May CAHN
N020415 003 Mar 17, 1997 Apr CAHN
N020415 003 Mar 17, 1997 May CAHNTABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTABAB +! ORGANON USA ORGANON 15MG
AB + 30MG
AB + 45MGN021208 001 Jan 12, 2001 May CAHN
N021208 002 Jan 12, 2001 May CAHN
N021208 003 Jan 12, 2001 May CAHNMISOPROSTOL

TABLET; ORAL

MISOPROSTOL

@ NOVEL LABS INC 0.1MG
@ 0.2MGA091667 001 Jul 25, 2012 Feb DISC
A091667 002 Jul 25, 2012 Feb DISC

MOMETASONE FUROATE

LOTION;TOPICAL
ELOCON
+ @ ORGANON 0.1% N019796 001 Mar 30, 1989 Mar DISC
MOMETASONE FUROATE
AB ! PADAGIS ISRAEL 0.1% A077180 001 Apr 06, 2005 Mar CHRS

MONTELUKAST SODIUM

TABLET, CHEWABLE;ORAL
MONTELUKAST SODIUM
AB CHARTWELL MOLECULAR EQ 4MG BASE A207464 001 Dec 06, 2018 Jan CAHN
AB EQ 5MG BASE A207464 002 Dec 06, 2018 Jan CAHN

MORPHINE SULFATE

INJECTABLE;INJECTION
MORPHINE SULFATE

AP HIKMA 2MG/ML A211452 001 Jan 12, 2023 Jan NFTG
AP 4MG/ML A211452 002 Jan 12, 2023 Jan NEWA
AP 8MG/ML A211452 003 Jan 12, 2023 Jan NEWA
AP 10MG/ML A211452 004 Jan 12, 2023 Jan NEWA
AP 15MG/ML A211452 005 Jan 12, 2023 Jan NFTG
AP +! HOSPIRA INC 2MG/ML N202515 001 Nov 14, 2011 Jan CFTG

TABLET;ORAL

MORPHINE SULFATE

@ DR REDDYS LABS SA 15MG A207270 001 Jan 12, 2022 Apr CAHN
@ 30MG A207270 002 Jan 12, 2022 Apr CAHN
@ MAYNE PHARMA INC 15MG A207270 001 Jan 12, 2022 Apr DISC
@ 30MG A207270 002 Jan 12, 2022 Apr DISC

TABLET, EXTENDED RELEASE;ORAL

MORPHABOND ER

>D> + @ DAIICHI SANKYO INC 15MG N206544 001 Oct 02, 2015 Jun CAHN
>D> + @ 30MG N206544 002 Oct 02, 2015 Jun CAHN
>D> + @ 60MG N206544 003 Oct 02, 2015 Jun CAHN
>D> + @ 100MG N206544 004 Oct 02, 2015 Jun CAHN
>A> + @ OHMO LIFE 15MG N206544 001 Oct 02, 2015 Jun CAHN
>A> + @ 30MG N206544 002 Oct 02, 2015 Jun CAHN
>A> + @ 60MG N206544 003 Oct 02, 2015 Jun CAHN
>A> + @ 100MG N206544 004 Oct 02, 2015 Jun CAHN

MORPHINE SULFATE

@ DR REDDYS LABS SA 15MG A205386 001 Oct 28, 2016 Apr CAHN
@ 30MG A205386 002 Oct 28, 2016 Apr CAHN
@ 60MG A205386 003 Oct 28, 2016 Apr CAHN
@ 100MG A205386 004 Oct 28, 2016 Apr CAHN
@ MAYNE PHARMA INC 15MG A205386 001 Oct 28, 2016 Apr DISC
@ 30MG A205386 002 Oct 28, 2016 Apr DISC
@ 60MG A205386 003 Oct 28, 2016 Apr DISC
@ 100MG A205386 004 Oct 28, 2016 Apr DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

>D> MOXEZA
>D> AT2 +! HARROW EYE EQ 0.5% BASE N022428 001 Nov 19, 2010 Jun DISC
>A> + @ EQ 0.5% BASE N022428 001 Nov 19, 2010 Jun DISC
AT2 +!
MOXIFLOXACIN HYDROCHLORIDE

@ AKORN EQ 0.5% BASE A202916 001 Nov 09, 2017 Jan DISC
>D> AT2 LUPIN LTD EQ 0.5% BASE A204079 001 May 28, 2015 Jun CHRS
>A> ! EQ 0.5% BASE A204079 001 May 28, 2015 Jun CHRS

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB CHARTWELL RX EQ 400MG BASE A207285 001 Feb 13, 2017 Apr CAHN
AB HETERO LABS LTD V EQ 400MG BASE A204836 001 Mar 02, 2023 Feb NEWA
@ TORRENT EQ 400MG BASE A200160 001 Apr 03, 2014 Feb DISC

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP BPI LABS 500MG/VIAL A214283 001 Jun 01, 2023 May NEWA

NABUMETONE

TABLET;ORAL

NABUMETONE

@ AUROBINDO PHARMA USA 500MG
@ 750MGA090516 001 Jul 12, 2010 Apr CAHN
A090516 002 Jul 12, 2010 Apr CAHNNADOLOL

TABLET;ORAL

NADOLOL

AB	ALEMBIC	20MG	A211763	001	Jun 02, 2023	May NEWA
AB		40MG	A211763	002	Jun 02, 2023	May NEWA
AB		80MG	A211763	003	Jun 02, 2023	May NEWA
>A>	AB RK PHARMA	20MG	A212856	001	Sep 13, 2019	Jun CAHN
>A>	AB	40MG	A212856	002	Sep 13, 2019	Jun CAHN
>A>	AB	80MG	A212856	003	Sep 13, 2019	Jun CAHN
>D>	AB VGYAAN	20MG	A212856	001	Sep 13, 2019	Jun CAHN
>D>	AB	40MG	A212856	002	Sep 13, 2019	Jun CAHN
>D>	AB	80MG	A212856	003	Sep 13, 2019	Jun CAHN

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP	! EUGIA PHARMA SPECLTS	EQ 1GM BASE/VIAL	A091613	001	Dec 26, 2012	Jan CHRS
AP	!	EQ 2GM BASE/VIAL	A091613	002	Dec 26, 2012	Jan CHRS
AP	!	EQ 10GM BASE/VIAL	A091614	001	Dec 26, 2012	Jan CHRS
	@ SANDOZ	EQ 1GM BASE/VIAL	A062527	002	Aug 02, 1984	Jan DISC
	@	EQ 1GM BASE/VIAL	A062732	001	Dec 23, 1986	Jan DISC
	@	EQ 2GM BASE/VIAL	A062527	003	Aug 02, 1984	Jan DISC
	@	EQ 2GM BASE/VIAL	A062732	002	Dec 23, 1986	Jan DISC
	@	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Jan DISC

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB	AMNEAL	2%	A206960	001	Apr 10, 2017	Feb CAHN
	GEL;TOPICAL					
	NAFTIFINE HYDROCHLORIDE					
AB	AMNEAL	1%	A206165	001	Mar 20, 2019	Feb CAHN
AB	TARO	2%	A208201	001	Apr 10, 2019	Mar CMFD
	NAFTIN					
AB	+! SEBELA IRELAND LTD	2%	N204286	001	Jun 27, 2013	May CTEC
	+!	2%	N204286	001	Jun 27, 2013	Feb CTEC

NALMEFENE HYDROCHLORIDE

SPRAY;NASAL

OPVEE

>A>	+! INDIVIOR	EQ 2.7MG BASE/SPRAY	N217470	001	May 22, 2023	Jun CAHN
>D>	+! OPIANT PHARMS	EQ 2.7MG BASE/SPRAY	N217470	001	May 22, 2023	Jun CAHN
	+!	EQ 2.7MG BASE/SPRAY	N217470	001	May 22, 2023	May NEWA

NALOXEGOL OXALATE

TABLET;ORAL

MOVANTIK

+	VALINOR	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Feb CAHN
+	!	EQ 25MG BASE	N204760	002	Sep 16, 2014	Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

	@ PAR STERILE PRODUCTS	1MG/ML	A215964	001	Jul 29, 2022	Jan DISC
>D>	NALOXONE HYDROCHLORIDE					
>D>	+! AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023	Jun CTNA
	+!	4MG/SPRAY	N208969	001	Mar 07, 2023	Mar NEWA
>A>	REXTOVY					
>A>	+! AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023	Jun CTNA

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

>A>	NALTREXONE						
>A> AP	TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023	Jun	NFTG
	VIVITROL						
>D>	+! ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006	Jun	CFTG
>A> AP	+!	380MG/VIAL	N021897	001	Apr 13, 2006	Jun	CFTG

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

@	AUROBINDO PHARMA USA	375MG	A075390	001	Apr 19, 2001	Apr	CAHN
@		500MG	A075390	002	Apr 19, 2001	Apr	CAHN
AB	TULEX PHARMS INC	375MG	A216908	001	May 31, 2023	May	NEWA
AB		500MG	A216908	002	May 31, 2023	May	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

@	AUROBINDO PHARMA USA	EQ 1MG BASE	A202431	001	May 31, 2012	Apr	CAHN
@		EQ 2.5MG BASE	A202431	002	May 31, 2012	Apr	CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

AB	BEXIMCO PHARMS USA	EQ 2.5MG BASE	A216568	001	Mar 30, 2023	Mar	NEWA
AB		EQ 5MG BASE	A216568	002	Mar 30, 2023	Mar	NEWA
AB		EQ 10MG BASE	A216568	003	Mar 30, 2023	Mar	NEWA
AB		EQ 20MG BASE	A216568	004	Mar 30, 2023	Mar	NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@	AUROBINDO PHARMA USA	100MG	A076129	002	Sep 16, 2003	Apr	CAHN
@		150MG	A076129	003	Sep 16, 2003	Apr	CAHN
@		200MG	A076129	004	Sep 16, 2003	Apr	CAHN
@		250MG	A076129	005	Sep 16, 2003	Apr	CAHN

NELARABINE

INJECTABLE; INTRAVENOUS

ARRANON

AP	+! SANDOZ NELARABINE	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	May	CAHN
AP	AMNEAL	250MG/50ML (5MG/ML)	A216346	001	Apr 04, 2023	Mar	NEWA
AP	NEXUS PHARMS	250MG/50ML (5MG/ML)	A215057	001	Jun 02, 2023	May	NEWA
AP	SHORLA	250MG/50ML (5MG/ML)	A214809	001	Mar 03, 2023	Feb	NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP	HIKMA	5MG/10ML (0.5MG/ML)	A207042	001	Dec 28, 2015	May	CAHN
AP		10MG/10ML (1MG/ML)	A207042	002	Dec 28, 2015	May	CAHN
AP	SAGENT PHARMS INC	5MG/10ML (0.5MG/ML)	A216542	001	Feb 17, 2023	Feb	NEWA
AP		10MG/10ML (1MG/ML)	A216542	002	Feb 17, 2023	Feb	NEWA

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

+!	HARROW EYE NEVANAC	0.3%	N203491	001	Oct 16, 2012	May	CAHN
+!	HARROW EYE	0.1%	N021862	001	Aug 19, 2005	May	CAHN

NETARSUDIL MESYLATE

SOLUTION/DROPS; OPHTHALMIC

RHOPRESSA

+!	ALCON LABS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	May	CAHN
----	----------------	---------------	---------	-----	--------------	-----	------

NICARDIPIINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPIINE HYDROCHLORIDE

AB	SQUARE PHARMS	20MG	A217555	001	May 03, 2023	Apr NEWA
AB		30MG	A217555	002	May 03, 2023	Apr NEWA
INJECTABLE; INJECTION						
NICARDIPIINE HYDROCHLORIDE						
>D>	+! HIKMA INTL PHARMS	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Jun CTEC
>A> AP	+!	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Jun CTEC
>A> AP	MICRO LABS	25MG/10ML (2.5MG/ML)	A216420	001	Jul 07, 2023	Jun NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

@ PHARMADAX INC	30MG	A216019	001	Nov 18, 2022	Apr DISC
@	60MG	A216019	002	Nov 18, 2022	Apr DISC

NIRAPARIB TOSYLATE

TABLET;ORAL

ZEJULA

+ GLAXOSMITHKLINE	EQ 100MG BASE	N214876	001	Apr 26, 2023	Apr NEWA
+	EQ 200MG BASE	N214876	002	Apr 26, 2023	Apr NEWA
+!	EQ 300MG BASE	N214876	003	Apr 26, 2023	Apr NEWA

NIRMATRELVIR; RITONAVIR

TABLET;ORAL

PAXLOVID (COPACKAGED)

+ PFIZER	150MG;100MG	N217188	001	May 25, 2023	May NEWA
+!	300MG;100MG	N217188	002	May 25, 2023	May NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

AB	AMTA	8.5MG	A216606	001	Apr 10, 2023	Mar NEWA
----	------	-------	---------	-----	--------------	----------

NITISINONE

CAPSULE;ORAL

NITISINONE

AB	MEDUNIK	20MG	A212390	004	Apr 27, 2023	Apr NEWA
AB	ZENARA	2MG	A216201	001	May 25, 2023	May NEWA
AB		5MG	A216201	002	May 25, 2023	May NEWA
AB		10MG	A216201	003	May 25, 2023	May NEWA
AB		20MG	A216201	004	May 25, 2023	May NEWA

NITRIC OXIDE

GAS;INHALATION

GENOSYL

+! VERO BIOTECH INC	800PPM	N202860	001	Dec 20, 2019	Jan CAHN
---------------------	--------	---------	-----	--------------	----------

NITROFURANTOIN

SUSPENSION;ORAL

FURADANTIN

>D> AB	+! CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun CHRS
>A> AB	+	25MG/5ML	N009175	001		Jun CHRS
>A>	+!	50MG/5ML	N009175	002	Jun 09, 2023	Jun NEWA
NITROFURANTOIN						
AUROBINDO PHARMA						
AB	AUROBINDO PHARMA	25MG/5ML	A212607	001	May 11, 2023	May NEWA
AB	NOVITIUM PHARMA	25MG/5ML	A216385	001	Apr 14, 2023	Apr NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB	AUROBINDO PHARMA USA	50MG	A074967	001	Jul 09, 1997	Apr CMFD
AB		100MG	A074967	002	Jul 09, 1997	Apr CMFD
AB		100MG	A077025	001	Aug 18, 2004	May CMFD
AB	MANKIND PHARMA	25MG	A217272	001	Mar 21, 2023	Mar NEWA
AB		50MG	A217272	002	Mar 21, 2023	Mar NEWA
AB		100MG	A217272	003	Mar 21, 2023	Mar NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	@ ALVOGEN	75MG;25MG	A215002	001	Jul 20, 2022	Jan DISC
>A> AB	AUROBINDO PHARMA	75MG;25MG	A209225	001	Mar 30, 2023	Mar NEWA
>A> AB	MANKIND PHARMA	75MG;25MG	A217357	001	Jul 11, 2023	Jun NEWA

NITROGLYCERIN

INJECTABLE;INJECTION

NITROGLYCERIN IN DEXTROSE 5%

+! BAXTER HLTHCARE	10MG/100ML	N019970	001	Dec 29, 1989	May CTEC
+!	20MG/100ML	N019970	002	Dec 29, 1989	May CTEC
+!	40MG/100ML	N019970	003	Dec 29, 1989	May CTEC

OINTMENT;TRANSDERMAL

NITROGLYCERIN

+! FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	May CRLD
-----------------------	----	---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+ @ LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	May CAHN
+ @	EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	May CAHN
+ @	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	May CAHN
+ @ NEVAKAR INJECTABLES	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Apr DISC
+ @	EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Apr DISC
+ @	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Apr DISC

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

@ TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Mar DISC
SUSPENSION;ORAL		N050299	001		Apr CAHN

NILSTAT

+ @ CHARTWELL MOLECULES	100,000 UNITS/ML	N050299	001		Apr CAHN
-------------------------	------------------	---------	-----	--	----------

OBETICHOLIC ACID

TABLET;ORAL

OBETICHOLIC ACID

AB	APOTEX	5MG	A214862	001	May 30, 2023	May NFTG
AB		10MG	A214862	002	May 30, 2023	May NFTG
AB	LUPIN LTD	5MG	A214980	001	May 30, 2023	May NFTG
AB		10MG	A214980	002	May 30, 2023	May NFTG
>D> AB	MSN	5MG	A215017	001	May 30, 2023	Jun DISC
>A>	@	5MG	A215017	001	May 30, 2023	Jun DISC
>D> AB		5MG	A215017	001	May 30, 2023	May NFTG
>A>		10MG	A215017	002	May 30, 2023	Jun DISC
>A>	@	10MG	A215017	002	May 30, 2023	Jun DISC
AB		10MG	A215017	002	May 30, 2023	May NFTG
	OCALIVA					
AB	+ INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	May CFTG
AB	+!	10MG	N207999	002	May 27, 2016	May CFTG

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

>A> AP	GLAND PHARMA LTD	EQ 0.1MG BASE/ML	A216839	002	Jun 22, 2023	Jun NEWA
>A> AP		EQ 0.2MG BASE/ML	A216807	001	Jun 13, 2023	Jun NEWA
>A> AP		EQ 0.5MG BASE/ML	A216839	001	Jun 22, 2023	Jun NEWA
>A> AP		EQ 1MG BASE/ML	A216807	002	Jun 13, 2023	Jun NEWA

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP	ASPIRO	10MG/VIAL	A217466	001	Mar 22, 2023	Mar NEWA
----	--------	-----------	---------	-----	--------------	----------

TABLET;ORAL

OLANZAPINE

AB	CADILA PHARMS LTD	2.5MG	A210022	001	Feb 24, 2023	Feb NEWA
AB		5MG	A210022	002	Feb 24, 2023	Feb NEWA
AB		7.5MG	A210022	003	Feb 24, 2023	Feb NEWA
AB		10MG	A210022	004	Feb 24, 2023	Feb NEWA
AB		15MG	A210022	005	Feb 24, 2023	Feb NEWA
AB		20MG	A210022	006	Feb 24, 2023	Feb NEWA
	<u>TABLET, ORALLY DISINTEGRATING;ORAL</u>					
	OLANZAPINE					
AB	HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020	Apr CMFD
AB		10MG	A206892	002	Dec 31, 2020	Apr CMFD
AB		15MG	A206892	003	Dec 31, 2020	Apr CMFD
AB		20MG	A206892	004	Dec 31, 2020	Apr CMFD
AB	ZYDUS PHARMS	5MG	A202889	001	Mar 09, 2023	Mar NEWA
AB		10MG	A202889	002	Mar 09, 2023	Mar NEWA
AB		15MG	A202889	003	Mar 09, 2023	Mar NEWA
AB		20MG	A202889	004	Mar 09, 2023	Mar NEWA

OLMESARTAN MEDOXOMILTABLET;ORAL

OLMESARTAN MEDOXOMIL

>A> AB	AMNEAL	5MG	A207480	001	Jul 11, 2023	Jun NEWA
>A> AB		20MG	A207480	002	Jul 11, 2023	Jun NEWA
>A> AB		40MG	A207480	003	Jul 11, 2023	Jun NEWA
AB	MSN	5MG	A217399	001	Jan 18, 2023	Jan NEWA
AB		20MG	A217399	002	Jan 18, 2023	Jan NEWA
AB		40MG	A217399	003	Jan 18, 2023	Jan NEWA

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB	! AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	May CHRS
	PATANASE		N021861	001	Apr 15, 2008	May DISC

OMAVELOXOLONE

CAPSULE;ORAL

SKYCLARYS

+!	REATA PHARMS	50MG	N216718	001	Feb 28, 2023	Feb NEWA
----	--------------	------	---------	-----	--------------	----------

OMIDENEPAK ISOPROPYL

SOLUTION;OPHTHALMIC

OMLONTI

+ @	SANTEN	0.002%	N215092	001	Sep 22, 2022	May DISC
-----	--------	--------	---------	-----	--------------	----------

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

!	CHARTWELL MOLECULES	16MG	A077406	001	Dec 26, 2006	Mar CHRS
!		24MG	A077406	002	Dec 26, 2006	Mar CHRS
	ZOFRAN ODT					
+	@ SANDOZ	4MG	N020781	001	Jan 27, 1999	May CAHN
+	@	8MG	N020781	002	Jan 27, 1999	May CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ZOFRAN

+	@ SANDOZ	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	May CAHN
	ZOFRAN PRESERVATIVE FREE		N020007	003	Dec 10, 1993	May CAHN

+	@ SANDOZ	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	May CAHN
---	----------	----------------	---------	-----	--------------	----------

SOLUTION;ORAL	ZOFRAN		N020605	001	Jan 24, 1997	May CAHN
---------------	--------	--	---------	-----	--------------	----------

+ @ SANDOZ	EQ 4MG BASE/5ML		N020605	001	Jan 24, 1997	May CAHN
------------	-----------------	--	---------	-----	--------------	----------

TABLET;ORAL	ONDANSETRON HYDROCHLORIDE		N020605	001	Jan 24, 1997	May CAHN
!	CHARTWELL MOLECULES	EQ 24MG BASE	A077303	004	Jun 25, 2007	Feb CTEC
	ZOFRAN					
+	@ SANDOZ	EQ 4MG BASE	N020103	001	Dec 31, 1992	May CAHN
+	@	EQ 8MG BASE	N020103	002	Dec 31, 1992	May CAHN
+	@	EQ 24MG BASE	N020103	003	Aug 27, 1999	May CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL
ORPHENADRINE CITRATE

AB	RISING	100MG	A040249	001	Jan 29, 1999	Jan CAHN
----	--------	-------	---------	-----	--------------	----------

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

@ ACCORD HLTHCARE	EQ 30MG BASE	A214726	001	Jul 25, 2022	Feb DISC	
@	EQ 45MG BASE	A214726	002	Jul 25, 2022	Feb DISC	
@	EQ 75MG BASE	A214726	003	Jul 25, 2022	Feb DISC	
>D>	@ SUNSHINE	EQ 30MG BASE	A212739	001	Mar 04, 2020	Jun CMFD
>A> AB		EQ 30MG BASE	A212739	001	Mar 04, 2020	Jun CMFD
>D>	@	EQ 45MG BASE	A212739	002	Mar 04, 2020	Jun CMFD
>A> AB		EQ 45MG BASE	A212739	002	Mar 04, 2020	Jun CMFD
>D>	@	EQ 75MG BASE	A212739	003	Mar 04, 2020	Jun CMFD
>A> AB		EQ 75MG BASE	A212739	003	Mar 04, 2020	Jun CMFD

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

AB	EPIC PHARMA LLC	EQ 6MG BASE/ML	A215538	001	Feb 14, 2023	Feb NEWA
----	-----------------	----------------	---------	-----	--------------	----------

OXCARBAZEPINE

SUSPENSION;ORAL
OXCARBAZEPINE

AB	CHARTWELL RX	300MG/5ML	A212428	001	Jun 21, 2021	May CAHN
TABLET;ORAL						
OXCARBAZEPINE						
>A> AB	ZYDUS	150MG	A211747	001	Jul 03, 2023	Jun NEWA
>A> AB		300MG	A211747	002	Jul 03, 2023	Jun NEWA
>A> AB		600MG	A211747	003	Jul 03, 2023	Jun NEWA

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL
GELNIQUE

+! ABBVIE 10% (100MG/PACKET)

N022204 001 Jan 27, 2009 Apr CAHN

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA	CHARTWELL RX	5MG/5ML	A075039	001	Jan 29, 1999	Mar CMFD
@ XTRIUM LABS INC		5MG/5ML	A074868	001	Feb 12, 1997	Mar CAHN
TABLET;ORAL						
OXYBUTYNIN CHLORIDE						
! APPCO	2.5MG		A209025	002	Feb 07, 2023	Jan NFTG
>D> BX AVET LIFESCIENCES	5MG		A211682	001	May 10, 2019	Jun CTEC
>A> AB	5MG		A211682	001	May 10, 2019	Jun CTEC

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

@ DR REDDYS LABS SA	5MG	A203107	001	Jul 26, 2012	Apr CAHN
@ MAYNE PHARMA INC	5MG	A203107	001	Jul 26, 2012	Apr DISC

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

@ DR REDDYS LABS SA	100MG/5ML	A204092	001	Jun 05, 2014	Apr CAHN
---------------------	-----------	---------	-----	--------------	----------

@ MAYNE PHARMA INC	100MG/5ML	A204092	001	Jun 05, 2014	Apr DISC
--------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

@ DR REDDYS LABS SA	5MG	A091313	001	Feb 18, 2011	Apr CAHN
@	10MG	A091313	004	Apr 29, 2016	Apr CAHN
@	15MG	A091313	002	Feb 18, 2011	Apr CAHN
@	20MG	A091313	005	Apr 29, 2016	Apr CAHN
@	30MG	A091313	003	Feb 18, 2011	Apr CAHN

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

@ DASH PHARMS	6MG/ML	A091540	001	Sep 29, 2011	Feb CAHN
---------------	--------	---------	-----	--------------	----------

POWDER;INTRAVENOUS

PACLITAXEL

+! AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022	Apr CAHN
--------------	------------	---------	-----	--------------	----------

+! TEVA PHARMS INC	100MG/VIAL	N216338	001	May 11, 2023	May NEWA
--------------------	------------	---------	-----	--------------	----------

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@ CIPLA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018	Feb DISC
@ INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Feb DISC

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP2	DR REDDYS	30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May CTEC
AP2		90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May CTEC
AP1	+! HIKMA	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	May CTEC
AP1	+!	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	May CTEC
AP2	HOSPIRA	30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	May CTEC
AP		30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	Apr CHRS
AP2		90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	May CTEC
AP		90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	Apr CHRS
AP2	MYLAN LABS LTD	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	May CTEC
AP2		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	May CTEC
AP1	SAGENT PHARMS INC	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	May CTEC
AP1		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	May CTEC

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	AJANTA PHARMA LTD	EQ 40MG BASE	A217416	001	Feb 09, 2023	Feb NEWA
>A> AB	DEXCEL	EQ 40MG BASE	A216247	001	Jun 16, 2023	Jun NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

@ EPIC PHARMA LLC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan CAHN
@	EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan CAHN
@	EQ 37.5MG BASE	A213612	003	May 26, 2022	Jan CAHN

PAROXETINE MESYLATE

TABLET; ORAL

PEXEVA

+ @ SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003	May DISC
+ @	EQ 20MG BASE	N021299	002	Jul 03, 2003	May DISC
+ @	EQ 30MG BASE	N021299	003	Jul 03, 2003	May DISC

PEGCETACOPLAN

SOLUTION; INTRAVITREAL

SYFOVRE

+! APELLIS PHARMS	15MG/0.1ML (15MG/0.1ML)	N217171	001	Feb 17, 2023	Feb NEWA
-------------------	-------------------------	---------	-----	--------------	----------

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

PEMETREXED DISODIUM

>D> AP	AMNEAL	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Jun DISC
>A>	@	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Jun DISC
AP		EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Apr NEWA
>D> AP		EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022	Jun DISC
>A>	@	EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022	Jun DISC
AP	MEITHEAL	EQ 100MG BASE/VIAL	A215479	001	Dec 13, 2022	Jan CAHN
AP		EQ 500MG BASE/VIAL	A215479	002	Dec 13, 2022	Jan CAHN
AP		EQ 750MG BASE/VIAL	A215479	003	Dec 13, 2022	Jan CAHN
AP		EQ 1GM BASE/VIAL	A215479	004	Dec 13, 2022	Jan CAHN
	@ MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar DISC
AP		EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar NEWA
	SOLUTION; INTRAVENOUS					
	PEMETREXED					
+! SHILPA		EQ 100MG/10ML BASE (10MG/ML)	N215179	001	May 22, 2023	May NEWA
+!		EQ 500MG/50ML BASE (10MG/ML)	N215179	002	May 22, 2023	May NEWA
+!		EQ 1GM/100ML BASE (10MG/ML)	N215179	003	May 22, 2023	May NEWA
	PEMETREXED DISODIUM					
+! SANDOZ		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214657	001	May 26, 2022	Jan CMS1

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

PENTAMIDINE ISETHIONATE

AN X-GEN PHARMS INC 300MG/VIAL A206983 001 Jan 20, 2023 Jan NEWA

PERAMPANEL

SUSPENSION; ORAL

FYCOMPRA

+! CATALYST PHARMS	0.5MG/ML	N 208277	001	Apr 29, 2016	Feb CAHN
TABLET; ORAL					
FYCOMPRA					
+ CATALYST PHARMS	2MG	N 202834	001	Oct 22, 2012	Feb CAHN
+	4MG	N 202834	002	Oct 22, 2012	Feb CAHN
+	6MG	N 202834	003	Oct 22, 2012	Feb CAHN
+	8MG	N 202834	004	Oct 22, 2012	Feb CAHN
+	10MG	N 202834	005	Oct 22, 2012	Feb CAHN
+!	12MG	N 202834	006	Oct 22, 2012	Feb CAHN

PERFLUOROHEXYLOCTANE

SOLUTION/DROPS; OPHTHALMIC

MIEBO

+! BAUSCH AND LOMB INC 1.338GM/ML N 216675 001 May 18, 2023 May NEWA

PEXIDARTINIB HYDROCHLORIDE

CAPSULE; ORAL

TURALIO

>D>	+! DAIICHI SANKYO INC	EQ 200MG BASE	N 211810	001	Aug 02, 2019	Jun DISC
>A>	+ @	EQ 200MG BASE	N 211810	001	Aug 02, 2019	Jun DISC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB	AUROBINDO PHARMA	10MG	A 215600	001	May 08, 2023	Apr NEWA
>A> AB	RISING	10MG	A 204551	001	Jun 20, 2023	Jun NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

@ LANNETT	15MG	A 087022	002	Jan 20, 2012	Feb DISC
@	30MG	A 087022	001	Feb 03, 1983	Feb DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

IMMPHENITIV

+! HIKMA	0.5MG/5ML (0.1MG/ML)	N 203826	004	Mar 09, 2023	May CAHN
+!	0.5MG/5ML (0.1MG/ML)	N 203826	004	Mar 09, 2023	Mar NEWA
+!	1MG/10ML (0.1MG/ML)	N 203826	005	Mar 09, 2023	May CAHN
+!	1MG/10ML (0.1MG/ML)	N 203826	005	Mar 09, 2023	Mar NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2	AVET LIFESCIENCES	10MG/ML (10MG/ML)	A 209968	001	Feb 28, 2023	Feb NEWA
>A> AP2	BE PHARMS	10MG/ML (10MG/ML)	A 217521	001	Jun 26, 2023	Jun NEWA
>A> AP2		50MG/5ML (10MG/ML)	A 217521	002	Jun 26, 2023	Jun NEWA
>A> AP2		100MG/10ML (10MG/ML)	A 217521	003	Jun 26, 2023	Jun NEWA
AP2	+! HIKMA	10MG/ML (10MG/ML)	N 203826	001	Dec 20, 2012	May CAHN
>D> AP2	+!	50MG/5ML (10MG/ML)	N 203826	002	Jun 19, 2019	Jun CTEC
>A>	+!	50MG/5ML (10MG/ML)	N 203826	002	Jun 19, 2019	Jun CTEC
AP2	+!	50MG/5ML (10MG/ML)	N 203826	002	Jun 19, 2019	May CAHN
>D> AP2	+!	100MG/10ML (10MG/ML)	N 203826	003	Jun 19, 2019	Jun CTEC
>A>	+!	100MG/10ML (10MG/ML)	N 203826	003	Jun 19, 2019	Jun CTEC
AP2	+!	100MG/10ML (10MG/ML)	N 203826	003	Jun 19, 2019	May CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC PLAIN

@ XTTRIUM LABS INC 5MG/5ML; 6.25MG/5ML A 088897 001 Jan 04, 1985 Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE

SPRAY, METERED;OPHTHALMIC
MYDCOMBI
+! EYENOVA 2.5%;1% N215352 001 May 05, 2023 May NEWA

PHENYTOIN SODIUM

CAPSULE;ORAL
EXTENDED PHENYTOIN SODIUM
@ MYLAN 100MG EXTENDED A040298 001 Dec 28, 1998 Mar DISC
@ UNICHEM 100MG EXTENDED A213834 001 Oct 13, 2022 Apr DISC

PHYTONADIONE

TABLET;ORAL
MEPHYTON
+ @ BAUSCH 5MG N010104 003 Feb DISC
PHYTONADIONE
AB ! ZYDUS 5MG A210189 001 Feb 20, 2019 Feb CHRS

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION
PIPERACILLIN AND TAZOBACTAM
AP SHANDONG EQ 2GM BASE/VIAL;EQ 250MG A204959 001 Aug 10, 2018 Apr CAHN
BASE/VIAL
AP EQ 3GM BASE/VIAL;EQ 375MG A204959 002 Aug 10, 2018 Apr CAHN
BASE/VIAL
AP EQ 4GM BASE/VIAL;EQ 500MG A204959 003 Aug 10, 2018 Apr CAHN
BASE/VIAL
AP EQ 36GM BASE/VIAL;EQ 4.5GM A217243 001 Apr 14, 2023 Apr NEWA
BASE/VIAL
ZOSYN IN PLASTIC CONTAINER
+! BAXTER HLTHCARE CORP EQ 40MG BASE/ML;EQ 5MG BASE/ML N050750 001 Feb 24, 1998 Mar CAHN
+! EQ 60MG BASE/ML;EQ 7.5MG BASE/ML N050750 002 Feb 24, 1998 Mar CAHN
+! EQ 4GM BASE/100ML;EQ 500MG N050750 003 Feb 24, 1998 Mar CAHN
BASE/100ML

PIRFENIDONE

CAPSULE;ORAL
PIRFENIDONE
>A> AB APOTEX 267MG A212687 001 Jun 09, 2023 Jun NEWA
TABLET;ORAL
PIRFENIDONE
AB APOTEX 267MG A212709 001 May 31, 2023 May NEWA
AB 801MG A212709 002 May 31, 2023 May NEWA

PIRTOBRUTINIB

TABLET;ORAL
JAYPIRCA
+ LOXO ONCOL 50MG N216059 001 Jan 27, 2023 Jan NEWA
+! 100MG N216059 002 Jan 27, 2023 Jan NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL
PITAVASTATIN CALCIUM
AB ZYDUS PHARMS EQ 1MG BASE A206047 001 Feb 22, 2023 Feb NEWA
AB EQ 2MG BASE A206047 002 Feb 22, 2023 Feb NEWA
AB EQ 4MG BASE A206047 003 Feb 22, 2023 Feb NEWA

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC
POLYTRIM
+ @ ALLERGAN 10,000 UNITS/ML;EQ 1MG BASE/ML N050567 001 Oct 20, 1988 Feb DISC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
AT ! SANDOZ 10,000 UNITS/ML;EQ 1MG BASE/ML A064211 001 Apr 13, 1998 Feb CHRS

POMALIDOMIDE

CAPSULE;ORAL
POMALYST
+ BRISTOL 1MG N204026 001 Feb 08, 2013 Jan CAHN
+ 2MG N204026 002 Feb 08, 2013 Jan CAHN
+ 3MG N204026 003 Feb 08, 2013 Jan CAHN
+! 4MG N204026 004 Feb 08, 2013 Jan CAHN

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL

POSACONAZOLE

@ ACTAVIS LABS FL INC 100MG

A207355 001 Nov 30, 2022 May DISC

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

AP EXELA PHARMA 2MEQ/ML

A212692 001 Oct 20, 2021 Feb CMFD

POTASSIUM CHLORIDE

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

>A> AA NOVITIUM PHARMA 20MEQ

A212816 001 Jul 12, 2023 Jun NEWA

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA BELCHER 20MEQ/15ML

A216156 001 Mar 07, 2023 Feb NEWA

AA 40MEQ/15ML

A216156 002 Mar 07, 2023 Feb NEWA

@ STRIDES PHARMA 40MEQ/15ML

A211665 001 Nov 17, 2022 May DISC

TABLET, EXTENDED RELEASE;ORAL

K-TAB

+ @ ABBVIE 10MEQ

N018279 001 Feb DISC

+ @ 20MEQ

N018279 003 Nov 25, 2013 Feb DISC

POTASSIUM CHLORIDE

>A> AB1 RUBICON 10MEQ

A216321 001 Jun 16, 2023 Jun NEWA

>A> AB1 15MEQ

A216321 002 Jun 16, 2023 Jun NEWA

>A> AB1 20MEQ

A216321 003 Jun 16, 2023 Jun NEWA

AB3 TWI PHARMS 10MEQ

A209688 001 Jan 12, 2018 Apr CAHN

AB3 ! 20MEQ

A209688 002 Jan 12, 2018 Apr CAHN

AB3 ! VITRUVIAS THERAP 20MEQ

A209688 002 Jan 12, 2018 Feb CHRS

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

AB AMNEAL PHARMS EQ 5MG BASE

A205913 001 Jun 19, 2018 Mar CTEC

AB EQ 10MG BASE

A205913 002 Jun 19, 2018 Mar CTEC

@ LUPIN LTD EQ 5MG BASE

A205930 001 Jan 09, 2023 Feb DISC

@ EQ 10MG BASE

A205930 002 Jan 09, 2023 Feb DISC

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB CHARTWELL RX 10MG

A077917 001 Jan 08, 2008 May CAHN

AB 20MG

A077917 002 Jan 08, 2008 May CAHN

AB 40MG

A077917 003 Jan 08, 2008 May CAHN

AB 80MG

A077917 004 Jan 08, 2008 May CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

AB ALEMBIC EQ 1MG BASE

A217268 001 Mar 06, 2023 Feb NEWA

AB EQ 2MG BASE

A217268 002 Mar 06, 2023 Feb NEWA

AB EQ 5MG BASE

A217268 003 Mar 06, 2023 Feb NEWA

AB AUROBINDO PHARMA LTD EQ 1MG BASE

A213052 001 Mar 31, 2023 Mar NEWA

AB EQ 2MG BASE

A213052 002 Mar 31, 2023 Mar NEWA

AB EQ 5MG BASE

A213052 003 Mar 31, 2023 Mar NEWA

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

>D> AA ! AKORN 15MG/5ML

A040401 001 Feb 27, 2003 Jun CHRS

>A> AA 15MG/5ML

A040401 001 Feb 27, 2003 Jun CHRS

>D> AA CHARTWELL RX 15MG/5ML

A040323 001 May 13, 1999 Jun CHRS

>A> AA ! 15MG/5ML

A040323 001 May 13, 1999 Jun CHRS

AA XTTRIUM LABS INC 15MG/5ML

A040313 001 Sep 10, 2003 Jan CAHN

TABLET;ORAL

PREDNISOLONE

AB AUROBINDO PHARMA LTD 5MG

A215673 001 Mar 17, 2023 Mar NEWA

BX CHARTWELL MOLECULAR 5MG

A080531 002 May CMFD

AB +! WATSON LABS 5MG

A080354 001 Mar CTEC

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

PRED FORTE

AB	+! ABBVIE	1%	N017011	001	Jan CAHN
	PRED MILD				
	+! ABBVIE	0.12%	N017100	001	Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	EDENBRIDGE PHARMS	EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan NEWA
AA		EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan NEWA
AA	! MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jan CTEC
AA	XTTRIUM LABS INC	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Jan CAHN
AA	!	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan CAHN

PREDNISONE

SOLUTION; ORAL

PREDNISONE

@ XTTRIUM LABS INC 5MG/5ML

A089726 001 Aug 02, 1988 Jan CAHN

TABLET; ORAL

PREDNISONE

AB	+! HIKMA	2.5MG	A087801	001	Apr 22, 1982	Jan CRLD
AB	+!	5MG	A080352	001		Jan CRLD
AB	+!	50MG	A084283	001		Jan CRLD
AB	JUBILANT CADISTA	2.5MG	A040362	004	Apr 17, 2023	Apr NEWA
AB		50MG	A040362	005	Apr 17, 2023	Apr NEWA

PREGABALIN

CAPSULE; ORAL

PREGABALIN

AB	ACI	25MG	A215755	001	Apr 26, 2023	Apr NEWA
AB		50MG	A215755	002	Apr 26, 2023	Apr NEWA
AB		75MG	A215755	003	Apr 26, 2023	Apr NEWA
AB		100MG	A215755	004	Apr 26, 2023	Apr NEWA
AB		150MG	A215755	005	Apr 26, 2023	Apr NEWA
AB		200MG	A215755	006	Apr 26, 2023	Apr NEWA
AB		225MG	A215755	007	Apr 26, 2023	Apr NEWA
AB		300MG	A215755	008	Apr 26, 2023	Apr NEWA
AB	AUROBINDO PHARMA	25MG	A205321	001	Mar 29, 2023	Mar NEWA
AB		50MG	A205321	002	Mar 29, 2023	Mar NEWA
AB		75MG	A205321	003	Mar 29, 2023	Mar NEWA
AB		100MG	A205321	004	Mar 29, 2023	Mar NEWA
AB		150MG	A205321	005	Mar 29, 2023	Mar NEWA
AB		200MG	A205321	006	Mar 29, 2023	Mar NEWA
AB		225MG	A205321	007	Mar 29, 2023	Mar NEWA
AB		300MG	A205321	008	Mar 29, 2023	Mar NEWA
>A> AB	CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023	Jun NEWA
>A> AB		50MG	A206452	002	Jul 12, 2023	Jun NEWA
>A> AB		75MG	A206452	003	Jul 12, 2023	Jun NEWA
>A> AB		100MG	A206452	004	Jul 12, 2023	Jun NEWA
>A> AB		150MG	A206452	005	Jul 12, 2023	Jun NEWA
>A> AB		200MG	A206452	006	Jul 12, 2023	Jun NEWA
>A> AB		225MG	A206452	007	Jul 12, 2023	Jun NEWA
>A> AB		300MG	A206452	008	Jul 12, 2023	Jun NEWA
AB	CHARTWELL RX	50MG	A212865	001	Mar 20, 2020	Mar CAHN
AB		75MG	A212865	002	Mar 20, 2020	Mar CAHN
AB		100MG	A212865	003	Mar 20, 2020	Mar CAHN
AB		150MG	A212865	004	Mar 20, 2020	Mar CAHN
AB	YILING	75MG	A210891	001	Sep 30, 2019	Mar CAHN
AB		300MG	A210891	002	Sep 30, 2019	Mar CAHN
@ ZYDUS PHARMS		25MG	A206752	001	Dec 09, 2022	May DISC
@		50MG	A206752	002	Dec 09, 2022	May DISC
@		75MG	A206752	003	Dec 09, 2022	May DISC
@		100MG	A206752	004	Dec 09, 2022	May DISC
@		150MG	A206752	005	Dec 09, 2022	May DISC
@		200MG	A206752	006	Dec 09, 2022	May DISC
@		225MG	A206752	007	Dec 09, 2022	May DISC
@		300MG	A206752	008	Dec 09, 2022	May DISC

SOLUTION;ORAL

PREGABALIN

AA	PATRIN	20MG/ML	A212604	001	Feb 18, 2022	Jan CAHN
<u>TABLET, EXTENDED RELEASE;ORAL</u>						
	PREGABALIN					
	© SCIEGEN PHARMS INC	82.5MG	A215675	001	Sep 14, 2022	May DISC
	©	165MG	A215675	002	Sep 14, 2022	May DISC
	©	330MG	A215675	003	Sep 14, 2022	May DISC
AB	SINOATHERAPEUTICS INC	82.5MG	A214496	001	Jun 01, 2023	May NEWA
AB		165MG	A214496	002	Jun 01, 2023	May NEWA
AB		330MG	A214496	003	Jun 01, 2023	May NEWA
	© ZYDUS PHARMS	82.5MG	A215577	001	Aug 26, 2022	Jan DISC
	©	165MG	A215577	002	Aug 26, 2022	Jan DISC
	©	330MG	A215577	003	Aug 26, 2022	Jan DISC

PRIMIDONE

TABLET;ORAL

PRIMIDONE

RUBICON

125MG

A214896 003 Dec 28, 2022 May CTEC

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP	! HOSPIRA	500MG/ML	A089070	001	Feb 12, 1986	Feb CTEC
----	-----------	----------	---------	-----	--------------	----------

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

AB	AMNEAL	EQ 5MG BASE	A216598	001	Apr 17, 2023	Apr NEWA
AB		EQ 10MG BASE	A216598	002	Apr 17, 2023	Apr NEWA
AB	BIONPHARMA	EQ 5MG BASE	A217478	001	Apr 04, 2023	Mar NEWA
AB		EQ 10MG BASE	A217478	002	Apr 04, 2023	Mar NEWA
AB	GLENMARK PHARMS LTD	EQ 5MG BASE	A216595	001	Mar 17, 2023	Mar NEWA
AB		EQ 10MG BASE	A216595	002	Mar 17, 2023	Mar NEWA

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

>D> AA	AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Jun DISC
>A>	©	6.25MG/5ML	A040882	001	Dec 30, 2009	Jun DISC

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

© AUROBINDO PHARMA USA	12.5MG	A091054	001	Aug 30, 2011	Apr CAHN
©	25MG	A091054	002	Aug 30, 2011	Apr CAHN
©	50MG	A091054	003	Aug 30, 2011	Apr CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	225MG	A213096	001	Feb 21, 2023	Feb NEWA
AB		325MG	A213096	002	Feb 21, 2023	Feb NEWA
AB		425MG	A213096	003	Feb 21, 2023	Feb NEWA

PROPOFOL

INJECTABLE;INJECTION

PROPOFOL

AB	AVET LIFESCIENCES	10MG/ML	A206408	001	Oct 12, 2021	Jan CAHN
----	-------------------	---------	---------	-----	--------------	----------

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

>D> AB	IMPAK LABS INC	80MG	A071976	001	Apr 06, 1988	Jun CHRS
>A> AB	!	80MG	A071976	001	Apr 06, 1988	Jun CHRS
>D> AB	! WATSON LABS	80MG	A070178	001	May 13, 1986	Jun CHRS
>A> AB		80MG	A070178	001	May 13, 1986	Jun CHRS

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

AB	+! DAVA PHARMS INC	50MG	N006188	001		Apr CTEC
AB	MACLEODS PHARMS LTD	50MG	A208867	001	May 10, 2023	Apr NEWA

QUININE SULFATE

CAPSULE;ORAL
QUININE SULFATE
@ AUROBINDO PHARMA USA 324MG

A202581 001 Dec 14, 2012 May CAHN

RAMELTEON

TABLET;ORAL
RAMELTEON

>A> AB	AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Jun NEWA
AB	INNOGENIX	8MG	A215435	001	Aug 24, 2022	May CMFD
	@	8MG	A215435	001	Aug 24, 2022	Mar DISC
AB		8MG	A215435	001	Aug 24, 2022	Jan CAHN
AB	MICRO LABS	8MG	A215243	001	Feb 09, 2023	Feb NEWA

RAMIPRIL

CAPSULE;ORAL
RAMIPRIL
AB COREPHARMA 1.25MG
AB 2.5MG
AB 5MG
AB 10MG

A079116 001 Jun 20, 2008 Feb CAHN
A079116 002 Jun 20, 2008 Feb CAHN
A079116 003 Jun 20, 2008 Feb CAHN
A079116 004 Jun 20, 2008 Feb CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
RANITIDINE HYDROCHLORIDE
@ HIKMA EQ 25MG BASE/ML
@ EQ 25MG BASE/ML
@ ZYDUS PHARMS USA INC EQ 25MG BASE/ML
ZANTAC
+ @ PAI HOLDINGS PHARM EQ 25MG BASE/ML

A074777 001 Mar 02, 2005 May DISC
A077458 001 Feb 16, 2006 May DISC
A091534 001 Feb 22, 2013 May DISC
N019090 001 Oct 19, 1984 May DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL
RANEXA
+ @ GILEAD 500MG
+ @ 1GM
RANOLAZINE
AB ! SUN PHARM 1GM
AB UNICHEM 500MG
AB 1GM

N021526 002 Jan 27, 2006 Jan DISC
N021526 001 Feb 12, 2007 Jan DISC
A211707 002 May 28, 2019 Jan CHRS
A213083 001 Mar 16, 2023 Mar NEWA
A213083 002 Mar 16, 2023 Mar NEWA

REGADERONOSON

SOLUTION;INTRAVENOUS
REGADERONOSON
AP BAXTER HLTHCARE CORP 0.4MG/5ML (0.08MG/ML)
AP HIKMA 0.4MG/5ML (0.08MG/ML)
AP IMS LTD 0.4MG/5ML (0.08MG/ML)

A217455 001 May 23, 2023 May NEWA
A215827 001 Feb 02, 2023 Jan NEWA
A214252 001 May 23, 2022 Apr CMFD

REPAGLINIDE

TABLET;ORAL
REPAGLINIDE
AB MACLEODS PHARMS LTD 0.5MG
AB 1MG
AB 2MG

A207209 001 Mar 22, 2023 Mar NEWA
A207209 002 Mar 22, 2023 Mar NEWA
A207209 003 Mar 22, 2023 Mar NEWA

REZAFUNGIN ACETATE

POWDER;INTRAVENOUS
REZZAYO
+! CIDARA THERAPS EQ 200MG BASE/VIAL

N217417 001 Mar 22, 2023 Mar NEWA

RIBOFLAVIN 5'-PHOSPHATE

>A> SOLUTION/DROPS;OPHTHALMIC

>A> PHOTREXA

>A> +! GLAUKOS 0.146%

N203324 001 Apr 15, 2016 Jun CAIN

>A> PHOTREXA VISCOSUS IN DEXTRAN 20%

N203324 002 Apr 15, 2016 Jun CAIN

>A> +! GLAUKOS 0.146%

>D>	<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM</u>					
>D>	SOLUTION/DROPS;OPHTHALMIC					
>D>	PHOTREXA					
>D>	+!	GLAUKOS	0.146%	N 203324	001	Apr 15, 2016
>D>	PHOTREXA VISCOSUS IN DEXTRAN 20%					Jun CAIN
>D>	+!	GLAUKOS	0.146%	N 203324	002	Apr 15, 2016
	<u>RIMEGEPEANT SULFATE</u>					
	TABLET, ORALLY DISINTEGRATING;ORAL					
	NURTEC ODT					
	+!	PFIZER	EQ 75MG BASE	N 212728	001	Feb 27, 2020
						Feb CAHN
	<u>RISPERIDONE</u>					
	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR					
	RYKINDO					
	+!	SHANDONG LUYE	12.5MG	N 212849	001	Jan 13, 2023
	+!		25MG	N 212849	002	Jan 13, 2023
	+!		37.5MG	N 212849	003	Jan 13, 2023
	+!		50MG	N 212849	004	Jan 13, 2023
	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS					
	UZEDY					
	+!	TEVA	50MG/0.14ML (50MG/0.14ML)	N 213586	001	Apr 28, 2023
	+!		75MG/0.21ML (75MG/0.21ML)	N 213586	002	Apr 28, 2023
	+!		100MG/0.28ML (100MG/0.28ML)	N 213586	003	Apr 28, 2023
	+!		125MG/0.35ML (125MG/0.35ML)	N 213586	004	Apr 28, 2023
	+!		150MG/0.42ML (150MG/0.42ML)	N 213586	005	Apr 28, 2023
	+!		200MG/0.56ML (200MG/0.56ML)	N 213586	006	Apr 28, 2023
	+!		250MG/0.7ML (250MG/0.7ML)	N 213586	007	Apr 28, 2023
	TABLET;ORAL					
	RISPERIDONE					
	@	DASH PHARMS	0.25MG	A 076288	001	Sep 15, 2008
	@		0.5MG	A 076288	002	Sep 15, 2008
	@		1MG	A 076288	003	Sep 15, 2008
	@		2MG	A 076288	004	Sep 15, 2008
	@		3MG	A 076288	005	Sep 15, 2008
	@		4MG	A 076288	006	Sep 15, 2008
	TABLET, ORALLY DISINTEGRATING;ORAL					
	RISPERIDONE					
	@	DASH PHARMS	0.25MG	A 091537	006	Feb 12, 2013
	@		0.5MG	A 091537	001	Mar 30, 2011
	@		1MG	A 091537	002	Mar 30, 2011
	@		2MG	A 091537	003	Mar 30, 2011
	@		3MG	A 091537	004	Mar 30, 2011
	@		4MG	A 091537	005	Mar 30, 2011
>A>	<u>RITLEGITINIB TOSYLATE</u>					
>A>	CAPSULE;ORAL					
>A>	LITFULO					
>A>	+!	PFIZER	EQ 50MG BASE	N 215830	001	Jun 23, 2023
						Jun NEWA
	<u>RITONAVIR</u>					
	SOLUTION;ORAL					
	NORVIR					
	+ @	ABBVIE	80MG/ML	N 020659	001	Mar 01, 1996
						Feb DISC
	<u>RIZATRIPTAN BENZOATE</u>					
	FILM;ORAL					
	RIZAFILM					
	+!	INTEGENX CORP	EQ 10MG BASE	N 205394	001	Apr 14, 2023
	TABLET;ORAL					
	RIZATRIPTAN BENZOATE					
AB		CHARTWELL RX	EQ 5MG BASE	A 077526	001	Mar 26, 2013
AB			EQ 10MG BASE	A 077526	002	Mar 26, 2013
						May CAHN
	<u>ROCURONIUM BROMIDE</u>					
	INJECTABLE;INJECTION					
	ROCURONIUM BROMIDE					
AP		CAPLIN	50MG/5ML (10MG/ML)	A 216234	001	Mar 02, 2023
AP			100MG/10ML (10MG/ML)	A 216234	002	Mar 02, 2023
AP		HIKMA	50MG/5ML (10MG/ML)	A 217034	001	May 24, 2023
AP		HONG KONG	50MG/5ML (10MG/ML)	A 213453	001	May 08, 2023
						May NEWA
						Apr NEWA

INJECTABLE; INJECTION
ROCURONIUM BROMIDE

AP 100MG/10ML (10MG/ML) A213453 002 May 08, 2023 Apr NEWA

ROFLUMILAST

TABLET; ORAL
ROFLUMILAST

AB	ALKEM LABS LTD	250MCG	A212490	001	Apr 18, 2023	Apr NEWA
AB		500MCG	A212490	002	Apr 18, 2023	Apr NEWA
AB	AUROBINDO PHARMA LTD	500MCG	A213298	001	Apr 17, 2023	Apr NEWA
AB	HETERO LABS LTD III	250MCG	A208213	002	Apr 18, 2023	Apr NEWA
AB	MICRO LABS	250MCG	A208180	002	Apr 18, 2023	Apr NEWA
>A> AB	STRIDES PHARMA	250MCG	A208247	002	Jun 20, 2023	Jun NEWA
AB	ZYDUS PHARMS	250MCG	A208303	002	Apr 18, 2023	Apr NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
ROPINIROLE HYDROCHLORIDE

>D> AB	CELLTRION	EQ 0.25MG BASE	A079050	001	May 29, 2008	Jun CAHN
>D> AB		EQ 0.5MG BASE	A079050	002	May 29, 2008	Jun CAHN
>D> AB		EQ 1MG BASE	A079050	003	May 29, 2008	Jun CAHN
>D> AB		EQ 2MG BASE	A079050	004	May 29, 2008	Jun CAHN
>D> AB		EQ 3MG BASE	A079050	005	May 29, 2008	Jun CAHN
>D> AB		EQ 4MG BASE	A079050	006	May 29, 2008	Jun CAHN
>D> AB		EQ 5MG BASE	A079050	007	May 29, 2008	Jun CAHN
>A> AB	CHARTWELL RX	EQ 0.25MG BASE	A079050	001	May 29, 2008	Jun CAHN
>A> AB		EQ 0.5MG BASE	A079050	002	May 29, 2008	Jun CAHN
>A> AB		EQ 1MG BASE	A079050	003	May 29, 2008	Jun CAHN
>A> AB		EQ 2MG BASE	A079050	004	May 29, 2008	Jun CAHN
>A> AB		EQ 3MG BASE	A079050	005	May 29, 2008	Jun CAHN
>A> AB		EQ 4MG BASE	A079050	006	May 29, 2008	Jun CAHN
>A> AB		EQ 5MG BASE	A079050	007	May 29, 2008	Jun CAHN
@ MYLAN		EQ 0.25MG BASE	A078881	001	May 05, 2008	May DISC
@		EQ 0.5MG BASE	A078881	002	May 05, 2008	May DISC
@		EQ 1MG BASE	A078881	003	May 05, 2008	May DISC
@		EQ 2MG BASE	A078881	004	May 05, 2008	May DISC
@		EQ 3MG BASE	A078881	005	May 05, 2008	May DISC
@		EQ 4MG BASE	A078881	006	May 05, 2008	May DISC
@		EQ 5MG BASE	A078881	007	May 19, 2008	Mar DISC

TABLET, EXTENDED RELEASE; ORAL
ROPINIROLE HYDROCHLORIDE

>D> AB	CELLTRION	EQ 2MG BASE	A091395	001	Aug 27, 2012	Jun CAHN
>D> AB		EQ 4MG BASE	A091395	002	Aug 27, 2012	Jun CAHN
>D> AB		EQ 6MG BASE	A091395	003	Aug 27, 2012	Jun CAHN
>D> AB		EQ 8MG BASE	A091395	004	Aug 27, 2012	Jun CAHN
>D> AB		EQ 12MG BASE	A091395	005	Aug 27, 2012	Jun CAHN
>A> AB	CHARTWELL RX	EQ 2MG BASE	A091395	001	Aug 27, 2012	Jun CAHN
>A> AB		EQ 4MG BASE	A091395	002	Aug 27, 2012	Jun CAHN
>A> AB		EQ 6MG BASE	A091395	003	Aug 27, 2012	Jun CAHN
>A> AB		EQ 8MG BASE	A091395	004	Aug 27, 2012	Jun CAHN
>A> AB		EQ 12MG BASE	A091395	005	Aug 27, 2012	Jun CAHN

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION
ROPIVACAINE HYDROCHLORIDE

AP	AMNEAL	200MG/100ML (2MG/ML)	A216605	001	Mar 08, 2023	Feb NEWA
AP		400MG/200ML (2MG/ML)	A216605	002	Mar 08, 2023	Feb NEWA
AP		500MG/100ML (5MG/ML)	A216605	003	Mar 07, 2023	Feb NEWA
AP		1GM/200ML (5MG/ML)	A216605	004	Mar 07, 2023	Feb NEWA

>D> ROSIGLITAZONE MALEATE

>D>	TABLET; ORAL					
>D>	AVANDIA					
>D>	+ WOODWARD	EQ 2MG BASE	N021071	002	May 25, 1999	Jun DISC
>A>	+ @	EQ 2MG BASE	N021071	002	May 25, 1999	Jun DISC
>D>	+	EQ 4MG BASE	N021071	003	May 25, 1999	Jun DISC
>A>	+ @	EQ 4MG BASE	N021071	003	May 25, 1999	Jun DISC

RUCAPARIB CAMSYLATE

TABLET;ORAL						
RUBRACA						
+ ZR PHARMA	EQ 200MG BASE		N209115	001	Dec 19, 2016	May CAHN
+ ZR PHARMA	EQ 250MG BASE		N209115	003	May 01, 2017	May CAHN

RUFINAMIDE

SUSPENSION;ORAL						
RUFINAMIDE						
AB CHARTWELL RX	40MG/ML		A214009	001	Nov 07, 2022	May CAHN
TABLET;ORAL						
RUFINAMIDE						
>A> AB AUROBINDO PHARMA	200MG		A217230	001	Jun 16, 2023	Jun NEWA
>A> AB AUROBINDO PHARMA	400MG		A217230	002	Jun 16, 2023	Jun NEWA
AB MICRO LABS	200MG		A216688	001	May 15, 2023	May NEWA
AB MICRO LABS	400MG		A216688	002	May 15, 2023	May NEWA

SAFINAMIDE MESYLATE

TABLET;ORAL						
SAFINAMIDE MESYLATE						
>A> @ AUROBINDO PHARMA	EQ 50MG BASE		A215902	001	Jun 14, 2023	Jun DISC
>A> @ XADAGO	EQ 100MG BASE		A215902	002	Jun 14, 2023	Jun DISC
>D> + MDD US	EQ 50MG BASE		N207145	001	Mar 21, 2017	Jun CTEC
>A> + SELEGILINE HYDROCHLORIDE	EQ 50MG BASE		N207145	001	Mar 21, 2017	Jun CTEC
>D> +! SELEGILINE HYDROCHLORIDE	EQ 100MG BASE		N207145	002	Mar 21, 2017	Jun CTEC
>A> +! SELEGILINE HYDROCHLORIDE	EQ 100MG BASE		N207145	002	Mar 21, 2017	Jun CTEC

SELEGILINE HYDROCHLORIDE

TABLET;ORAL						
SELEGILINE HYDROCHLORIDE						
@ DASH PHARMS NATCO	5MG		A074866	001	Nov 26, 1997	Mar CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL						
SELENIUM SULFIDE						
@ XTTRIUM LABS INC	2.5%		A088228	001	Sep 01, 1983	Mar CAHN

SELEXIPAG

TABLET;ORAL						
SELEXIPAG						
@ ZYDUS	0.2MG		A214302	001	Dec 21, 2022	May DISC
@	0.4MG		A214302	002	Dec 21, 2022	May DISC
@	0.6MG		A214302	003	Dec 21, 2022	May DISC
@	0.8MG		A214302	004	Dec 21, 2022	May DISC
@	1MG		A214302	005	Dec 21, 2022	May DISC
@	1.2MG		A214302	006	Dec 21, 2022	May DISC
@	1.4MG		A214302	007	Dec 21, 2022	May DISC
@	1.6MG		A214302	008	Dec 21, 2022	May DISC
UPTRAVI						
+ ACTELION	0.2MG		N207947	001	Dec 21, 2015	May CTEC
+!	0.4MG		N207947	002	Dec 21, 2015	May CTEC
+	0.6MG		N207947	003	Dec 21, 2015	May CTEC
+	0.8MG		N207947	004	Dec 21, 2015	May CTEC
+	1MG		N207947	005	Dec 21, 2015	May CTEC
+	1.2MG		N207947	006	Dec 21, 2015	May CTEC
+	1.4MG		N207947	007	Dec 21, 2015	May CTEC
+	1.6MG		N207947	008	Dec 21, 2015	May CTEC

SERTRALINE HYDROCHLORIDE

TABLET;ORAL						
SERTRALINE HYDROCHLORIDE						
AB HERITAGE PHARMA AVET	EQ 25MG BASE		A076465	001	Aug 11, 2006	Mar CMFD
AB HERITAGE PHARMA AVET	EQ 50MG BASE		A076465	002	Aug 11, 2006	Mar CMFD
AB HERITAGE PHARMA AVET	EQ 100MG BASE		A076465	003	Aug 11, 2006	Mar CMFD
@ ZYDUS	EQ 25MG BASE		A077106	001	Feb 06, 2007	May CAHN
@	EQ 50MG BASE		A077106	002	Feb 06, 2007	May CAHN
@	EQ 100MG BASE		A077106	003	Feb 06, 2007	May CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL
SEVELAMER CARBONATE

AB	HANGZHOU ANPRIME	800MG/PACKET	A217319	001	Mar 02, 2023	Feb NEWA
AB		2.4GM/PACKET	A217319	002	Mar 02, 2023	Feb NEWA
	TABLET;ORAL SEVELAMER CARBONATE					
AB	MACLEODS PHARMS LTD	800MG	A206100	001	Apr 19, 2023	Apr NEWA

SEVELAMER HYDROCHLORIDE

TABLET;ORAL
SEVELAMER HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023	Jun NEWA
>A> AB		800MG	A212599	002	Jul 11, 2023	Jun NEWA
AB	MACLEODS PHARMS LTD	400MG	A206883	001	May 26, 2023	May NEWA
AB		800MG	A206883	002	May 26, 2023	May NEWA

SILDENAFIL CITRATE

SUSPENSION;ORAL
LIQREV

+! CMP DEV LLC EQ 10MG BASE/ML

TABLET;ORAL
SILDENAFIL CITRATE

AB	MACLEODS PHARMS LTD	EQ 25MG BASE	A202255	001	Apr 19, 2023	Apr NEWA
AB		EQ 50MG BASE	A202255	002	Apr 19, 2023	Apr NEWA
AB		EQ 100MG BASE	A202255	003	Apr 19, 2023	Apr NEWA

SILODOSIN

CAPSULE;ORAL
SILODOSIN

@ ZYDUS PHARMS 4MG
@ 8MG

A204816	001	Dec 08, 2022	May DISC
A204816	002	Dec 08, 2022	May DISC

SIPONIMOD

TABLET;ORAL
MAYZENT

+ NOVARTIS EQ 0.25MG BASE
+ EQ 1MG BASE
+! EQ 2MG BASE

N209884	001	Mar 26, 2019	May CAIN
N209884	003	Aug 24, 2021	May CAIN
N209884	002	Mar 26, 2019	May CAIN

SIROLIMUS

SOLUTION;ORAL
SIROLIMUS

AA	MSN	1MG/ML	A216728	001	Jan 19, 2023	Jan NEWA
AB	TABLET;ORAL SIROLIMUS					
AB	ZYDUS PHARMS	1MG	A201676	001	Feb 15, 2023	Feb NEWA

AB 2MG A201676 002 Feb 15, 2023 Feb NEWA

SODIUM BICARBONATE

INJECTABLE;INJECTION
SODIUM BICARBONATE

>A> AP	OMNIVIUM PHARMS	1MEQ/ML	A216364	001	Jun 15, 2023	Jun NEWA
>A> AP	STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Jun NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	@ ABRAXIS PHARM	9MG/ML	A088909	001	Feb 07, 1985	Jun CPOT
>D> AP	FRESENIUS KABI USA	9MG/ML	A088911	001	Feb 07, 1985	Jun CPOT
>D> AP	+! HOSPIRA	9MG/ML	N018800	001	Oct 29, 1982	Jun CPOT
	SODIUM CHLORIDE 0.9%					
>D>	+ B BRAUN	9MG/ML	N019635	005	Aug 08, 2016	Jun CPOT
	+	9MG/ML	N019635	005	Aug 08, 2016	Mar CPOT
>D>	HIKMA	9MG/ML	A201833	001	Sep 24, 2013	Jun CPOT
>D> AP		9MG/ML	A201850	001	Jan 20, 2012	Jun CPOT
>D> AP	SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017	Jun CPOT
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	@ ABBOTT	9MG/ML	N019218	001	Jul 13, 1984	Jun CPOT
>D> AP	+! BAXTER HLTHCARE	9MG/ML	N016677	004	Oct 30, 1985	Jun CTEC
>D> AP	+	9MG/ML	N020178	002	Dec 07, 1992	Jun CPOT

>D> INJECTABLE; INJECTION
 >D> SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 >D> AP +! 900MG/100ML N016677 001 Jun CDFR
 >D> AP +! 900MG/100ML N020178 001 Dec 07, 1992 Jun CDFR
 >D> AP ! FRESENIUS KABI USA 9MG/ML A088912 001 Jan 10, 1985 Jun CPOT
 >D> AP +! HOSPIRA 9MG/ML N018803 001 Oct 29, 1982 Jun CPOT
 >D> AP + 9MG/ML N019465 002 Jul 15, 1985 Jun CPOT
 >D> AP +! 900MG/100ML N019465 001 Jul 15, 1985 Jun CDFR
 >D> + @ ICU MEDICAL INC 9MG/ML N019217 001 Jul 13, 1984 Jun CPOT
 >D> @ JUBILANT CADISTA 9MG/ML A203352 001 May 18, 2016 Jun CPOT
 >D> + @ LIEBEL-FLARSHEIM 450MG/50ML (9MG/ML) N021569 001 Jul 27, 2006 Mar CPOT
 >D> + 1.125GM/125ML (9MG/ML) N021569 002 Jul 27, 2006 Mar CPOT
 >D> @ MILES 900MG/100ML N018502 001 Jun CDFR
 >D> AP NEPHRON 9MG/ML A211968 001 Apr 23, 2020 Jun CPOT
 >D> AP ! TARO 9MG/ML A077407 001 Aug 11, 2006 Jun CPOT
 SODIUM CHLORIDE 23.4%
 >D> FRESENIUS KABI USA 234MG/ML A212248 001 Apr 28, 2021 Jun CTEC
 >A> AP 234MG/ML A212248 001 Apr 28, 2021 Jun CTEC
 >A> AP 234MG/ML A217796 001 Jul 11, 2023 Jun NEWA
 SOLUTION; INJECTION
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 >A> @ ABRAXIS PHARM 90MG/10ML (9MG/ML) A088909 002 May 15, 1985 Jun CMS1
 >A> @ 270MG/30ML (9MG/ML) A088909 001 Feb 07, 1985 Jun CPOT
 >A> AP FRESENIUS KABI USA 90MG/10ML (9MG/ML) A088911 002 May 17, 1985 Jun CMS1
 >A> AP 270MG/30ML (9MG/ML) A088911 001 Feb 07, 1985 Jun CPOT
 >A> AP +! HOSPIRA 90MG/10ML (9MG/ML) N018800 001 Oct 29, 1982 Jun CPOT
 >A> AP +! 180MG/20ML (9MG/ML) N018800 002 Oct 29, 1982 Jun CMS1
 >A> AP +! 270MG/30ML (9MG/ML) N018800 003 Oct 29, 1982 Jun CMS1
 SODIUM CHLORIDE 0.9%
 >A> + B BRAUN 90MG/10ML (9MG/ML) N019635 005 Aug 08, 2016 Jun CPOT
 >A> HIKMA 18MG/2ML (9MG/ML) A201833 001 Sep 24, 2013 Jun CPOT
 >A> AP 90MG/10ML (9MG/ML) A201833 002 Jan 07, 2015 Jun CMS1
 >A> AP 90MG/10ML (9MG/ML) A201850 001 Jan 20, 2012 Jun CPOT
 >A> AP SPECTRA MDCL DEVICES 45MG/5ML (9MG/ML) A206171 001 Jul 21, 2017 Jun CPOT
 >A> AP 90MG/10ML (9MG/ML) A206171 002 Jul 21, 2017 Jun CMS1
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 >A> @ ABBOTT 90MG/10ML (9MG/ML) N019218 001 Jul 13, 1984 Jun CPOT
 >A> @ 180MG/20ML (9MG/ML) N019218 002 Apr 30, 1985 Jun CMS1
 >A> +! BAXTER HLTHCARE 225MG/25ML (9MG/ML) N016677 004 Oct 30, 1985 Jun CTEC
 >A> AP +! 450MG/50ML (9MG/ML) N016677 003 Jun CMS1
 >A> AP + 450MG/50ML (9MG/ML) N020178 002 Dec 07, 1992 Jun CPOT
 >A> AP +! 900MG/100ML N016677 001 Jun CDFR
 >A> AP +! 900MG/100ML N020178 001 Dec 07, 1992 Jun CDFR
 >A> ! FRESENIUS KABI USA 18MG/2ML (9MG/ML) A088912 004 Nov 29, 1985 Jun CMS1
 >A> AP ! 90MG/10ML (9MG/ML) A088912 001 Jan 10, 1985 Jun CPOT
 >A> AP ! 180MG/20ML (9MG/ML) A088912 002 Jan 10, 1985 Jun CMS1
 >A> AP ! 270MG/30ML (9MG/ML) A088912 003 Jan 10, 1985 Jun CMS1
 >A> AP +! HOSPIRA 90MG/10ML (9MG/ML) N018803 001 Oct 29, 1982 Jun CPOT
 >A> + @ 18MG/2ML (9MG/ML) N018803 004 Jan 22, 2015 Jun CMS1
 >A> + @ 27MG/3ML (9MG/ML) N018803 005 Jan 22, 2015 Jun CMS1
 >A> + @ 45MG/5ML (9MG/ML) N018803 006 Jan 22, 2015 Jun CMS1
 >A> AP +! 180MG/20ML (9MG/ML) N018803 002 Oct 29, 1982 Jun CMS1
 >A> AP +! 450MG/50ML (9MG/ML) N018803 003 Oct 29, 1982 Jun CMS1
 >A> AP + 450MG/50ML (9MG/ML) N019465 002 Jul 15, 1985 Jun CPOT
 >A> AP +! 900MG/100ML N019465 001 Jul 15, 1985 Jun CDFR
 >A> + @ ICU MEDICAL INC 45MG/5ML (9MG/ML) N019217 002 Nov 18, 1998 Jun CMS1
 >A> + @ 90MG/10ML (9MG/ML) N019217 003 Nov 18, 1998 Jun CMS1
 >A> + @ 360MG/40ML (9MG/ML) N019217 004 Apr 01, 1999 Jun CMS1
 >A> @ JUBILANT CADISTA 27MG/3ML (9MG/ML) A203352 002 May 18, 2016 Jun CMS1
 >A> @ 90MG/10ML (9MG/ML) A203352 001 May 18, 2016 Jun CPOT
 >A> @ MILES 450MG/50ML (9MG/ML) N018502 002 Jun CMS1
 >A> @ 900MG/100ML N018502 001 Jun CDFR
 >A> AP NEPHRON 450MG/50ML (9MG/ML) A211968 001 Apr 23, 2020 Jun CPOT
 >A> AP 900MG/100ML A211968 002 Apr 23, 2020 Jun CMS1
 >A> AP ! TARO 45MG/5ML (9MG/ML) A077407 001 Aug 11, 2006 Jun CPOT
 >A> AP ! 90MG/10ML (9MG/ML) A077407 002 Aug 11, 2006 Jun CMS1
 SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE
 >A> + @ ICU MEDICAL INC 90MG/10ML (9MG/ML) N019217 001 Jul 13, 1984 Jun CPOT

SODIUM OXYBATE

FOR SUSPENSION, EXTENDED RELEASE;ORAL
LUMRYZ

>D>	+ AVADEL CNS	4.5GM/PACKET	N 214755	001	May 01, 2023	Jun CHRS
>A>	+!	4.5GM/PACKET	N 214755	001	May 01, 2023	Jun CHRS
	+	4.5GM/PACKET	N 214755	001	May 01, 2023	May NEWA
	+	6GM/PACKET	N 214755	002	May 01, 2023	May NEWA
	+	7.5GM/PACKET	N 214755	003	May 01, 2023	May NEWA
	+	9GM/PACKET	N 214755	004	May 01, 2023	May NEWA

SODIUM PHENYLBUTYRATE

POWDER;ORAL
BUPHENYL

AB	+! HORIZON THERAP US	3GM/TEASPOONFUL	N 020573	001	Apr 30, 1996	Jan CAHN
AB	+! HORIZON THERAP US	500MG	N 020572	001	May 13, 1996	Jan CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION
SODIUM PHOSPHATES

AP	! FRESENIUS KABI USA	142MG/ML;276MG/ML	A 209997	001	Mar 30, 2022	Mar CHRS
----	----------------------	-------------------	----------	-----	--------------	----------

SOLIFENACIN SUCCINATE

TABLET;ORAL
SOLIFENACIN SUCCINATE

AB	CHARTWELL RX	5MG	A 210582	001	May 20, 2019	May CAHN
AB		10MG	A 210582	002	May 20, 2019	May CAHN
AB	LANNETT CO INC	5MG	A 211622	001	Jun 06, 2023	May NEWA
AB		10MG	A 211622	002	Jun 06, 2023	May NEWA

SORAFENIB TOSYLATE

TABLET;ORAL
SORAFENIB TOSYLATE

AB	TORRENT	EQ 200MG BASE	A 217095	001	Apr 12, 2023	Mar NEWA
----	---------	---------------	----------	-----	--------------	----------

SOTAGLIFLOZIN

TABLET;ORAL
INPEFA
+ LEXICON PHARMS INC

+! 400MG

N 216203	001	May 26, 2023	May NEWA
N 216203	002	May 26, 2023	May NEWA

SOTORASIB

TABLET;ORAL
LUMAKRAS

+ AMGEN INC 120MG
+! 320MG
+ 320MG

N 214665	001	May 28, 2021	Mar CHRS
N 214665	002	Jan 20, 2023	Mar CHRS
N 214665	002	Jan 20, 2023	Feb NEWA

SPARENTEAN

TABLET;ORAL
FILSPARI

+ TRAVERE 200MG
+! 400MG

N 216403	001	Feb 17, 2023	Feb NEWA
N 216403	002	Feb 17, 2023	Feb NEWA

STERILE WATER FOR INJECTION

LIQUID;N/A
STERILE WATER FOR INJECTION

AP	HIKMA	100%	A 212735	001	Jan 31, 2023	Jan NEWA
>D>	+! HOSPIRA	100% (20ML)	N 018801	003	Oct 27, 1982	Jun CFTG
>A> AP	+!	100% (20ML)	N 018801	003	Oct 27, 1982	Jun CFTG
>D>	+!	100% (5.2ML)	N 018801	006	May 02, 2023	Jun DISC
>A>	+ @	100% (5.2ML)	N 018801	006	May 02, 2023	Jun DISC
	+!	100% (5.2ML)	N 018801	006	May 02, 2023	May NEWA
>A> AP	NEXUS PHARMS	100% (10ML)	A 217536	001	Jul 11, 2023	Jun NEWA
>A> AP		100% (20ML)	A 217536	002	Jul 11, 2023	Jun NFTG

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

AP	@ BRECKENRIDGE	20MG/ML	A212638	001	Oct 09, 2019	Apr DISC
	MANKIND PHARMA	20MG/ML	A216127	001	Feb 02, 2023	Jan NEWA

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB	ZYDUS LIFESCIENCES	1GM	A215705	001	May 03, 2023	Apr NEWA
----	--------------------	-----	---------	-----	--------------	----------

SUFENTANIL CITRATE

TABLET; SUBLINGUAL

DSUVIA

+! VERTICAL PHARMS

EQ 0.03MG BASE

N209128 001 Nov 02, 2018 Apr CAHN

SUGAMMADEX SODIUMSOLUTION; INTRAVENOUS
BRIDION

>D>	+	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jun CFTG
>A> AP	+		EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jun CFTG
>D>	+!		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jun CFTG
>A> AP	+!		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jun CFTG
		SUGAMMADEX SODIUM					
>A> AP		ASPIRO	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214337	001	Jun 09, 2023	Jun NFTG
>A> AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214337	002	Jun 09, 2023	Jun NFTG
>A> AP		MYLAN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A213915	001	Jun 15, 2023	Jun NEWA
>A> AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A213915	002	Jun 15, 2023	Jun NEWA
>A> AP		SANDOZ	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214311	001	Jun 23, 2023	Jun NEWA
>A> AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214311	002	Jun 23, 2023	Jun NEWA

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

@ AKORN

10%

A040215 001 May 25, 1999 Jan DISC

SULINDAC

TABLET; ORAL

SULINDAC

@ CHARTWELL RX

150MG

A072712 001 Aug 30, 1991 Jan CAHN

@

200MG

A072713 001 Aug 30, 1991 Jan CAHN

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

AB	HANGZHOU ZHONGMEI	EQ 0.5MG BASE	A210929	001	Apr 17, 2023	Apr NEWA
AB		EQ 1MG BASE	A210929	002	Apr 17, 2023	Apr NEWA
AB		EQ 5MG BASE	A210929	003	Apr 17, 2023	Apr NEWA

Tadalafil

TABLET; ORAL

ALYQ

@ TEVA PHARMS INC

20MG

A216932 001 Oct 12, 2022 Apr DISC

Tadalafil

AB2	CHARTWELL RX	20MG	A210572	001	Feb 05, 2019	May CAHN
AB1	NOVITIUM PHARMA	5MG	A215949	001	Mar 03, 2023	Feb NEWA
AB1		10MG	A215949	002	Mar 03, 2023	Feb NEWA
AB1		20MG	A215949	003	Mar 03, 2023	Feb NEWA
AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Jan CTEC
AB1		5MG	A209250	002	Mar 26, 2019	Jan CTEC
AB1		10MG	A209250	003	Mar 26, 2019	Jan CTEC
AB1		20MG	A209250	004	Mar 26, 2019	Jan CTEC
AB2	ZYDUS PHARMS	20MG	A212515	001	Jun 06, 2023	May NEWA

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

+! MAYNE PHARMA COMMRCIAL EQ 20MG BASE/10ML

N021807 001 Oct 29, 2005 Feb CAHN

TASIMELTEON

CAPSULE;ORAL

TASIMELTEON

AB	APOTEX	20MG	A211607	001	Dec 20, 2022	Jan CAHN
AB	MSN	20MG	A211654	001	Jan 12, 2023	Jan NEWA

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

AB	ZYDUS LIFESCIENCES	5%	A212294	001	Apr 10, 2023	Mar NEWA
----	--------------------	----	---------	-----	--------------	----------

TAZAROTENE

GEL;TOPICAL

TAZAROTENE

AB	PADAGIS ISRAEL	0.05%	A213079	001	Apr 25, 2023	Apr NEWA
AB		0.1%	A213079	002	Apr 25, 2023	Apr NEWA
AB	SOLARIS PHARMA CORP	0.05%	A213644	001	Mar 20, 2023	Mar NEWA
AB		0.1%	A213644	002	Mar 20, 2023	Mar NEWA

TECHNETIUM TC-99M MERTIATIDE KIT

POWDER;INTRAVENOUS

TECHNETIUM TC 99M MERTIATIDE KIT

+! JUBILANT DRAXIMAGE N/A

N216820 001 Jan 30, 2023 Jan NEWA

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB	CHARTWELL RX	20MG	A078710	001	Jan 08, 2014	May CAHN
AB		40MG	A078710	002	Jan 08, 2014	May CAHN
AB		80MG	A078710	003	Jan 08, 2014	May CAHN

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

TENOFOVIR ALAFENAMIDE

AB	LUPIN LTD	EQ 25MG BASE	A214226	001	Mar 30, 2023	Mar NFTG
AB	VEMLIDY		N208464	001	Nov 10, 2016	Mar CFTG
+!	GILEAD SCIENCES INC	EQ 25MG BASE				

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB	REYOUNG PHARM	300MG	A211337	001	Mar 02, 2023	Feb NEWA
----	---------------	-------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

@	BIONPHARMA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Apr CAHN
@		EQ 2MG BASE	A075667	002	Jul 28, 2000	Apr CAHN
@		EQ 5MG BASE	A075667	003	Jul 28, 2000	Apr CAHN
@		EQ 10MG BASE	A075667	004	Jul 28, 2000	Apr CAHN

TABLET;ORAL

TERAZOSIN HYDROCHLORIDE

@	CHARTWELL RX	EQ 1MG BASE	A074657	001	Apr 28, 2000	May CAHN
@		EQ 2MG BASE	A074657	002	Apr 28, 2000	May CAHN
@		EQ 5MG BASE	A074657	003	Apr 28, 2000	May CAHN
@		EQ 10MG BASE	A074657	004	Apr 28, 2000	May CAHN

TERIFLUONIDE

TABLET;ORAL

TERIFLUONIDE

AB	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb CMFD
AB		14MG	A209613	002	Sep 28, 2018	Feb CMFD
AB	APOTEX	7MG	A209601	001	Nov 02, 2018	Jan CMFD
AB		14MG	A209601	002	Nov 02, 2018	Jan CMFD
AB	AUROBINDO PHARMA	7MG	A209638	001	Oct 26, 2018	Jan CMFD
AB		14MG	A209638	002	Oct 26, 2018	Jan CMFD

TABLET;ORALTERIFLUONOMIDE

AB	BIOCON PHARMA	7MG	A209639	001	Mar 13, 2023	Mar NEWA
AB		14MG	A209639	002	Mar 13, 2023	Mar NEWA
AB	HETERO LABS LTD V	7MG	A209598	001	Mar 13, 2023	Mar NEWA
AB		14MG	A209598	002	Mar 13, 2023	Mar NEWA
AB	MSN	7MG	A209623	001	Apr 24, 2019	Feb CMFD
AB		14MG	A209623	002	Apr 24, 2019	Feb CMFD
AB	MYLAN	7MG	A209702	001	Feb 28, 2020	Feb CMFD
AB		14MG	A209702	002	Feb 28, 2020	Feb CMFD
AB	NATCO	7MG	A209555	001	May 15, 2023	May NEWA
AB		14MG	A209555	002	May 15, 2023	May NEWA
AB	SOLA PHARMS	14MG	A209677	001	Jun 17, 2020	Feb CMFD
AB	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Feb CMFD
AB		14MG	A209700	002	Sep 04, 2018	Feb CMFD
AB	ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	Jan CMFD
AB		14MG	A209668	002	Nov 30, 2018	Jan CMFD

TESTOSTERONEGEL, METERED;NASAL
NATESTO

+! ACERUS 5.5MG/0.122GM ACTUATION
+ 5.5MG/0.122GM ACTUATION

N205488 001 May 28, 2014 Jan CHRS
N205488 001 May 28, 2014 Jan CRLD

GEL, METERED;TRANSDERMAL
ANDROGEL

AB +! BESINS HLTHCARE 1.62% (20.25MG/1.25GM ACTUATION)
+ @ 12.5MG/1.25GM ACTUATION

N022309 001 Apr 29, 2011 Feb CAHN
N021015 003 Sep 26, 2003 Feb CAHN

TESTOSTERONE

AB ENCUBE 1.62% (20.25MG/1.25GM ACTUATION)

A208620 001 Apr 10, 2019 Jan CAHN

TESTOSTERONE CYPIONATEINJECTABLE;INJECTION
TESTOSTERONE CYPIONATE

AO XIROMED 100MG/ML
AO 200MG/ML

A215351 001 Apr 13, 2023 Mar NEWA
A215351 002 Apr 13, 2023 Mar NEWA

TETRABENAZINETABLET;ORAL
TETRABENAZINE

AB	CHARTWELL RX	12.5MG	A210544	001	Apr 20, 2018	May CAHN
AB		25MG	A210544	002	Apr 20, 2018	May CAHN
	@ SUN PHARM	12.5MG	A206129	001	Aug 17, 2015	Jan DISC
	@	25MG	A206129	002	Aug 17, 2015	Jan DISC

TETRACYCLINE HYDROCHLORIDECAPSULE;ORAL
TETRACYCLINE HYDROCHLORIDE

@ AUROBINDO PHARMA USA	250MG	A060783	001	Apr CAHN
@	500MG	A060783	002	Apr CAHN

THALIDOMIDECAPSULE;ORAL
THALIDOMIDE

AB	NATCO	150MG	A213267	001	Apr 27, 2023	Apr NFTG
	THALOMID					
AB	+ CELGENE	150MG	N020785	004	Jan 10, 2007	Apr CFTG

THEOPHYLLINETABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB	AMNEAL	300MG	A216276	001	Mar 20, 2023	Mar NEWA
AB		450MG	A216276	002	Mar 20, 2023	Mar NEWA
AB	BIONPHARMA	300MG	A216300	001	Apr 26, 2023	Apr NEWA
AB		450MG	A216300	002	Apr 26, 2023	Apr NEWA
AB	LEADING	300MG	A214950	001	Jan 30, 2023	Jan NEWA
AB		450MG	A214950	002	Jan 30, 2023	Jan NEWA
AB	RHODES PHARMS	300MG	A214113	001	May 11, 2023	May NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A215692	001	Mar 06, 2023	Feb NEWA
AP	DR REDDYS	100MG/ML	A080571	001		Mar CMFD
!		200MG/ML	A080571	002		Mar CMFD

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

@	CHARTWELL RX	10MG	A088131	001	Aug 30, 1983	Jan CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan CAHN

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

AP	PENN LIFE	15MG/VIAL	A208242	001	Jan 10, 2020	May CAHN
----	-----------	-----------	---------	-----	--------------	----------

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

AB	RISING	1MG	A071093	002	Jun 23, 1987	Feb CAHN
AB		2MG	A071093	003	Jun 23, 1987	Feb CAHN
AB		5MG	A071093	004	Jun 23, 1987	Feb CAHN
AB		10MG	A071093	001	Jun 23, 1987	Feb CAHN

TICAGRELOR

TABLET; ORAL

TICAGRELOR

AB	ALKEM LABS LTD	90MG	A208567	001	Apr 21, 2023	Apr NEWA
----	----------------	------	---------	-----	--------------	----------

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

+!	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Jan CTEC
+!		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Jan CTEC
@	AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Jan DISC
@		EQ 0.5% BASE	A205309	002	Sep 30, 2016	Jan DISC

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AB	EUGIA PHARMA	EQ 0.5% BASE	A213540	001	Mar 23, 2023	Mar NEWA
AB	GLAND PHARMA LTD	EQ 0.5% BASE	A214645	002	Feb 14, 2023	Feb NEWA

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

@	AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Jan DISC
AT1	MICRO LABS	EQ 0.25% BASE	A217343	001	May 26, 2023	May NEWA
AT1		EQ 0.5% BASE	A217343	002	May 26, 2023	May NEWA
AT3	SENTISS PHARMA	EQ 0.5% BASE	A217195	001	May 08, 2023	Apr NEWA

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

AB	CHARTWELL RX	250MG	A202044	001	Apr 30, 2012	Apr CAHN
AB		500MG	A202044	002	Apr 30, 2012	Apr CAHN

TIOPRONIN

TABLET, DELAYED RELEASE; ORAL

THIOLA EC

+!	MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019	Apr CTEC
AB	+	100MG	N211843	001	Jun 28, 2019	Feb CFTG
AB	+	300MG	N211843	002	Jun 28, 2019	Apr CTEC
AB	+	300MG	N211843	002	Jun 28, 2019	Feb CFTG

TABLET, DELAYED RELEASE;ORALTIOPRONIN

AB	@ PAR PHARM	100MG 100MG	A217219 001 Feb 24, 2023 A217219 001 Feb 24, 2023	Apr DISC Feb NFTG
AB	@	300MG 300MG	A217219 002 Feb 24, 2023 A217219 002 Feb 24, 2023	Apr DISC Feb NFTG

TIOTROPIUM BROMIDEPOWDER; INHALATION
SPIRIVA

>D>	+! BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395 001 Jan 30, 2004	Jun CFTG
>A> AB	+!	EQ 0.018MG BASE/INH	N021395 001 Jan 30, 2004	Jun CFTG
>A>	TIOTROPIUM BROMIDE			
>A> AB	LUPIN	EQ 0.018MG BASE/INH	A211287 001 Jun 20, 2023	Jun NFTG

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINETABLET;ORAL
LONSURF

>D>	+ TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981 001 Sep 22, 2015	Jun CFTG
>A> AB	+	EQ 6.14MG BASE;15MG	N207981 001 Sep 22, 2015	Jun CFTG
>D>	+!	EQ 8.19MG BASE;20MG	N207981 002 Sep 22, 2015	Jun CFTG
>A> AB	+!	EQ 8.19MG BASE;20MG	N207981 002 Sep 22, 2015	Jun CFTG
>A>	TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE			
>A> AB	NATCO	EQ 6.14MG BASE;15MG	A214008 001 Jun 13, 2023	Jun NFTG
>A> AB		EQ 8.19MG BASE;20MG	A214008 002 Jun 13, 2023	Jun NFTG

TIROFIBAN HYDROCHLORIDESOLUTION;INTRAVENOUS
AGGRASTAT

AP	+ MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913 002 May 17, 2002	Jan CFTG
AP	TIROFIBAN HYDROCHLORIDE EUGIA PHARMA	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	A216379 001 May 01, 2023	Apr NEWA
AP		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A216379 002 May 01, 2023	Apr NEWA
AP	NEXUS PHARMS	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	A213947 001 Feb 07, 2023	Jan NFTG

TIZANIDINE HYDROCHLORIDETABLET;ORAL
TIZANIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA USA	EQ 2MG BASE	A076282 001 Dec 16, 2003	Apr CAHN
@	EQ 4MG BASE	A076282 002 Dec 16, 2003	Apr CAHN

TOBRAMYCINSOLUTION;INHALATION
TOBRAMYCIN

>A> AN	MANKIND PHARMA	300MG/5ML	A214478 001 Jun 30, 2023	Jun NEWA
	SOLUTION/DROPS;OPHTHALMIC AKTOB			

@ AKORN 0.3%

A064096 001 Jan 31, 1996 Feb DISC

TOBRAMYCIN SULFATEINJECTABLE;INJECTION
TOBRAMYCIN SULFATE

>A> AP	EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519 001 Jun 21, 2023	Jun NEWA
AP	HAINAN POLY	EQ 1.2GM BASE/VIAL	A217029 001 Feb 01, 2023	Jan NEWA

TOFACITINIB CITRATETABLET;ORAL
TOFACITINIB CITRATE

AB	@ MICRO LABS	EQ 5MG BASE	A209738 001 Mar 13, 2023	Mar DISC
AB	ZYDUS PHARMS	EQ 5MG BASE	A209738 001 Mar 13, 2023	Mar NFTG
	XELJANZ		A209829 001 Mar 13, 2023	Mar NEWA
AB	+ PF PRISM CV	EQ 5MG BASE	N203214 001 Nov 06, 2012	Mar CFTG

TOFERSEN

SOLUTION; INTRATHECAL
QALSODY
+! BIOGEN MA 100MG/15ML (6.7MG/ML) N215887 001 Apr 25, 2023 Apr NEWA

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM
! RISING EQ 600MG BASE A074473 001 Aug 30, 1994 May CMFD

TOLVAPTAN

TABLET; ORAL
TOLVAPTAN
>A> AB MSN 15MG A216949 001 Jun 21, 2023 Jun NEWA
>A> AB 30MG A216949 002 Jun 21, 2023 Jun NEWA

TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL
TOPIRAMATE
AB1 ACTAVIS LABS FL 25MG A206210 001 Mar 10, 2023 Mar NEWA
AB1 50MG A206210 002 Mar 10, 2023 Mar NEWA
AB1 100MG A206210 003 Mar 10, 2023 Mar NEWA
AB1 200MG A206210 004 Mar 10, 2023 Mar NEWA
>A> AB1 ALKEM LABS LTD 25MG A217248 001 Jun 20, 2023 Jun NEWA
>A> AB1 50MG A217248 002 Jun 20, 2023 Jun NEWA
>A> AB1 100MG A217248 003 Jun 20, 2023 Jun NEWA
>A> AB1 200MG A217248 004 Jun 20, 2023 Jun NEWA
AB1 PAR PHARM 25MG A205976 002 May 04, 2023 Apr NEWA
AB1 50MG A205976 003 May 04, 2023 Apr NEWA
AB1 100MG A205976 004 May 04, 2023 Apr NEWA
AB1 200MG A205976 001 Mar 01, 2023 Feb NEWA
AB1 ZYDUS 25MG A207382 001 Nov 24, 2017 Jan CAHN
AB2 25MG A208949 001 Nov 29, 2022 Jan CAHN
AB1 50MG A207382 002 Nov 24, 2017 Jan CAHN
AB2 50MG A208949 002 Nov 29, 2022 Jan CAHN
AB1 100MG A207382 003 Nov 24, 2017 Jan CAHN
AB2 100MG A208949 003 Nov 29, 2022 Jan CAHN
AB2 150MG A208949 004 Nov 29, 2022 Jan CAHN
AB2 200MG A208949 005 Nov 29, 2022 Jan CAHN
AB1 ZYDUS PHARMS TROKENDI XR A216167 001 Feb 09, 2023 Jan NFTG
AB1 +! SUPERNUS PHARMS 200MG N201635 004 Aug 16, 2013 Jan CFTG

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL
HYCAMTIN
+! SANDOZ EQ 0.25MG BASE N020981 001 Oct 11, 2007 May CAHN
+! EQ 1MG BASE N020981 002 Oct 11, 2007 May CAHN
INJECTABLE; INJECTION
HYCAMTIN
AP +! SANDOZ EQ 4MG BASE/VIAL N020671 001 May 28, 1996 May CAHN
SOLUTION; INTRAVENOUS
TOPOTECAN HYDROCHLORIDE
@ DASH PHARMS EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A206074 001 Nov 24, 2017 Mar CAHN

TORSEMIDE

TABLET; ORAL
SOAANZ
>D> +! SARFE PHARMS 20MG N213218 001 Jun 14, 2021 Jun DISC
>A> + @ 20MG N213218 001 Jun 14, 2021 Jun DISC
>D> + 60MG N213218 002 Jun 14, 2021 Jun DISC
>A> + @ 60MG N213218 002 Jun 14, 2021 Jun DISC

TRAMETINIB DIMETHYL SULFOXIDE

SOLUTION; ORAL
MEKINIST
+! NOVARTIS EQ 0.05MG BASE/ML N217513 001 Mar 16, 2023 Mar NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB	AUROBINDO PHARMA	50MG	A204852	001	Feb 05, 2020	Jan CAHN
AB		100MG	A204852	002	Feb 05, 2020	Jan CAHN
AB		150MG	A204852	003	Feb 05, 2020	Jan CAHN
AB		300MG	A204852	004	Feb 05, 2020	Jan CAHN

TREPROSTINILINJECTABLE;IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

AP	DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Feb CMFD
AP		2.5MG/ML	A210214	002	May 22, 2020	Feb CMFD
AP		5MG/ML	A210214	003	May 22, 2020	Feb CMFD
AP		10MG/ML	A210214	004	May 22, 2020	Feb CMFD

TRETINOIN

CREAM;TOPICAL

RETIN-A

AB	+! BAUSCH	0.025%	N019049	001	Sep 16, 1988	Jan CAHN
	GEL;TOPICAL					
	AVITA					

@ MYLAN

0.025%

N020400 001 Jan 29, 1998 May DISC

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	CHARTWELL RX	0.025%	A208763	001	Feb 01, 2017	May CAHN
AT		0.1%	A208763	002	Feb 01, 2017	May CAHN
AT		0.5%	A208763	003	Feb 01, 2017	May CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	CHARTWELL RX	0.05%	A214532	001	Jan 27, 2023	May CAHN
AT		0.1%	A207365	001	Oct 12, 2018	Apr CAHN
AT	GLASSHOUSE PHARMS	0.05%	A214532	001	Jan 27, 2023	Jan NEWA

SPRAY;TOPICAL

KENALOG

>D>	KENALOG					
>D> AT	+! SUN PHARM INDNS INC	0.147MG/GM	N012104	001		Jun DISC

>A> + @

0.147MG/GM

N012104 001 Jun DISC

TRIAMCINOLONE ACETONIDE

>D> AT	PADAGIS ISRAEL	0.147MG/GM	A205782	001	Apr 13, 2015	Jun CHRS
>A> AT	!	0.147MG/GM	A205782	001	Apr 13, 2015	Jun CHRS

TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE

@ EYWA	50MG	A214768	001	Jul 06, 2022	Jan DISC
@	100MG	A214768	002	Jul 06, 2022	Jan DISC

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

AB	MSN	250MG	A211134	001	May 22, 2019	Mar CTEC
----	-----	-------	---------	-----	--------------	----------

TROFINETIDE

SOLUTION;ORAL

DAYBUE

+! ACADIA PHARMS INC	200MG/ML	N217026	001	Mar 10, 2023	Mar NEWA
----------------------	----------	---------	-----	--------------	----------

UBROGEPEANT

TABLET;ORAL

UBREIVY

+! ABBVIE	50MG	N211765	001	Dec 23, 2019	Jan CAHN
+!	100MG	N211765	002	Dec 23, 2019	Jan CAHN

URSODIOL

CAPSULE;ORAL	URSODIOL					
@ MYLAN	300MG	A090530	001	Feb 17, 2010	Jan DISC	
>A> AB	RK PHARMA	300MG	A214329	001	Jul 28, 2021	Jun CAHN
>D> AB	VGYAAN	300MG	A214329	001	Jul 28, 2021	Jun CAHN
AB		300MG	A214329	001	Jul 28, 2021	Apr CMFD

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL	VALACYCLOVIR HYDROCHLORIDE					
AB	CHARTWELL RX	EQ 500MG BASE	A090216	001	May 24, 2010	Jan CAHN
AB		EQ 1GM BASE	A090216	002	May 24, 2010	Jan CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL	VALCYTE					
AB	+! CHEPLAPHARM	50MG/ML	N022257	001	Aug 28, 2009	Mar CAHN
	VALGANCICLOVIR HYDROCHLORIDE					
AB	APPCO	50MG/ML	A216317	001	Apr 11, 2023	Mar NEWA
	TABLET;ORAL					
	VALCYTE					
AB	+! CHEPLAPHARM	EQ 450MG BASE	N021304	001	Mar 29, 2001	Mar CAHN

VALPROIC ACID

SYRUP;ORAL	VALPROIC ACID					
AA	QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Apr CAHN
@	XTTRIUM LABS INC	250MG/5ML	A070868	001	Jul 01, 1986	Mar CAHN

VALSARTAN

SOLUTION;ORAL	VALSARTAN					
!	NOVITIUM PHARMA	20MG/5ML	A214102	001	Nov 02, 2021	Jan CHRS

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION;ORAL	VANCOCIN HYDROCHLORIDE					
>D>	! ANI PHARMS	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Jun CTEC
>A> AA	!	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Jun CTEC
	VANCOMYCIN HYDROCHLORIDE					
>A> AA	AMNEAL	EQ 250MG BASE/5ML	A215338	001	Jun 23, 2023	Jun NEWA
	INJECTABLE; INJECTION					
	VANCOMYCIN HYDROCHLORIDE					
AP	GLAND PHARMA LTD	EQ 5GM BASE/VIAL	A205694	003	Jun 06, 2023	May NEWA
AP		EQ 10GM BASE/VIAL	A205694	004	Jun 06, 2023	May NEWA
AP	HIKMA	EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Jan CMFD
	POWDER; INTRAVENOUS					
	VANCOMYCIN HYDROCHLORIDE					
>A> AP	HIKMA	EQ 1.25GM BASE/VIAL	A217489	001	Jun 29, 2023	Jun NFTG
>A> AP		EQ 1.5GM BASE/VIAL	A217489	002	Jun 29, 2023	Jun NFTG
>D>	+! MYLAN LABS LTD	EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018	Jun CFTG
>A> AP	+	EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018	Jun CFTG
>D>	+	EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018	Jun CFTG
>A> AP	+	EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018	Jun CFTG
	POWDER; INTRAVENOUS, ORAL					
	VANCOMYCIN HYDROCHLORIDE					
+!	ZHEJIANG NOVUS PHARM	EQ 500MG BASE/VIAL	N210274	001	Jan 20, 2023	Jan NEWA
+!		EQ 1GM BASE/VIAL	N210274	002	Jan 20, 2023	Jan NEWA
+!		EQ 5GM BASE/VIAL	N210274	003	Jan 20, 2023	Jan NEWA
+!		EQ 10GM BASE/VIAL	N210274	004	Jan 20, 2023	Jan NEWA

VARENICLINE TARTRATE

TABLET;ORAL	VARENICLINE TARTRATE					
AB	APOTEX	EQ 0.5MG BASE	A201962	001	Jan 25, 2023	Jan NEWA
AB		EQ 1MG BASE	A201962	002	Jan 25, 2023	Jan NEWA
AB	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jan CTEC
AB	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Jan CTEC
>A> AB	ZYDUS	EQ 0.5MG BASE	A216723	001	Jun 12, 2023	Jun CAHN
>A> AB		EQ 1MG BASE	A216723	002	Jun 12, 2023	Jun CAHN

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

AP	FRESENIUS KABI USA VASOSTRICT	20UNITS/ML (20UNITS/ML)	A213206	001	May 26, 2023	May NEWA
+!	PAR STERILE PRODUCTS	50UNITS/50ML (1UNITS/ML)	N204485	006	Apr 12, 2023	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	GRANULES	EQ 37.5MG BASE	A217390	001	May 18, 2023	May NEWA
AB		EQ 75MG BASE	A217390	002	May 18, 2023	May NEWA
AB		EQ 150MG BASE	A217390	003	May 18, 2023	May NEWA
AB	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	Mar NEWA
AB		EQ 75MG BASE	A200430	002	Apr 04, 2023	Mar NEWA
AB		EQ 150MG BASE	A200430	003	Apr 04, 2023	Mar NEWA

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

@	CHARTWELL RX	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan CAHN
@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan CAHN
@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan CAHN
@		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan CAHN
@		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 37.5MG BASE	A214691	001	Apr 12, 2023	Mar NEWA
AB		EQ 75MG BASE	A214691	002	Apr 12, 2023	Mar NEWA
AB		EQ 150MG BASE	A214691	003	Apr 12, 2023	Mar NEWA
AB		EQ 225MG BASE	A214691	004	Apr 12, 2023	Mar NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

+ @	Pfizer	120MG	N019152	003	Mar 06, 1991	Mar DISC
+ @		240MG	N019152	001	Dec 16, 1986	Mar DISC
		VERAPAMIL HYDROCHLORIDE				
AB	CADILA PHARMS LTD	120MG	A206173	003	Nov 14, 2022	Mar NEWA
AB	! GLENMARK GENERICS	120MG	A090700	001	Aug 03, 2011	Mar CHRS
AB	!	240MG	A078906	001	Sep 17, 2009	Mar CHRS

VIGABATRIN

FOR SOLUTION; ORAL

VIGABATRIN

@	ACCORD HLTHCARE	500MG/PACKET	A214425	001	Nov 13, 2020	Mar DISC
@	CHARTWELL RX	500MG/PACKET	A211790	001	Mar 10, 2022	May CAHN
AA	ZYDUS	500MG/PACKET	A214671	001	Mar 02, 2023	Feb NEWA
		VIGABATRIN				
AB	PROPEL PHARMA	500MG	A215519	001	Apr 28, 2023	Apr NEWA
>A> AB	ZENARA	500MG	A214749	001	Jun 29, 2023	Jun NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

AB	+! ABBVIE	10MG	N022567	001	Jan 21, 2011	Jan CAHN
AB	+	20MG	N022567	002	Jan 21, 2011	Jan CAHN
AB	+	40MG	N022567	003	Jan 21, 2011	Jan CAHN
		VILAZODONE HYDROCHLORIDE				
>A> AB	APOTEX	10MG	A208228	001	Jul 07, 2023	Jun NEWA
>A> AB		20MG	A208228	002	Jul 07, 2023	Jun NEWA
>A> AB		40MG	A208228	003	Jul 07, 2023	Jun NEWA

VORICONAZOLE

INJECTABLE; INTRAVENOUS

VORICONAZOLE

AP	EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Jan NEWA
AP	UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Mar NEWA
AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar CDFR

TABLET;ORAL
VORICONAZOLE

AB	CHARTWELL RX	50MG	A207371	001	May 24, 2016	Apr CAHN
AB		200MG	A207371	002	May 24, 2016	Apr CAHN

VUTRISIRAN SODIUM

SOLUTION;SUBCUTANEOUS
AMVUTTRA

+!	ALNYLAM PHARMS INC	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N215515	001	Jun 13, 2022	Feb CPOT
+!		25MG/0.5ML (25MG/0.5ML)	N215515	001	Jun 13, 2022	Feb CAIN

WARFARIN SODIUM

TABLET;ORAL
WARFARIN SODIUM

@	AUROBINDO PHARMA USA	1MG	A040415	001	Sep 27, 2004	May CAHN
@		2MG	A040415	002	Sep 27, 2004	May CAHN
@		2.5MG	A040415	003	Sep 29, 2004	May CAHN
@		3MG	A040415	004	Sep 27, 2004	May CAHN
@		4MG	A040415	005	Sep 27, 2004	May CAHN
@		5MG	A040415	006	Sep 27, 2004	May CAHN
@		6MG	A040415	007	Sep 27, 2004	May CAHN
@		7.5MG	A040415	008	Sep 27, 2004	May CAHN
@		10MG	A040415	009	Sep 27, 2004	May CAHN

XENON XE-129 HYPERPOLARIZED

GAS;INHALATION
XENOVIEW

+!	POLAREAN	N/A	N214375	001	Dec 23, 2022	Jan NEWA
----	----------	-----	---------	-----	--------------	----------

ZAVEGEPAINT HYDROCHLORIDE

SPRAY, METERED;NASAL
ZAVZPRET

+!	PFIZER	EQ 10MG BASE/SPRAY	N216386	001	Mar 09, 2023	Mar NEWA
----	--------	--------------------	---------	-----	--------------	----------

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL
ZILEUTON

AB	! RISING	600MG	A204929	001	Mar 17, 2017	Jan CHRS
	ZYFLO CR					
+ @	CHIESI	600MG	N022052	001	May 30, 2007	Jan DISC

ZINC SULFATE

SOLUTION;INTRAVENOUS
ZINC SULFATE

AP	FRESENIUS KABI USA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216145	001	Dec 27, 2022	May CAIN
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216145	002	Dec 27, 2022	May CAIN
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216145	003	Dec 27, 2022	May CAIN

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS
RECLAST

AP	+! SANDOZ	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	May CAHN
AP	ZOLEDRONIC ACID					
>D> AP	HONG KONG	EQ 5MG BASE/100ML	A213371	001	Jun 05, 2023	May NEWA
>A> AP	INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Jun DISC
>A>	@	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Jun DISC

ZOLMITRIPTAN

SPRAY;NASAL
ZOMIG

AB	+ AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Jan CAHN
AB	+!	5MG/SPRAY	N021450	004	Sep 30, 2003	Jan CAHN

TABLET;ORAL
ZOLMITRIPTAN

>D> AB	AJANTA PHARMA LTD	5MG	A204041	002	May 20, 2016	Jun CHRS
>A> AB	!	5MG	A204041	002	May 20, 2016	Jun CHRS
	ZOMIG					
>D> AB	+ IPR	2.5MG	N020768	001	Nov 25, 1997	Jun DISC
>A>	+ @	2.5MG	N020768	001	Nov 25, 1997	Jun DISC
>D> AB	+ !	5MG	N020768	002	Nov 25, 1997	Jun DISC
>A>	+ @	5MG	N020768	002	Nov 25, 1997	Jun DISC

TABLET, ORALLY DISINTEGRATING;ORAL
ZOLMITRIPTAN

>D> AB	ZYDUS PHARMS USA INC	5MG	A202890	002	May 15, 2013	Jun CHRS
>A> AB	!	5MG	A202890	002	May 15, 2013	Jun CHRS
>D>	ZOMIG-ZMT					
>D> AB	+ ASTRazeneca	2.5MG	N021231	001	Feb 13, 2001	Jun DISC
>A>	+ @	2.5MG	N021231	001	Feb 13, 2001	Jun DISC
>D> AB	+!	5MG	N021231	002	Sep 17, 2001	Jun DISC
>A>	+ @	5MG	N021231	002	Sep 17, 2001	Jun DISC

ZOLPIDEM TARTRATE

CAPSULE;ORAL
ZOLPIDEM TARTRATE

+! ALMATICHA	7.5MG	N215721	001	May 09, 2023	May NEWA
TABLET, EXTENDED RELEASE;ORAL					
ZOLPIDEM TARTRATE					
@ ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011	May DISC
@	12.5MG	A078148	001	Dec 03, 2010	May DISC

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL
EXCEDRIN (MIGRAINE RELIEF)
+! GLAXOSMITHKLINE CONS 250MG;250MG;65MG N 020802 001 Jan 14, 1998 Apr CTNA

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL
ACETAMINOPHEN AND IBUPROFEN
>A> L PERRIGO CO 250MG;125MG A 214836 001 Feb 28, 2023 Feb NEWA
MARKSANS PHARMA 250MG;125MG A 216994 001 Jul 10, 2023 Jun NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC
ALCAFTADINE
>A> EUGIA PHARMA 0.25% A 210659 001 Jun 23, 2023 Jun NEWA

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
AUROBINDO PHARMA LTD 5MG;120MG A 212409 001 Mar 08, 2023 Feb NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL
SOLUPREP S
+! 3M HEALTH CARE 2%;70% N 208288 001 Aug 08, 2018 Mar CTNA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
COREPHARMA 25MG;220MG A 211830 001 Aug 22, 2019 Feb CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM
GUARDIAN DRUG EQ 20MG BASE A 216149 001 Mar 15, 2023 Mar NEWA
TABLET, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM
>A> AUROBINDO PHARMA LTD EQ 20MG BASE A 214473 001 Jul 12, 2023 Jun NEWA

FAMOTIDINE

TABLET;ORAL
FAMOTIDINE
MARKSANS PHARMA 10MG A 217543 001 Mar 08, 2023 Feb NEWA
20MG A 217543 002 Mar 08, 2023 Feb NEWA

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL
FEXOFENADINE HYDROCHLORIDE
AUROBINDO PHARMA LTD 30MG/5ML A 213466 001 May 23, 2023 May NEWA
TABLET;ORAL
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
AUROBINDO PHARMA USA 30MG A 202039 001 Nov 19, 2014 Apr CAHN
FEXOFENADINE HYDROCHLORIDE ALLERGY
AUROBINDO PHARMA USA 60MG A 202039 002 Nov 19, 2014 Apr CAHN
180MG A 202039 003 Nov 19, 2014 Apr CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE
GRANULES 600MG;60MG A 216082 001 Aug 22, 2022 Feb DISC
@ 1.2GM;120MG A 216082 002 Aug 22, 2022 Feb DISC

IBUPROFEN

SUSPENSION;ORAL
IBUPROFEN
>D> ARISE 100MG/5ML A 200457 001 Aug 18, 2011 Jun DISC
>A> @ 100MG/5ML A 200457 001 Aug 18, 2011 Jun DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
AUROBINDO PHARMA LTD 200MG;30MG

A213565 001 Mar 10, 2023 Mar NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
© GRANULES 2MG;125MG

A215981 001 Aug 29, 2022 Feb DISC

LORATADINE

CAPSULE; ORAL

LORATADINE

AUROBINDO PHARMA 10MG

A211900 001 Mar 24, 2023 Mar NEWA

MOMETASONE FUBROATE

SPRAY, METERED; NASAL

MOMETASONE FUBROATE

>A> AMNEAL 0.05MG/SPRAY

A217460 001 Jun 14, 2023 Jun NFTG

NALOXONE HYDROCHLORIDE

SPRAY, METERED; NASAL

NARCAN

+! EMERGENT 4MG/SPRAY

N208411 001 Nov 18, 2015 Mar CMKT

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

@ STRIDES PHARMA EQ 200MG BASE

A215472 001 Aug 17, 2022 Feb DISC

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

>D> FERTIN PHARMA EQ 4MG BASE
>A> © EQ 4MG BASEA214354 001 Dec 21, 2022 Jun DISC
A214354 001 Dec 21, 2022 Jun DISCOLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ AKORN EQ 0.1% BASE
© EQ 0.2% BASEA204532 001 Jan 10, 2017 Jan DISC
A204723 001 Dec 05, 2017 Jan DISCOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE MAGNESIUM

AUROBINDO PHARMA LTD EQ 20MG BASE

A213201 001 Apr 28, 2023 Apr NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>A> AUROBINDO PHARMA 20MG;1.1GM
>D> AUROLIFE PHARMA LLC 20MG;1.1GM
ZYDUS 20MG;1.1GMA204923 001 Nov 07, 2016 Jun CAHN
A204923 001 Nov 07, 2016 Jun CAHN
A203345 001 Mar 16, 2018 May CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2023

NO JUNE 2023 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2023 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	>A> 8129385	Oct 05, 2027	DS DP			
	>A> 8129385*PED	Apr 05, 2028				
	>A> 9242986	Dec 08, 2029	DS DP			
	>A> 9242986*PED	Jun 08, 2030				
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD</u>						
N 215413 001	>A> 8129385	Oct 05, 2027	DS DP			
	>A> 8129385*PED	Apr 05, 2028				
	>A> 9242986	Dec 08, 2029	DS DP			
	>A> 9242986*PED	Jun 08, 2030				
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	8748382	Oct 03, 2027	U-2009		I-907	
	8748382	Oct 03, 2027	U-3543			Dec 19, 2025
	RE49444	Apr 28, 2031	U-2009			
	RE49444	Apr 28, 2031	U-3543			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABROCITINIB - CIBINOO</u>						
N 213871 001					NPP	
						Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 002					NPP	
						Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 003					NPP	
						Feb 09, 2026
<u>ACETAMINOPHEN; IBUPROFEN - COMBOGESIC</u>						
N 209471 001	10532036	Sep 22, 2025	U-3553		NP	
	11197830	Feb 27, 2039	DP U-3553			
	11534407	Feb 27, 2039	DP U-3553			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001					NCE ODE-352	Dec 12, 2027 Dec 12, 2029
<u>ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA</u>						
N 214070 001	9415009	May 28, 2030	U-3509		NP	Jan 10, 2026
<u>ALENDRONATE SODIUM - ALENDRONATE SODIUM</u>						
A 214512 001					CGT	Nov 20, 2023
<u>ALPELISIB - PIORAY</u>						
N 212526 001 >A> 8227462		Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - PIORAY</u>						
N 212526 002 >A> 8227462		Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - PIORAY</u>						
N 212526 003 >A> 8227462		Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - VIJOICE</u>						
N 215039 001 >A> 8227462		Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039 002 >A> 8227462		Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039 003 >A> 8227462		Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001 >A> 11571478		Jan 12, 2038	U-3163			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001 11540981		Feb 07, 2028	DP			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR</u>						
N 208147 001 11590228		Sep 07, 2036	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5</u>						
N 210526 001 11590081		Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10</u>						
N 210526 002 11590081		Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15</u>						
N 210526 003 11590081		Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20</u>						
N 210526 004 11590081		Sep 24, 2038	DP U-3538			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001 11559559		Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002 11559559		Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003 11559559		Dec 18, 2034	U-3514			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001 10052314		Sep 23, 2033	U-2381	Y		
	10052314	Sep 23, 2033	U-2382	Y		
	9481663	Jun 04, 2033	DS DP U-2237			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	9481663 RE49353	Jun 04, 2033 Sep 23, 2033	DS DP U-2624 U-2381			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	10702508 10849888 8445507 8445507 8802689 8802689 9388159 9481663 9481663 9884054 9987261 RE49353	Apr 30, 2038 Sep 23, 2033 Sep 15, 2030 Sep 15, 2030 Mar 27, 2027 Mar 27, 2027 Mar 27, 2027 Jun 04, 2033 Jun 04, 2033 Sep 23, 2033 Mar 27, 2027 Sep 23, 2033	U-3012 U-3013 DS DP U-2237 DS DP U-2624 U-2237 U-2624 DS DP DS DP U-2237 DS DP U-2624 U-2237 DP U-2381			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	>A> 11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	>A> 11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	>A> 11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	>A> 11648347	Apr 06, 2034	DP			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFI</u>						
N 217006 001	10517951 10517951 11097007 11097007 11638757 11638757 8338427 8338428 8399469 8759351	Apr 23, 2033 Apr 23, 2033 Apr 23, 2033 Apr 23, 2033 Apr 23, 2033 Apr 23, 2033 Mar 15, 2025 Aug 06, 2023 Jun 29, 2025 Aug 06, 2023	DP U-3245 DP U-814 DP U-3245 DP U-814 DP U-3245 DP U-814 DP U-1530 DP U-1530 DS DP U-1530			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFI</u>						
N 217006 002	10517951 10517951 11097007 11097007 11638757 11638757 8338427 8338428 8399469 8759351	Apr 23, 2033 Apr 23, 2033 Apr 23, 2033 Apr 23, 2033 Apr 23, 2033 Apr 23, 2033 Mar 15, 2025 Aug 06, 2023 Jun 29, 2025 Aug 06, 2023	DP U-3245 DP U-814 DP U-3245 DP U-814 DP U-3245 DP U-814 DP U-1530 DP U-1530 DS DP U-1530			
<u>ASPIRIN - VAZALORE</u>						
N 203697 001	10646431 10786444	Sep 29, 2032 Sep 29, 2032	DP U-3559			
<u>ASPIRIN - VAZALORE</u>						
N 203697 002	10646431 10786444	Sep 29, 2032 Sep 29, 2032	DP U-3559			
<u>ATOGEPANT - OULIPTA</u>						
N 215206 001	8754096 9499545	Jul 19, 2032 Nov 10, 2031	DS DP U-3534 DS DP U-3534	I-909		Apr 17, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOGEPANT - OULIPTA</u>						
N 215206 001	8754096 9499545	Jul 19, 2032 Nov 10, 2031	DS DP U-3534 DS DP U-3534		I-909	Apr 17, 2026
<u>ATOGEPANT - OULIPTA</u>						
N 215206 002	8754096 9499545	Jul 19, 2032 Nov 10, 2031	DS DP U-3534 DS DP U-3534		I-909	Apr 17, 2026
<u>ATOGEPANT - OULIPTA</u>						
N 215206 003	8754096 9499545	Jul 19, 2032 Nov 10, 2031	DS DP U-3534 DS DP U-3534		I-909	Apr 17, 2026
<u>ATORVASTATIN CALCIUM - ATORVALTO</u>						
N 213260 001	11369567 11654106 11654106	Jun 07, 2037 Jun 07, 2037 Jun 07, 2037	DP DP U-3612 DP U-3613			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11603356	May 29, 2041	DS DP U-3558			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	>A> 9200002 >A> 9200002 >A> 9944651 >A> 9944651 >A> 9994575 >A> 9994575	Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034	DS DP U-3168 DS DP U-3506 DS DP U-3168 DS DP U-3506 DS DP U-3168 DS DP U-3506			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001					NPP	Dec 20, 2025
<u>AZACITIDINE - VIDAZA</u>						
N 050794 001					ODE-399	May 20, 2029
<u>AZACITIDINE - ONUREG</u>						
N 214120 001	11571436	May 14, 2029	DP			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	11571436	May 14, 2029	DP			
<u>BACLOFEN - BACLOFEN</u>						
A 217252 001					>A> PC	Dec 16, 2023
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	>A> 11654124	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	>A> 11654124	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	>A> 11654124	Jul 29, 2039	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	9737469	Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	9737469	Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	9737469	Nov 02, 2031	U-3500			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11613511	Jun 19, 2040	DS			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	11613511	Jun 19, 2040	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11541026	Feb 19, 2040	U-3356			
	11628155	Dec 27, 2040	U-3356			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	11618733	Nov 01, 2039	U-3300			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	11618733	Nov 01, 2039	U-3300			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA</u>						
N 213422 001	>A> 11638711	Mar 18, 2039	DP			
<u>BEXAGLIFLOZIN - BRENZAVVY</u>						
N 214373 001	10533032	Jul 03, 2031	U-2214		NCE	Jan 20, 2028
	10981942	Jun 13, 2031	DS DP			
	7838499	Jan 30, 2029	DS DP U-2214			
	8106021	Aug 22, 2028	U-2214			
	8802637	Aug 22, 2028	DS DP U-2214			
	8987323	May 14, 2032	DS DP			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	>A> 7777050	Mar 13, 2024	DS DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 001	>A> 11679119	Sep 23, 2042	U-3632			
	>A> 11679119	Sep 23, 2042	U-3633			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 002	>A> 11679119	Sep 23, 2042	U-3632			
	>A> 11679119	Sep 23, 2042	U-3633			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	11590209	Apr 29, 2041	U-3539			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	11596600	Jul 27, 2029	U-2222			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - BUDESONIDE</u>						
A 215328 001					CGT	Oct 24, 2023
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					ODE-389	Dec 15, 2028
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE</u>						
N 216579 001	10716753	May 28, 2030	DP U-3203			
	9415009	May 28, 2030	U-3203			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 001	10912772	Jul 26, 2032	U-3617			
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 002	10912772	Jul 26, 2032	U-3617			
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	10912772	Jul 26, 2032	U-3617			
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 004	10912772	Jul 26, 2032	U-3617			
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 005	10912772	Jul 26, 2032	U-3617			
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 006	10912772	Jul 26, 2032	U-3617			
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 007	10912772	Jul 26, 2032	U-3617			
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11534414	Nov 05, 2034	DP U-3419			
	11541021	Nov 05, 2034	U-3419			
	11541048	Nov 05, 2034	U-3419			
	11596627	Nov 05, 2034	U-3419			
	11617728	Nov 05, 2034	U-3419			
	11617747	Nov 05, 2034	U-3563			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11554102	Jan 11, 2033	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	11576894	Jul 06, 2030	DP			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11633369	Jun 17, 2035	DP U-2780			
	11633369	Jun 17, 2035	DP U-2781			
	11633369	Jun 17, 2035	DP U-3071			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	11529357	Jan 31, 2040	DP			
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11439613	Mar 28, 2039	U-3557			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750	I-904		Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 001	11654133	Jun 16, 2039	U-3610			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 002	11654133	Jun 16, 2039	U-3610			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 003	11654133	Jun 16, 2039	U-3610			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 004	11654133	Jun 16, 2039	U-3610			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 005	11654133	Jun 16, 2039	U-3610			
<u>CENOBAKATE - XCOPRI</u>						
N 212839 006	11654133	Jun 16, 2039	U-3610			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP S</u>						
N 208288 001					M-292	Jan 20, 2026
<u>CHLOROPROCaine HYDROCHLORIDE - IHEEZO</u>						
N 216227 001					NP	Sep 27, 2025
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Sep 06, 2023	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	8143240	Jan 12, 2024	U-2942			
	>A> 8865690	Jul 24, 2024	U-2942			
	>A> 9211295	Jul 24, 2024	DP			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 001	11541002	Jan 31, 2040	DP U-724			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 002	11541002	Jan 31, 2040	DP	U-724		
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 003	11541002	Jan 31, 2040	DP	U-724		
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	11597699	Oct 05, 2026	U-3554		ODE-416	Oct 28, 2029
<u>COLCHICINE - LODOCO</u>						
N 215727 001	>A> 10130585 >A> 10206891 >A> 10265281 >A> 10842762 >A> 11026899 >A> 11026900 >A> 11026901 >A> 9744144	Dec 31, 2034 Jan 22, 2035 Jan 22, 2035 Jan 22, 2035 Jan 22, 2035 Jan 22, 2035 Jan 22, 2035 Jan 22, 2035	U-3642 U-3641 U-3639 U-3640 U-3639 U-3639 U-3638 U-3643			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE-407	Jul 14, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE-407	Jul 14, 2029
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 001	>A> 10849916 >A> 11382923	Jul 13, 2035 Dec 01, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 002	>A> 10849916 >A> 11382923	Jul 13, 2035 Dec 01, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 003	>A> 10849916 >A> 11382923	Jul 13, 2035 Dec 01, 2035	DP			
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	11612658	Jan 27, 2026	U-3560		NP	Jun 23, 2024
<u>CYCLOSPORINE - VEVYE</u>						
N 217469 001	>A> 10813976 >A> 11154513 >A> 11413323 >A> 8614178	Sep 22, 2037 Nov 20, 2038 Oct 11, 2039 Dec 13, 2030	DP DP U-1900 U-3627 DP			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11642370 11648262 >A> 11679125 >A> 11684636	Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039	DP DP DP DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11510941 11510942	Mar 02, 2039 Jan 15, 2039	DP DP U-2752			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912 10028912	Oct 15, 2032 Oct 15, 2032	DP U-3149 DP U-3150			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869 10869869*PED 7994185	Aug 30, 2033 Mar 02, 2034 Jan 20, 2030	U-3185 I-894 I-908 DS DP U-1406		ODE-147	Jun 22, 2025 Mar 16, 2026 Jun 22, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP		ODE-428	Mar 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8703781	Oct 15, 2030	DS DP U-3565			
	8835443	Jun 10, 2025	U-3565			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	May 23, 2028		U-3499		
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 001	11117871	Mar 13, 2038	DS DP	U-3535	NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS	U-3535		
	11649217	Mar 13, 2038		DP U-3535		
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027		U-1238		
	8815884	Jun 22, 2027	DP	U-1238		
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 002	11117871	Mar 13, 2038	DS DP	U-3535	NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS	U-3535		
	11649217	Mar 13, 2038		DP U-3535		
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027		U-1238		
	8815884	Jun 22, 2027	DP	U-1238		
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 003	11117871	Mar 13, 2038	DS DP	U-3535	NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS	U-3535		
	11649217	Mar 13, 2038		DP U-3535		
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027		U-1238		
	8815884	Jun 22, 2027	DP	U-1238		
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 004	11117871	Mar 13, 2038	DS DP	U-3535	NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS	U-3535		
	11649217	Mar 13, 2038		DP U-3535		
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027		U-1238		
	8815884	Jun 22, 2027	DP	U-1238		
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 005	11117871	Mar 13, 2038	DS DP	U-3535	NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS	U-3535		
	11649217	Mar 13, 2038		DP U-3535		
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027		U-1238		
	8815884	Jun 22, 2027	DP	U-1238		
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	8975254	Mar 25, 2033	DS DP	U-2605		
<u>DARUNAVIR - DARUNAVIR</u>						
A 202073 002				>A PC		Nov 28, 2023
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001				ODE-417	Apr 30, 2028	
				ODE-420	Apr 30, 2028	
				ODE-421	Apr 30, 2028	
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002				ODE-417	Apr 30, 2028	
				ODE-420	Apr 30, 2028	
				ODE-421	Apr 30, 2028	
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001				ODE-417	Apr 30, 2028	
				ODE-418	Apr 30, 2028	
				ODE-419	Apr 30, 2028	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002					ODE-417 ODE-418 ODE-419	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001					ODE-417 ODE-420 ODE-421	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	11446291 11446291*PED 11564917 11564917*PED 11648244 11648244*PED >A> 11666566	Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Sep 18, 2033	U-1995	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11446291 11446291*PED 11564917 11564917*PED 11648244 11648244*PED >A> 11666566	Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Sep 18, 2033	U-1995	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	11446291 11446291*PED 11564917 11564917*PED 11648244 11648244*PED >A> 11666566	Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Sep 18, 2033	U-1995	DP		
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	10959996 10959996*PED 11179386 11179386 11179386*PED 11311488 11311488 11357772 11357772 11357772*PED 11446291 11446291*PED 11564917 11564917*PED 11648244 11648244*PED 8524733 8524733*PED 9550780 9550780 9550780*PED	Mar 07, 2036 Sep 07, 2036 Mar 15, 2038 Mar 15, 2038 Sep 15, 2038 Jun 10, 2041 Jun 10, 2041 Mar 07, 2036 Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Mar 07, 2036 Sep 07, 2036 Apr 03, 2031 Oct 03, 2031 Sep 18, 2033 Sep 18, 2033 Mar 18, 2034	U-3055	DP U-1995 DP U-3055 DP U-1995 DP U-3055 DP U-1995 DP U-3055 U-1995 U-1995 U-1995 U-1995 U-1995 U-1995 U-1995 DS DP DS DP U-1995 DS DP U-3055		
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	10959996 10959996*PED 11179386 11179386 11179386*PED 11311488	Mar 07, 2036 Sep 07, 2036 Mar 15, 2038 Mar 15, 2038 Sep 15, 2038 Jun 10, 2041	U-3055	DP U-1995 DP U-3055 DP U-1995 DP U-3055		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 005					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	>A> 11497711	Jun 26, 2039	DP U-3645			
	>A> 11517524	Jun 26, 2039	DP U-3645			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	>A> 11497711	Jun 26, 2039	DP U-3645			
	>A> 11517524	Jun 26, 2039	DP U-3645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	11559501	Jan 06, 2042	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 001	>A> 10398785	Mar 14, 2036	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 002	>A> 10398785	Mar 14, 2036	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 003	>A> 10398785	Mar 14, 2036	DP			
<u>DONEPEZIL HYDROCHLORIDE - ADILARITY</u>						
N 212304 001	11648214	Sep 23, 2037	DP U-3334			
	>A> 11679086	May 26, 2037	U-3334			
<u>DONEPEZIL HYDROCHLORIDE - ADILARITY</u>						
N 212304 002	11648214	Sep 23, 2037	DP U-3334			
	>A> 11679086	May 26, 2037	U-3334			
<u>DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE</u>						
A 215408 001				CGT		Aug 16, 2023
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	11617751	Jul 17, 2030	DP U-1			
	11617751	Jul 17, 2030	DP U-3572			
	11617751	Jul 17, 2030	DP U-3573			
	11617751	Jul 17, 2030	DP U-3574			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	11617751	Jul 17, 2030	DP U-1			
	11617751	Jul 17, 2030	DP U-3572			
<u>DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM - XACDURO (COPACKAGED)</u>						
N 216974 001	>A> 10376499	Nov 17, 2035	DP U-2840			
	>A> 9309245	Apr 02, 2033	DS			
	>A> 9623014	Apr 02, 2033	U-2840			
	>A> 9968593	Nov 17, 2035	DP U-2840			
<u>EFINACONAZOLE - JUBILIA</u>						
N 203567 001	>A> 11654139	Oct 02, 2034	U-1969			
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 001	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2023	DS DP U-3523			
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 002	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 002	7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2023	DS DP U-3523			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	11542239	Jul 23, 2039	DS DP			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	11542239	Jul 23, 2039	DS DP			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	11542239	Jul 23, 2039	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	11639347	Apr 09, 2027	DS DP U-3587			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	11639347	Apr 09, 2027	DS DP U-3587			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		>A> ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		>A> ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	>A> 10258637	Apr 03, 2034	U-2290		>A> I-869	Aug 18, 2024
	>A> 10258637*PED	Oct 03, 2034			>A> M-82	Feb 24, 2025
	>A> 11090323	Apr 03, 2034	U-3191		>A> PED	Feb 18, 2025
	>A> 11090323*PED	Oct 03, 2034			>A> PED	Aug 24, 2025
	>A> 7579449	Aug 01, 2028	DS			
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027	DS DP			
	>A> 7713938*PED	Oct 15, 2027				
	>A> 8551957	Oct 14, 2029	U-1651			
	>A> 8551957*PED	Apr 14, 2030				
	>A> 9949997	May 17, 2034	U-2292			
	>A> 9949997	May 17, 2034	U-3199			
	>A> 9949997	May 17, 2034	U-3325			
	>A> 9949997*PED	Nov 17, 2034				
	>A> 9949998	Jun 11, 2034	U-2290			
	>A> 9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	>A> 10258637	Apr 03, 2034	U-2290			
	>A> 10258637*PED	Oct 03, 2034				
	>A> 11090323	Apr 03, 2034	U-3191			
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7579449	Aug 01, 2028	DS			
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027	DS DP			
	>A> 7713938*PED	Oct 15, 2027				
	>A> 8551957	Oct 14, 2029	U-1651			
	>A> 8551957*PED	Apr 14, 2030				
	>A> 9949997	May 17, 2034	U-2292			
	>A> 9949997*PED	Nov 17, 2034				
	>A> 9949998	Jun 11, 2034	U-2290			
	>A> 9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	>A> 10258637	Apr 03, 2034	U-2290			
	>A> 10258637*PED	Oct 03, 2034				
	>A> 11033552	May 04, 2027	DP			
	>A> 11033552*PED	Nov 04, 2027				
	>A> 11090323	Apr 03, 2034	U-3191			
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7407955	May 02, 2025	DS DP			
	>A> 7407955*PED	Nov 02, 2025				
	>A> 7579449	Aug 01, 2028	DS			
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027	DS DP			
	>A> 7713938*PED	Oct 15, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	>A> 8551957	Oct 14, 2029	DP U-1651			
	>A> 8551957*PED	Apr 14, 2030				
	>A> 8673927	May 04, 2027	U-1652		Y	
	>A> 8673927*PED	Nov 04, 2027				
	>A> 8883805	Nov 26, 2025	DP			
	>A> 8883805*PED	May 26, 2026				
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	>A> 10258637	Apr 03, 2034	U-2290			
	>A> 10258637*PED	Oct 03, 2034				
	>A> 11033552	May 04, 2027	DP			
	>A> 11033552*PED	Nov 04, 2027				
	>A> 11090323	Apr 03, 2034	U-3191			
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7407955	May 02, 2025	DS DP			
	>A> 7407955*PED	Nov 02, 2025				
	>A> 7579449	Aug 01, 2028	DS			
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027	DS DP			
	>A> 7713938*PED	Oct 15, 2027				
	>A> 8551957	Oct 14, 2029	DP U-1651			
	>A> 8551957*PED	Apr 14, 2030				
	>A> 8673927	May 04, 2027	U-1652		Y	
	>A> 8673927*PED	Nov 04, 2027				
	>A> 8883805	Nov 26, 2025	DP			
	>A> 8883805*PED	May 26, 2026				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	>A> 10258637	Apr 03, 2034	U-2290			
	>A> 10258637*PED	Oct 03, 2034				
	>A> 10610489	Sep 30, 2030	DP			
	>A> 10610489*PED	Mar 30, 2031				
	>A> 11090323	Apr 03, 2034	U-3193			
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7579449	Aug 01, 2028	DS			
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027	DS DP			
	>A> 7713938*PED	Oct 15, 2027				
	>A> 9949997	May 17, 2034	U-3532			
	>A> 9949997	May 17, 2034	U-3533			
	>A> 9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	>A> 10258637	Apr 03, 2034	U-2290			
	>A> 10258637*PED	Oct 03, 2034				
	>A> 10610489	Sep 30, 2030	DP			
	>A> 10610489*PED	Mar 30, 2031				
	>A> 11090323	Apr 03, 2034	U-3193			
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7579449	Aug 01, 2028	DS			
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027	DS DP			
	>A> 7713938*PED	Oct 15, 2027				
	>A> 9949997	May 17, 2034	U-3532			
	>A> 9949997	May 17, 2034	U-3533			
	>A> 9949997*PED	Nov 17, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	>A> 10258637	Apr 03, 2034			U-2290	
	>A> 10258637*PED	Oct 03, 2034				
	>A> 10610489	Sep 30, 2030		DP		
	>A> 10610489*PED	Mar 30, 2031				
	>A> 11090323	Apr 03, 2034			U-3193	
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7579449	Aug 01, 2028		DS		
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027		DS DP		
	>A> 7713938*PED	Oct 15, 2027				
	>A> 9949997	May 17, 2034			U-3532	
	>A> 9949997	May 17, 2034			U-3533	
	>A> 9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	>A> 10258637	Apr 03, 2034			U-2290	
	>A> 10258637*PED	Oct 03, 2034				
	>A> 10610489	Sep 30, 2030		DP		
	>A> 10610489*PED	Mar 30, 2031				
	>A> 11090323	Apr 03, 2034			U-3193	
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7579449	Aug 01, 2028		DS		
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027		DS DP		
	>A> 7713938*PED	Oct 15, 2027				
	>A> 9949997	May 17, 2034			U-3532	
	>A> 9949997	May 17, 2034			U-3533	
	>A> 9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	>A> 10258637	Apr 03, 2034			U-2290	
	>A> 10258637*PED	Oct 03, 2034				
	>A> 10596120	Mar 07, 2032		DP	U-2775	
	>A> 10596120	Mar 07, 2032		DP	U-2792	
	>A> 10596120*PED	Sep 07, 2032				
	>A> 11090323	Apr 03, 2034			U-3193	
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7579449	Aug 01, 2028		DS		
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027		DS DP		
	>A> 7713938*PED	Oct 15, 2027				
	>A> 9949997	May 17, 2034			U-3532	
	>A> 9949997	May 17, 2034			U-3533	
	>A> 9949997*PED	Nov 17, 2034				
	>A> 9949998	Jun 11, 2034			U-2290	
	>A> 9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	>A> 10258637	Apr 03, 2034			U-2290	
	>A> 10258637*PED	Oct 03, 2034				
	>A> 10596120	Mar 07, 2032		DP	U-2775	
	>A> 10596120	Mar 07, 2032		DP	U-2792	
	>A> 10596120*PED	Sep 07, 2032				
	>A> 11090323	Apr 03, 2034			U-3193	
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7579449	Aug 01, 2028		DS		
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027		DS DP		
	>A> 7713938*PED	Oct 15, 2027				
	>A> 9949997	May 17, 2034			U-3532	
	>A> 9949997	May 17, 2034			U-3533	
	>A> 9949997*PED	Nov 17, 2034				
	>A> 9949998	Jun 11, 2034			U-2290	
	>A> 9949998*PED	Dec 11, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	>A> 10258637	Apr 03, 2034		U-2290		
	>A> 10258637*PED	Oct 03, 2034				
	>A> 10596120	Mar 07, 2032		DP U-2775		
	>A> 10596120	Mar 07, 2032		DP U-2792		
	>A> 10596120*PED	Sep 07, 2032				
	>A> 11090323	Apr 03, 2034		U-3193		
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7579449	Aug 01, 2028	DS			
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027	DS DP			
	>A> 7713938*PED	Oct 15, 2027				
	>A> 9949997	May 17, 2034		U-3532		
	>A> 9949997	May 17, 2034		U-3533		
	>A> 9949997*PED	Nov 17, 2034				
	>A> 9949998	Jun 11, 2034		U-2290		
	>A> 9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	>A> 10258637	Apr 03, 2034		U-2290		
	>A> 10258637*PED	Oct 03, 2034				
	>A> 10596120	Mar 07, 2032		DP U-2775		
	>A> 10596120	Mar 07, 2032		DP U-2792		
	>A> 10596120*PED	Sep 07, 2032				
	>A> 11090323	Apr 03, 2034		U-3193		
	>A> 11090323*PED	Oct 03, 2034				
	>A> 7579449	Aug 01, 2028	DS			
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027	DS DP			
	>A> 7713938*PED	Oct 15, 2027				
	>A> 9949997	May 17, 2034		U-3532		
	>A> 9949997	May 17, 2034		U-3533		
	>A> 9949997*PED	Nov 17, 2034				
	>A> 9949998	Jun 11, 2034		U-2290		
	>A> 9949998*PED	Dec 11, 2034				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	8501758	Aug 27, 2030	DS DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11571398	May 16, 2040		U-3183		
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 002	11464752	May 16, 2040	DP			
	11571398	May 16, 2040		U-3183		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 001	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 002	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 003	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 004	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 005	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039		U-3567		
	11207280	Mar 21, 2039	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	11578044	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	11578044	Oct 19, 2037	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	>A> 8895601	Apr 12, 2033	DS DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	>A> 8895601	Apr 12, 2033	DS DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	>A> 8895601	Apr 12, 2033	DS DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001				>A> NPP		May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002				>A> NPP		May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003				>A> NPP		May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021365 001				>A> NPP		May 12, 2026
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001				M-289		Jan 27, 2026
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001				ODE-393		Mar 25, 2029
				PED		Sep 25, 2029
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 001	>A> 11364260	Jan 08, 2027	U-3637			
	>A> 11433091	Jan 08, 2027	U-3435			
	>A> 11433091	Jan 08, 2027	U-3436			
	>A> 11433091	Jan 08, 2027	U-3437			
	>A> 11433091	Jan 08, 2027	U-3438			
	>A> 11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	>A> 7754702	Feb 15, 2028	U-1432			
	>A> 7754702	Feb 15, 2028	U-2555			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	>A> 7754702	Feb 15, 2028	U-2556			
	>A> 7754702	Feb 15, 2028	U-2557			
	>A> 7754702	Feb 15, 2028	U-3312			
	>A> 7754702	Feb 15, 2028	U-3313			
	>A> 7754702	Feb 15, 2028	U-3314			
	>A> 7754702	Feb 15, 2028	U-3636			
	>A> 8895612	Jan 08, 2027	U-1620			
	>A> 8895612	Jan 08, 2027	U-3050			
	>A> 8895612	Jan 08, 2027	U-3051			
	>A> 8895612	Jan 08, 2027	U-3115			
	>A> 8895612	Jan 08, 2027	U-3116			
	>A> 8895612	Jan 08, 2027	U-3315			
	>A> 8895612	Jan 08, 2027	U-3316			
	>A> 8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	>A> 11364260	Jan 08, 2027	U-3637			
	>A> 11433091	Jan 08, 2027	U-3435			
	>A> 11433091	Jan 08, 2027	U-3436			
	>A> 11433091	Jan 08, 2027	U-3437			
	>A> 11433091	Jan 08, 2027	U-3438			
	>A> 11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	>A> 7754702	Feb 15, 2028	U-2555			
	>A> 7754702	Feb 15, 2028	U-2556			
	>A> 7754702	Feb 15, 2028	U-2557			
	>A> 7754702	Feb 15, 2028	U-3312			
	>A> 7754702	Feb 15, 2028	U-3313			
	>A> 7754702	Feb 15, 2028	U-3314			
	>A> 7754702	Feb 15, 2028	U-3636			
	>A> 8895612	Jan 08, 2027	U-1620			
	>A> 8895612	Jan 08, 2027	U-3050			
	>A> 8895612	Jan 08, 2027	U-3051			
	>A> 8895612	Jan 08, 2027	U-3115			
	>A> 8895612	Jan 08, 2027	U-3116			
	>A> 8895612	Jan 08, 2027	U-3315			
	>A> 8895612	Jan 08, 2027	U-3316			
	>A> 8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	>A> 11364260	Jan 08, 2027	U-3637			
	>A> 11433091	Jan 08, 2027	U-3435			
	>A> 11433091	Jan 08, 2027	U-3436			
	>A> 11433091	Jan 08, 2027	U-3437			
	>A> 11433091	Jan 08, 2027	U-3438			
	>A> 11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	>A> 7754702	Feb 15, 2028	U-2555			
	>A> 7754702	Feb 15, 2028	U-2556			
	>A> 7754702	Feb 15, 2028	U-2557			
	>A> 7754702	Feb 15, 2028	U-3312			
	>A> 7754702	Feb 15, 2028	U-3313			
	>A> 7754702	Feb 15, 2028	U-3314			
	>A> 7754702	Feb 15, 2028	U-3636			
	>A> 8895612	Jan 08, 2027	U-1620			
	>A> 8895612	Jan 08, 2027	U-3050			
	>A> 8895612	Jan 08, 2027	U-3051			
	>A> 8895612	Jan 08, 2027	U-3115			
	>A> 8895612	Jan 08, 2027	U-3116			
	>A> 8895612	Jan 08, 2027	U-3315			
	>A> 8895612	Jan 08, 2027	U-3316			
	>A> 8895612	Jan 08, 2027	U-3635			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	>A> 11364260	Jan 08, 2027	U-3637			
	>A> 11433091	Jan 08, 2027	U-3435			
	>A> 11433091	Jan 08, 2027	U-3436			
	>A> 11433091	Jan 08, 2027	U-3437			
	>A> 11433091	Jan 08, 2027	U-3438			
	>A> 11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP	U-3312		
	11590097	Oct 20, 2023	DS DP	U-3313		
	>A> 7754702	Feb 15, 2028		U-3312		
	>A> 7754702	Feb 15, 2028		U-3313		
	>A> 7754702	Feb 15, 2028		U-3314		
	>A> 7754702	Feb 15, 2028		U-3636		
	>A> 8895612	Jan 08, 2027		U-3115		
	>A> 8895612	Jan 08, 2027		U-3116		
	>A> 8895612	Jan 08, 2027		U-3315		
	>A> 8895612	Jan 08, 2027		U-3316		
	>A> 8895612	Jan 08, 2027		U-3635		
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	11633489	Jun 22, 2036	U-3594			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	11633489	Jun 22, 2036	U-3594			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	11633489	Jun 22, 2036	U-3594			
<u>FEZOLINETANT - VEOZAH</u>						
N 216578 001	10836768	Mar 28, 2034	U-3621			
	8871761	Apr 04, 2031	DS			
	9422299	Mar 28, 2034	DS DP	U-3622		
	9987274	Mar 28, 2034		U-3622		
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	11413360	Nov 22, 2038	DS	U-3614		
	11413360	Nov 22, 2038	DS	U-3615		
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	>A> 11116721	Feb 26, 2029	DP U-1401		NPP	May 13, 2026
	>A> 11116721	Feb 26, 2029	DP U-1691			
	>A> 11116721	Feb 26, 2029	DP U-3623			
	>A> 11116721*PED	Aug 26, 2029				
	>A> 7439393	May 21, 2025	DS DP U-1401			
	>A> 7439393	May 21, 2025	DS DP U-1691			
	>A> 7439393	May 21, 2025	DS DP U-2099			
	>A> 7439393	May 21, 2025	DS DP U-2100			
	>A> 7439393	May 21, 2025	DS DP U-3623			
	>A> 7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	>A> 8511304	Jun 14, 2027	DP U-1424			
	>A> 8511304	Jun 14, 2027	DP U-1691			
	>A> 8511304	Jun 14, 2027	DP U-3623			
	>A> 8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	>A> 11116721	Feb 26, 2029	DP U-1691			
	>A> 11116721	Feb 26, 2029	DP U-3623			
	>A> 11116721*PED	Aug 26, 2029				
	>A> 7439393	May 21, 2025	DS DP U-1691			
	>A> 7439393	May 21, 2025	DS DP U-2099			
	>A> 7439393	May 21, 2025	DS DP U-2100			
	>A> 7439393	May 21, 2025	DS DP U-3623			
	>A> 7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	>A> 8511304	Jun 14, 2027	DP U-1691			
	>A> 8511304	Jun 14, 2027	DP U-3623			
	>A> 8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 003	>A> 11116721	Feb 26, 2029	DP U-3623		NS	May 13, 2026
	>A> 7439393	May 21, 2025	DS DP U-3623			
	>A> 8113199	Oct 23, 2027	DP			
	>A> 8161968	Feb 05, 2028	DP			
	>A> 8511304	Jun 14, 2027	DP U-3623			
	>A> 8534281	Mar 08, 2030	DP			
	>A> 8746242	Oct 11, 2030	DP			
	>A> 9333310	Oct 02, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 004	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 005	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 006	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 008	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11554229	Feb 23, 2036	U-2133			
	11602603	Oct 27, 2028	DP U-2133			
	8327844	Oct 24, 2023	U-2133			
	8522778	Apr 20, 2024	DP			
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001					M-286	Oct 27, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11529362	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11529362	Jun 02, 2037	DP			
<u>FUTIBATINIB - LYTGOBI</u>						
N 214801 001					ODE-410	Sep 30, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	11590246	Jan 17, 2040	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007	11590246	Jan 17, 2040	DP			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001					ODE-395	Jun 01, 2029
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	9133461	Nov 30, 2033	DS DP U-2672			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 003	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 004	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE KIT</u>						
N 212097 005	11590205	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	10456354	Oct 25, 2038	DP			
	11110054	Oct 25, 2038	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	>A> 11648256	Jun 06, 2036	DP U-2625			
	>A> 11679115	Jun 06, 2036	DP U-2625			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 006	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>IBREXAFUNGERP CITRATE - BREXAFAEMME</u>						
N 214900 001	11534433	Jun 10, 2039	U-3159		I-903	Nov 30, 2025
	11534433	Jun 10, 2039	U-3508			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	>A> 10478439	Jun 03, 2031	U-1650		ODE-109	Mar 04, 2023
	>A> 10478439	Jun 03, 2031	U-1684		ODE-117	May 06, 2023
	>A> 10478439	Jun 03, 2031	U-1946		ODE-152	Aug 02, 2024
	>A> 10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	>A> 10478439	Jun 03, 2031	U-2242		PED	Feb 02, 2025
	>A> 10478439	Jun 03, 2031	U-2665		PED	Feb 24, 2030
	>A> 10478439	Jun 03, 2031	U-3422			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-1947			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	>A> 8497277	Dec 28, 2026	U-1947			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277	Dec 28, 2026	U-3422			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-1947			
	>A> 8952015*PED	Jun 28, 2027				
	>A> 9540382	Aug 18, 2033	U-1456			
	>A> 9540382	Aug 18, 2033	U-1650			
	>A> 9540382	Aug 18, 2033	U-1684			
	>A> 9540382	Aug 18, 2033	U-1946			
	>A> 9540382	Aug 18, 2033	U-1947			
	>A> 9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	>A> 10478439	Jun 03, 2031	U-1650	ODE*	Mar 04, 2023	
	>A> 10478439	Jun 03, 2031	U-1684	ODE*	May 06, 2023	
	>A> 10478439	Jun 03, 2031	U-1946	ODE*	Aug 02, 2024	
	>A> 10478439	Jun 03, 2031	U-2241	ODE-405	Aug 24, 2029	
	>A> 10478439	Jun 03, 2031	U-2242	PED	Feb 24, 2030	
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439	Jun 03, 2031	U-3422			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277	Dec 28, 2026	U-3422			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015*PED	Jun 28, 2027				
	>A> 9540382	Aug 18, 2033	U-1456			
	>A> 9540382	Aug 18, 2033	U-1491			
	>A> 9540382	Aug 18, 2033	U-1650			
	>A> 9540382	Aug 18, 2033	U-1946			
	>A> 9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 10478439	Jun 03, 2031	U-1650	ODE*	Mar 04, 2023	
	>A> 10478439	Jun 03, 2031	U-1684	ODE*	May 06, 2023	
	>A> 10478439	Jun 03, 2031	U-1946	ODE*	Aug 02, 2024	
	>A> 10478439	Jun 03, 2031	U-2241	ODE-405	Aug 24, 2029	
	>A> 10478439	Jun 03, 2031	U-2242	PED	Feb 24, 2030	
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439	Jun 03, 2031	U-3422			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277	Dec 28, 2026	U-3422			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	>A> 10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	>A> 10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	>A> 10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	>A> 10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	>A> 10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439	Jun 03, 2031	U-3422			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277	Dec 28, 2026	U-3422			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	>A> 10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	>A> 10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	>A> 10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	>A> 10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	>A> 10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439	Jun 03, 2031	U-3422			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277	Dec 28, 2026	U-3422			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Aug 02, 2024
					ODE-405	Aug 24, 2029
					PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10106548	Jun 03, 2033	DS DP		ODE-405	Aug 24, 2029
	10106548*PED	Dec 03, 2033			PED	Feb 24, 2030
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10478439	Jun 03, 2031		U-3422		
	10478439*PED	Dec 03, 2031				
	10961251	Jun 03, 2033		DP		
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8497277	Dec 28, 2026		U-3422		
	8497277*PED	Jun 28, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026		DP		
	8754091*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034		U-3422		
	9795604*PED	Apr 24, 2035				
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580 001					>A> I-911	Jun 05, 2026
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002	>A> 6812238	Oct 31, 2025	DS			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	11564916	Aug 13, 2029		U-3530		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	11564916	Aug 13, 2029		U-3528		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	11564916	Aug 13, 2029		U-3528		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	11564916	Aug 13, 2029		U-3528		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	10272046	Feb 27, 2033	DP	U-3605		
	10646481	Aug 13, 2029	DP			
	11147770	Feb 27, 2033	DP	U-3604		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	11564916	Aug 13, 2029	U-3603			
	7495103	May 20, 2027	DS DP			
	8324242	Aug 05, 2027	U-3609			
	8354427	Jul 06, 2026	U-3608			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-3607			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3606			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	10272046	Feb 27, 2033	DP U-3605			
	10646481	Aug 13, 2029	DP			
	11147770	Feb 27, 2033	DP U-3604			
	11564916	Aug 13, 2029	U-3603			
	7495103	May 20, 2027	DS DP			
	8324242	Aug 05, 2027	U-3609			
	8354427	Jul 06, 2026	U-3608			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-3607			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3606			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	11639347	Apr 09, 2027	DS DP U-2569			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	11639347	Apr 09, 2027	DS DP U-2569			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	11191766	Apr 04, 2037	U-2471			
	11484535	Apr 04, 2037	U-2470			
<u>LASMIDITAN SUCCINATE - REVVOW</u>						
N 211280 001 >A> 7423050		Feb 17, 2028	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REVVOW</u>						
N 211280 002 >A> 7423050		Feb 17, 2028	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REVVOW</u>						
N 211280 003 >A> 7423050		Feb 17, 2028	DS DP U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	11618748	Jan 27, 2030		U-1524		
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					ODE*	Aug 28, 2026
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002					ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001					M-293	Apr 20, 2026
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002					M-293	Apr 20, 2026
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037		U-3507		
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP	U-3507		
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037		U-3507		
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP	U-3507		
<u>LENIOLISIB PHOSPHATE - JOENJA</u>						
N 217759 001	8653092	Feb 19, 2032	DS DP		NCE	Mar 24, 2028
					ODE-430	Mar 24, 2030
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	11090386	Feb 23, 2036		U-3519		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	11090386	Feb 23, 2036		U-3519		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED KIT</u>						
N 020263 009	8921326	Feb 05, 2031	DP		NS	Apr 14, 2026
	9617303	Mar 22, 2028		U-3611		
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001					ODE-385	Dec 30, 2028
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 001	11541012	Mar 25, 2039	DP			
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 002	11541012	Mar 25, 2039	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	11571328	Sep 07, 2040	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	>A> 10702576	Aug 11, 2031		U-1516		
	>A> 10702576	Aug 11, 2031		U-3644		
	>A> 7304036	Aug 30, 2026	DS DP	U-1516		
	>A> 7304036	Aug 30, 2026	DS DP	U-3644		
	>A> 8110553	Jan 28, 2024		U-1516		
	>A> 8110553	Jan 28, 2024		U-3644		
	>A> 8933030	Feb 17, 2031	DP	U-1516		
	>A> 8933030	Feb 17, 2031	DP	U-3644		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
LINACLOTIDE - LINZESS						
N 202811 003	>A> 9708371 >A> 9708371	Aug 16, 2033 Aug 16, 2033	DP U-1516 DP U-3644			
LINAGLIPTIN - TRADJENTA						
N 201280 001	>A> 10034877 >A> 10034877*PED >A> 11033552 >A> 11033552*PED >A> 7407955 >A> 7407955*PED >A> 8673927 >A> 8673927*PED >A> 8846695 >A> 8846695*PED >A> 8853156 >A> 8853156*PED >A> 8883805 >A> 8883805*PED >A> 9486526 >A> 9486526*PED	Aug 05, 2029 Feb 05, 2030 May 04, 2027 Nov 04, 2027 May 02, 2025 Nov 02, 2025 May 04, 2027 Nov 04, 2027 Jun 04, 2030 Dec 04, 2030 Mar 05, 2031 Sep 05, 2031 Nov 26, 2025 May 26, 2026 Aug 05, 2029 Feb 05, 2030	U-2347 DP DS DP U-1503 Y U-1503 Y			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	>A> 10022379 >A> 10022379*PED >A> 10973827 >A> 10973827*PED >A> 7407955 >A> 7407955*PED >A> 8673927 >A> 8673927*PED >A> 8846695 >A> 8846695*PED >A> 8883805 >A> 8883805*PED >A> 9155705 >A> 9155705*PED >A> 9415016 >A> 9415016*PED	Apr 02, 2029 Oct 02, 2029 Apr 02, 2029 Oct 02, 2029 May 02, 2025 Nov 02, 2025 May 04, 2027 Nov 04, 2027 Jun 04, 2030 Dec 04, 2030 Nov 26, 2025 May 26, 2026 May 21, 2030 Nov 21, 2030 Apr 02, 2029 Oct 02, 2029	U-2339 DP DS DP U-1503 Y U-1503 DP U-1503 Y			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	>A> 10022379 >A> 10022379*PED >A> 10973827 >A> 10973827*PED >A> 7407955 >A> 7407955*PED >A> 8673927 >A> 8673927*PED >A> 8846695 >A> 8846695*PED >A> 8883805 >A> 8883805*PED >A> 9155705 >A> 9155705*PED >A> 9415016 >A> 9415016*PED	Apr 02, 2029 Oct 02, 2029 Apr 02, 2029 Oct 02, 2029 May 02, 2025 Nov 02, 2025 May 04, 2027 Nov 04, 2027 Jun 04, 2030 Dec 04, 2030 Nov 26, 2025 May 26, 2026 May 21, 2030 Nov 21, 2030 Apr 02, 2029 Oct 02, 2029	U-2339 DP DS DP U-1503 Y U-1503 DP U-1503 Y			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 003	>A> 10022379 >A> 10022379*PED >A> 10973827 >A> 10973827*PED >A> 7407955 >A> 7407955*PED >A> 8673927 >A> 8673927*PED >A> 8846695	Apr 02, 2029 Oct 02, 2029 Apr 02, 2029 Oct 02, 2029 May 02, 2025 Nov 02, 2025 May 04, 2027 Nov 04, 2027 Jun 04, 2030	U-2339 DP DS DP U-1503 Y U-1503 Y			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	>A> 8846695*PED	Dec 04, 2030				
	>A> 8883805	Nov 26, 2025		DP		
	>A> 8883805*PED	May 26, 2026				
	>A> 9155705	May 21, 2030		DP		
	>A> 9155705*PED	Nov 21, 2030				
	>A> 9415016	Apr 02, 2029		DP		
	>A> 9415016*PED	Oct 02, 2029				
<u>LINAGLIPPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	>A> 10022379	Apr 02, 2029		U-2339		
	>A> 10022379*PED	Oct 02, 2029				
	>A> 7407955	May 02, 2025	DS DP			
	>A> 7407955*PED	Nov 02, 2025				
	>A> 8673927	May 04, 2027		U-1503	Y	
	>A> 8673927*PED	Nov 04, 2027				
	>A> 8883805	Nov 26, 2025	DP			
	>A> 8883805*PED	May 26, 2026				
	>A> 9155705	May 21, 2030	DP			
	>A> 9155705*PED	Nov 21, 2030				
	>A> 9173859	May 04, 2027	DP	U-1503	Y	
	>A> 9173859*PED	Nov 04, 2027				
	>A> 9415016	Apr 02, 2029	DP			
	>A> 9415016*PED	Oct 02, 2029				
	>A> 9555001	Mar 06, 2033	DP	U-1967		
	>A> 9555001	Mar 06, 2033	DP	U-1968		
	>A> 9555001*PED	Sep 06, 2033				
<u>LINAGLIPPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	>A> 10022379	Apr 02, 2029		U-2339		
	>A> 10022379*PED	Oct 02, 2029				
	>A> 7407955	May 02, 2025	DS DP			
	>A> 7407955*PED	Nov 02, 2025				
	>A> 8673927	May 04, 2027		U-1503	Y	
	>A> 8673927*PED	Nov 04, 2027				
	>A> 8883805	Nov 26, 2025	DP			
	>A> 8883805*PED	May 26, 2026				
	>A> 9155705	May 21, 2030	DP			
	>A> 9155705*PED	Nov 21, 2030				
	>A> 9173859	May 04, 2027	DP	U-1503	Y	
	>A> 9173859*PED	Nov 04, 2027				
	>A> 9415016	Apr 02, 2029	DP			
	>A> 9415016*PED	Oct 02, 2029				
	>A> 9555001	Mar 06, 2033	DP	U-1967		
	>A> 9555001	Mar 06, 2033	DP	U-1968		
	>A> 9555001*PED	Sep 06, 2033				
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	11534395	Jan 26, 2036		DP	U-2764	
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11642317	May 03, 2033		DP		
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11596599	May 03, 2033		U-2985		
	11642317	May 03, 2033	DP			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001					ODE-415	Oct 06, 2029
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB</u>						
N 213135 001	11638697	Aug 04, 2037	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001				NPP	Mar 13, 2026	
				ODE-429	Mar 13, 2030	
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001				ODE-388	Nov 23, 2028	
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001				ODE-398	Apr 28, 2029	
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002				ODE-398	Apr 28, 2029	
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003				ODE-398	Apr 28, 2029	
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004				ODE-398	Apr 28, 2029	
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001 >A> 6992207		Jun 25, 2024	DS DP U-3093			
<u>METHSUXIMIDE - MENTSUXIMIDE</u>						
A 217213 001				CGT	Oct 28, 2023	
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	11633389	Aug 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	11633389	Aug 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	11633389	Aug 14, 2033	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	11628150	Dec 22, 2029	DP U-2843			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11612593	May 30, 2038	DS			
	11612594	May 30, 2038	DS			
	11622962	Mar 17, 2039	DS			
	11633387	May 30, 2038	DS			
	11633388	Mar 25, 2039	U-2371			
	11642334	Feb 20, 2039	U-2371			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001 >A> 11666564		May 30, 2038		U-2371		
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001					ODE-392	Feb 17, 2029
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002					ODE-392	Feb 17, 2029
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003					ODE-392	Feb 17, 2029
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001 11590095		Mar 18, 2036		U-1384		
<u>NALMEFENE HYDROCHLORIDE - OPVEE</u>						
N 217470 001 >A> 11458091		Jul 10, 2038		DP U-3630		
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001 11590286		Dec 12, 2026		DP		
<u>NALOXONE HYDROCHLORIDE - REXTOVY</u>						
N 208969 001					NP	Mar 07, 2026
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001 11590286		Dec 12, 2026		DP		
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001 11617713	11628139	Aug 26, 2034 Aug 26, 2034		DP U-3110 DP U-3110		
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854 001 11571518	11571518 11571518	Jun 14, 2041 Jun 14, 2041 Jun 14, 2041		DP U-3515 DP U-3516 DP U-3517		
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457 001 11590286		Dec 12, 2026		DP		
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001 11618748		Jan 27, 2030		U-1524		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001 11559523		Nov 18, 2030		DP U-3522		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002 11547758		Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003 11547758		Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004 11547758		Apr 18, 2027		U-1029		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002 11517563		Apr 16, 2038		DP	Y	
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001 10154990		Jan 08, 2026		U-2620		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	10154990	Jan 08, 2026		U-2620		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	>A> 11673877 >A> 11673877	Mar 27, 2038 Mar 27, 2038	DP DP	U-3646 U-3647		
N 214876 001	11091459 >A> 11673877 >A> 11673877 8071579 8071623 8143241 8436185 8859562	Mar 27, 2038 Mar 27, 2038 Mar 27, 2038 Aug 12, 2027 Mar 27, 2031 Aug 12, 2027 Apr 24, 2029 Aug 04, 2031	DP DP DP U-2655 DS DP U-2655 DS U-2655			
N 214876 002	11091459 >A> 11673877 >A> 11673877 8071579 8071623 8143241 8436185 8859562	Mar 27, 2038 Mar 27, 2038 Mar 27, 2038 Aug 12, 2027 Mar 27, 2031 Aug 12, 2027 Apr 24, 2029 Aug 04, 2031	DP DP DP U-2655 DS DP U-2655 DS U-2655			
N 214876 003	11091459 >A> 11673877 >A> 11673877 8071579 8071623 8143241 8436185 8859562	Mar 27, 2038 Mar 27, 2038 Mar 27, 2038 Aug 12, 2027 Mar 27, 2031 Aug 12, 2027 Apr 24, 2029 Aug 04, 2031	DP DP DP U-2655 DS DP U-2655 DS U-2655			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 001	11091459 >A> 11673877 >A> 11673877 8071579 8071623 8143241 8436185 8859562	Mar 27, 2038 Mar 27, 2038 Mar 27, 2038 Aug 12, 2027 Mar 27, 2031 Aug 12, 2027 Apr 24, 2029 Aug 04, 2031	DP DP DP U-2655 DS DP U-2655 DS U-2655			
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 001	>A> 11351149 >A> 11541034	Aug 05, 2041 Oct 31, 2041	DS DP	U-3629 U-3629	>A> NCE	May 25, 2028
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 002					>A> NCE	May 25, 2028
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	11511252 11554241 >A> 11672938	Sep 21, 2029 Aug 18, 2025 Jul 22, 2040	DP U-3037 U-3037			
<u>NOREpinephrine Bitartrate - NOREpinephrine Bitartrate in 0.9% Sodium Chloride</u>						
N 214628 001	11602508	Jan 30, 2038	DP			
<u>NOREpinephrine Bitartrate - NOREpinephrine Bitartrate in 0.9% Sodium Chloride</u>						
N 214628 002	11602508	Jan 30, 2038	DP			
<u>NOREpinephrine Bitartrate - NOREpinephrine Bitartrate in 0.9% Sodium Chloride</u>						
N 214628 003	11602508	Jan 30, 2038	DP			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	>A> 10011633 >A> 10011633 >A> 10011633 >A> 10011633 >A> 10093697 >A> 10093697	Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031	U-3186 U-3187 U-3648 U-3649 U-3186 U-3187			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	>A> 10093697	Nov 08, 2031	U-3648			
	>A> 10093697	Nov 08, 2031	U-3649			
	>A> 10487111	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3187			
	>A> 10487111	Nov 08, 2031	U-3648			
	>A> 10487111	Nov 08, 2031	U-3649			
	>A> 10981952	Nov 08, 2031	U-3186			
	>A> 10981952	Nov 08, 2031	U-3187			
	>A> 10981952	Nov 08, 2031	U-3648			
	>A> 10981952	Nov 08, 2031	U-3649			
	>A> 11365182	Jun 20, 2039	U-3186			
	>A> 11365182	Jun 20, 2039	U-3187			
	>A> 11365182	Jun 20, 2039	U-3648			
	>A> 11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	>A> 9694018	Nov 08, 2031	U-3186			
	>A> 9694018	Nov 08, 2031	U-3187			
	>A> 9694018	Nov 08, 2031	U-3648			
	>A> 9694018	Nov 08, 2031	U-3649			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	>A> 10011633	Nov 08, 2031	U-3186			
	>A> 10011633	Nov 08, 2031	U-3187			
	>A> 10011633	Nov 08, 2031	U-3648			
	>A> 10011633	Nov 08, 2031	U-3649			
	>A> 10093697	Nov 08, 2031	U-3186			
	>A> 10093697	Nov 08, 2031	U-3187			
	>A> 10093697	Nov 08, 2031	U-3648			
	>A> 10093697	Nov 08, 2031	U-3649			
	>A> 10487111	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3187			
	>A> 10487111	Nov 08, 2031	U-3648			
	>A> 10487111	Nov 08, 2031	U-3649			
	>A> 10981952	Nov 08, 2031	U-3186			
	>A> 10981952	Nov 08, 2031	U-3187			
	>A> 10981952	Nov 08, 2031	U-3648			
	>A> 10981952	Nov 08, 2031	U-3649			
	>A> 11365182	Jun 20, 2039	U-3186			
	>A> 11365182	Jun 20, 2039	U-3187			
	>A> 11365182	Jun 20, 2039	U-3648			
	>A> 11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	>A> 9694018	Nov 08, 2031	U-3186			
	>A> 9694018	Nov 08, 2031	U-3187			
	>A> 9694018	Nov 08, 2031	U-3648			
	>A> 9694018	Nov 08, 2031	U-3649			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	>A> 10011633	Nov 08, 2031	U-3186			
	>A> 10011633	Nov 08, 2031	U-3187			
	>A> 10011633	Nov 08, 2031	U-3648			
	>A> 10011633	Nov 08, 2031	U-3649			
	>A> 10093697	Nov 08, 2031	U-3186			
	>A> 10093697	Nov 08, 2031	U-3187			
	>A> 10093697	Nov 08, 2031	U-3648			
	>A> 10093697	Nov 08, 2031	U-3649			
	>A> 10487111	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3187			
	>A> 10487111	Nov 08, 2031	U-3648			
	>A> 10487111	Nov 08, 2031	U-3649			
	>A> 10981952	Nov 08, 2031	U-3186			
	>A> 10981952	Nov 08, 2031	U-3187			
	>A> 10981952	Nov 08, 2031	U-3648			
	>A> 10981952	Nov 08, 2031	U-3649			
	>A> 11365182	Jun 20, 2039	U-3186			
	>A> 11365182	Jun 20, 2039	U-3187			
	>A> 11365182	Jun 20, 2039	U-3648			
	>A> 11365182	Jun 20, 2039	U-3649			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	11583539	Nov 12, 2041	U-3186			
	>A> 9694018	Nov 08, 2031	U-3186			
	>A> 9694018	Nov 08, 2031	U-3187			
	>A> 9694018	Nov 08, 2031	U-3648			
	>A> 9694018	Nov 08, 2031	U-3649			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	>A> 10011633	Nov 08, 2031	U-3186			
	>A> 10011633	Nov 08, 2031	U-3187			
	>A> 10011633	Nov 08, 2031	U-3648			
	>A> 10011633	Nov 08, 2031	U-3649			
	>A> 10093697	Nov 08, 2031	U-3186			
	>A> 10093697	Nov 08, 2031	U-3187			
	>A> 10093697	Nov 08, 2031	U-3648			
	>A> 10093697	Nov 08, 2031	U-3649			
	>A> 10487111	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3187			
	>A> 10487111	Nov 08, 2031	U-3648			
	>A> 10487111	Nov 08, 2031	U-3649			
	>A> 10981952	Nov 08, 2031	U-3186			
	>A> 10981952	Nov 08, 2031	U-3187			
	>A> 10981952	Nov 08, 2031	U-3648			
	>A> 10981952	Nov 08, 2031	U-3649			
	>A> 10981952	Nov 08, 2031	U-3649			
	>A> 10981952	Nov 08, 2031	U-3649			
	>A> 10981952	Nov 08, 2031	U-3649			
	>A> 10981952	Nov 08, 2031	U-3649			
	>A> 11365182	Jun 20, 2039	U-3186			
	>A> 11365182	Jun 20, 2039	U-3187			
	>A> 11365182	Jun 20, 2039	U-3648			
	>A> 11365182	Jun 20, 2039	U-3649			
	>A> 11583539	Nov 12, 2041	U-3186			
	>A> 9694018	Nov 08, 2031	U-3186			
	>A> 9694018	Nov 08, 2031	U-3187			
	>A> 9694018	Nov 08, 2031	U-3648			
	>A> 9694018	Nov 08, 2031	U-3649			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11633396	Oct 07, 2029	DP			
	>A> 8071579	Aug 12, 2027	U-2101			
	>A> 8071579	Aug 12, 2027	U-2103			
	>A> 8071579	Aug 12, 2027	U-2480			
	>A> 8071579	Aug 12, 2027	U-2482			
	>A> 8071579	Aug 12, 2027	U-2483			
	>A> 8071579	Aug 12, 2027	U-2716			
	>A> 8071579	Aug 12, 2027	U-2819			
	>A> 8071579	Aug 12, 2027	U-2820			
	>A> 8071579	Aug 12, 2027	U-2821			
	>A> 8071579	Aug 12, 2027	U-2822			
	>A> 8071579	Aug 12, 2027	U-2823			
	>A> 8071579	Aug 12, 2027	U-2824			
	>A> 8071579	Aug 12, 2027	U-2832			
	>A> 8071579	Aug 12, 2027	U-2833			
	>A> 8071579	Aug 12, 2027	U-3333			
	>A> 8071579	Aug 12, 2027	U-3631			
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2103			
	>A> 8143241	Aug 12, 2027	U-2480			
	>A> 8143241	Aug 12, 2027	U-2482			
	>A> 8143241	Aug 12, 2027	U-2483			
	>A> 8143241	Aug 12, 2027	U-2716			
	>A> 8143241	Aug 12, 2027	U-2819			
	>A> 8143241	Aug 12, 2027	U-2820			
	>A> 8143241	Aug 12, 2027	U-2821			
	>A> 8143241	Aug 12, 2027	U-2822			
	>A> 8143241	Aug 12, 2027	U-2823			
	>A> 8143241	Aug 12, 2027	U-2824			
	>A> 8143241	Aug 12, 2027	U-2832			
	>A> 8143241	Aug 12, 2027	U-2833			
	>A> 8143241	Aug 12, 2027	U-3333			
	>A> 8143241	Aug 12, 2027	U-3631			
	>A> 8859562	Aug 04, 2031	U-2101			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 8859562	Aug 04, 2031	U-2103			
	>A> 8859562	Aug 04, 2031	U-2480			
	>A> 8859562	Aug 04, 2031	U-2482			
	>A> 8859562	Aug 04, 2031	U-2483			
	>A> 8859562	Aug 04, 2031	U-2716			
	>A> 8859562	Aug 04, 2031	U-2819			
	>A> 8859562	Aug 04, 2031	U-2820			
	>A> 8859562	Aug 04, 2031	U-2821			
	>A> 8859562	Aug 04, 2031	U-2822			
	>A> 8859562	Aug 04, 2031	U-2823			
	>A> 8859562	Aug 04, 2031	U-2824			
	>A> 8859562	Aug 04, 2031	U-2832			
	>A> 8859562	Aug 04, 2031	U-2833			
	>A> 8859562	Aug 04, 2031	U-3333			
	>A> 8859562	Aug 04, 2031	U-3631			
	>A> 9169235	Mar 12, 2024	U-2832			
	>A> 9169235	Mar 12, 2024	U-2833			
	>A> 9169235	Mar 12, 2024	U-3631			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11633396	Oct 07, 2029	DP			
	>A> 8071579	Aug 12, 2027	U-2101			
	>A> 8071579	Aug 12, 2027	U-2103			
	>A> 8071579	Aug 12, 2027	U-2480			
	>A> 8071579	Aug 12, 2027	U-2482			
	>A> 8071579	Aug 12, 2027	U-2483			
	>A> 8071579	Aug 12, 2027	U-2716			
	>A> 8071579	Aug 12, 2027	U-2819			
	>A> 8071579	Aug 12, 2027	U-2820			
	>A> 8071579	Aug 12, 2027	U-2821			
	>A> 8071579	Aug 12, 2027	U-2822			
	>A> 8071579	Aug 12, 2027	U-2823			
	>A> 8071579	Aug 12, 2027	U-2824			
	>A> 8071579	Aug 12, 2027	U-2832			
	>A> 8071579	Aug 12, 2027	U-2833			
	>A> 8071579	Aug 12, 2027	U-3333			
	>A> 8071579	Aug 12, 2027	U-3631			
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2103			
	>A> 8143241	Aug 12, 2027	U-2480			
	>A> 8143241	Aug 12, 2027	U-2482			
	>A> 8143241	Aug 12, 2027	U-2483			
	>A> 8143241	Aug 12, 2027	U-2716			
	>A> 8143241	Aug 12, 2027	U-2819			
	>A> 8143241	Aug 12, 2027	U-2820			
	>A> 8143241	Aug 12, 2027	U-2821			
	>A> 8143241	Aug 12, 2027	U-2822			
	>A> 8143241	Aug 12, 2027	U-2823			
	>A> 8143241	Aug 12, 2027	U-2824			
	>A> 8143241	Aug 12, 2027	U-2832			
	>A> 8143241	Aug 12, 2027	U-2833			
	>A> 8143241	Aug 12, 2027	U-3333			
	>A> 8143241	Aug 12, 2027	U-3631			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2103			
	>A> 8859562	Aug 04, 2031	U-2480			
	>A> 8859562	Aug 04, 2031	U-2482			
	>A> 8859562	Aug 04, 2031	U-2483			
	>A> 8859562	Aug 04, 2031	U-2716			
	>A> 8859562	Aug 04, 2031	U-2819			
	>A> 8859562	Aug 04, 2031	U-2820			
	>A> 8859562	Aug 04, 2031	U-2821			
	>A> 8859562	Aug 04, 2031	U-2822			
	>A> 8859562	Aug 04, 2031	U-2823			
	>A> 8859562	Aug 04, 2031	U-2824			
	>A> 8859562	Aug 04, 2031	U-2832			
	>A> 8859562	Aug 04, 2031	U-2833			
	>A> 8859562	Aug 04, 2031	U-3333			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 8859562	Aug 04, 2031	U-3631			
	>A> 9169235	Mar 12, 2024	U-2832			
	>A> 9169235	Mar 12, 2024	U-2833			
	>A> 9169235	Mar 12, 2024	U-3631			
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001					NCE ODE-413	Dec 01, 2027 Dec 01, 2029
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2024	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2024	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11091430	Apr 20, 2029	U-3552			
	8124799	Dec 03, 2029	DS		NCE ODE-427	Feb 28, 2028 Feb 28, 2030
	8440854	Apr 20, 2029	DP			
	8993640	Apr 24, 2033	DS DP			
	9670147	Apr 20, 2029	DS			
	9701709	Apr 24, 2033	DS DP			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEP</u>						
N 213593 001	11633478	Jul 16, 2039	DP			
<u>OMIDENE PAG ISOPROPYL - OMLONTI</u>						
N 215092 001	>A> 11666563	Jul 16, 2039	U-3454			
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001					ODE-397	Feb 28, 2029
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001					I-905 ODE-390	Dec 16, 2025 Nov 29, 2028
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	>A> 11666697	Nov 24, 2041	U-3626			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	>A> 11666697	Nov 24, 2041	U-3626			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	>A> 11661441	Jan 13, 2033	DS	U-3124	M-288	Feb 08, 2026
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		NP	Feb 22, 2026
	10875893	Nov 15, 2033	DS	U-3540		
	11292815	Nov 15, 2033	DS DP	U-3540		
>A>	11661441	Jan 13, 2033	DS	U-3540		
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	8168584	Apr 07, 2027	U-3540			
	8168584	Apr 07, 2027	U-3542			
	9056076	Oct 25, 2026	U-3540			
	9169307	Nov 18, 2027	DS	U-3541		
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 001	11147817	Mar 26, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 002	11147817	Mar 26, 2035	DP			
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 003	11147817	Mar 26, 2035	DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERFLUOROHEXYLOCTANE - MIEBO</u>						
N 216675 001	>A> 10058615	Sep 12, 2033	U-1900			
	>A> 10369117	Sep 12, 2033	U-1900			
	>A> 10449164	Sep 12, 2033	U-1900			
	>A> 10507132	Jun 21, 2037	U-1900			
	>A> 10576154	Sep 12, 2033	U-1900			
	>A> 11357738	Sep 29, 2036	DP			
<u>PHENOBARBITAL SODIUM - SEZABY</u>						
N 215910 001					ODE-414	Nov 17, 2029
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	7229630	Jul 31, 2023	DP			
	7575757	Jul 31, 2023	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
A 216496 001					CGT	Jul 17, 2023
<u>PHENYLEPHRINE HYDROCHLORIDE - IMMPHENТИV</u>						
N 203826 004	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV</u>						
N 203826 005	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001					>A> NP	May 05, 2026
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	10610518	Apr 24, 2039	U-3252		D-187	Mar 28, 2026
	10610518	Apr 24, 2039	U-3561			
	10610518	Apr 24, 2039	U-3562			
	11285134	Apr 24, 2039	U-3252			
	11285134	Apr 24, 2039	U-3561			
	11285134	Apr 24, 2039	U-3562			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10918622	Dec 16, 2036	U-3518			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10918622	Dec 16, 2036	U-3518			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POSACONAZOLE - POSACONAZOLE</u>						
A 208768 001				>A>	PC	Dec 26, 2023
<u>PREDNISOLONE - PREDNISOLONE</u>						
A 215673 001					CGT	Nov 18, 2023
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	8771733	Jun 02, 2030	DS DP U-257			
	8852632	Jan 28, 2028	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	8771733	Jun 02, 2030	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	8771733	Jun 02, 2030	DS DP U-257			
<u>REJUGOLIX - ORGOVYX</u>						
N 214621 001	11583526	Sep 29, 2037		U-3020		
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	>A> 11691948	Jul 14, 2030		DP		
<u>REZAFUNGIN ACETATE - REZZAYO</u>						
N 217417 001	10702573	Mar 14, 2033	DS DP U-3566		NCE	Mar 22, 2028
	11197909	Jul 14, 2038	DS DP U-3566		ODE-426	Mar 22, 2030
>A>	11654196	Mar 02, 2032	DS DP U-3566		GAIN	Mar 22, 2033
	8722619	Mar 02, 2032	DS DP U-3566		GAIN	Mar 22, 2035
	9526835	Mar 14, 2033	DS DP U-3566			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	11564912	Feb 26, 2029		U-3511		
	11564912	Feb 26, 2029		U-3512		
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11529336	Aug 12, 2040		U-3382		
	11534432	Aug 12, 2040		U-3442		
	11576903	Dec 30, 2040		DP		
	11576904	Aug 12, 2040		U-3537		
	11612591	Dec 30, 2040		DP		
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11534444	Oct 04, 2038		U-1943	ODE-400	May 27, 2029
<u>RISPERIDONE - RYKINDO</u>						
N 212849 001	10098882	Apr 10, 2032		DP U-3513		
	10406161	Apr 10, 2032		DP U-3513		
	11110094	Apr 10, 2032		DP		
	9446135	Apr 10, 2032		DP U-3513		
	9532991	Apr 10, 2032		DP U-3513		
<u>RISPERIDONE - RYKINDO</u>						
N 212849 002	10098882	Apr 10, 2032		DP U-3513		
	10406161	Apr 10, 2032		DP U-3513		
	11110094	Apr 10, 2032		DP		
	9446135	Apr 10, 2032		DP U-3513		
	9532991	Apr 10, 2032		DP U-3513		
<u>RISPERIDONE - RYKINDO</u>						
N 212849 003	10098882	Apr 10, 2032		DP U-3513		
	10406161	Apr 10, 2032		DP U-3513		
	11110094	Apr 10, 2032		DP		
	9446135	Apr 10, 2032		DP U-3513		
	9532991	Apr 10, 2032		DP U-3513		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RYKINDO						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - UZEDY						
N 213586 001	10736965	Jan 12, 2025	DP		>A> NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 002	10736965	Jan 12, 2025	DP		>A> NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 003	10736965	Jan 12, 2025	DP		>A> NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 004	10736965	Jan 12, 2025	DP		>A> NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 005	10736965	Jan 12, 2025	DP		>A> NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 006	10736965	Jan 12, 2025	DP		>A> NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - UZEDY						
N 213586 006	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 007	10736965	Jan 12, 2025	DP	>A>	NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001				M-285		Dec 19, 2025
				PED		Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002				M-285		Dec 19, 2025
				PED		Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003				M-285		Dec 19, 2025
				PED		Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004				M-285		Dec 19, 2025
				PED		Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 005				M-285		Dec 19, 2025
				PED		Jun 19, 2026
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	11510923	Sep 04, 2040	U-3505			
	11571425	May 20, 2031	DP			
	11590136	May 20, 2031	U-3229			
	11590136	May 20, 2031	U-3404			
	11590137	Sep 04, 2040	U-3505			
	11590138	Jun 10, 2040	U-3551			
	11602536	May 05, 2041	U-3550			
SECNIDAZOLE - SOLOSEC						
N 209363 001	11602522	Sep 04, 2035	DP U-3169			
	11602522	Sep 04, 2035	DP U-3302			
>A>	11684607	Sep 16, 2035	DP U-2583			
>A>	11684607	Sep 16, 2035	DP U-3169			
>A>	11684607	Sep 16, 2035	DP U-3270			
>A>	11684607	Sep 16, 2035	DP U-3302			
SELINEXOR - XPOVIO						
N 212306 001 >A>	8999996	Jul 03, 2033	DS DP			
SELINEXOR - XPOVIO						
N 212306 002 >A>	8999996	Jul 03, 2033	DS DP			
SELINEXOR - XPOVIO						
N 212306 003 >A>	8999996	Jul 03, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u> N 212306 004 >A> 8999996		Jul 03, 2033	DS DP			
<u>SEPERCATINIB - RETEVMO</u> N 213246 001					ODE-409 ODE-412	Sep 21, 2029 Sep 21, 2029
<u>SEPERCATINIB - RETEVMO</u> N 213246 002					ODE-409 ODE-412	Sep 21, 2029 Sep 21, 2029
<u>SELUMETINIB SULFATE - KOSELUGO</u> N 213756 001 7425637		Mar 13, 2024	DS			
<u>SELUMETINIB SULFATE - KOSELUGO</u> N 213756 002 7425637		Mar 13, 2024	DS			
<u>SEMAGLUTIDE - WEGOVY</u> N 215256 001					NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u> N 215256 002					NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u> N 215256 003					NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u> N 215256 004					NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u> N 215256 005					NPP	Dec 23, 2025
<u>SETMELANOTIDE ACETATE - IMCIVREE</u> N 213793 001					ODE-402	Jun 16, 2029
<u>SILDENAFIL CITRATE - REVATIO</u> N 021845 001					M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - REVATIO</u> N 022473 001					M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - REVATIO</u> N 203109 001					M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - LIOREV</u> N 214952 001 11337979 11464778		Dec 24, 2038 Dec 24, 2038	DP U-3582 DP U-3582			
<u>SIROLIMUS - FYARRO</u> N 213312 001					ODE-386	Nov 22, 2028
<u>SIROLIMUS - HYFTOR</u> N 213478 001					ODE-391	Mar 22, 2029
<u>SODIUM OXYBATE - LUMRYZ</u> N 214755 001 10272062 10736866 10925844 10952986 10973795 11000498 11052061 11065224		Jul 21, 2037 Jul 21, 2037 Feb 28, 2040 Jul 21, 2037 Jul 21, 2037 Jul 21, 2037 Jul 21, 2037 Jul 21, 2037	DP DP DP U-3601 DP DP U-3580 DP DP		NP ODE-431	May 01, 2026 May 01, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
SODIUM OXYBATE - LUMRYZ						
N 214755 001	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
SODIUM OXYBATE - LUMRYZ						
N 214755 002	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
SODIUM OXYBATE - LUMRYZ						
N 214755 003	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
SODIUM OXYBATE - LUMRYZ						
N 214755 004	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
>A>	11602513	Jul 21, 2037	U-3576			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 001	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 002	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 003	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 005	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE; TAURURSODIOL - RELYVRIO</u>						
N 216660 001	11583542	Jul 27, 2040	DP		ODE-411	Sep 29, 2029
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	11617793	Jul 01, 2039	DP		ODE-384	Sep 20, 2029
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP	U-3520		
	11648232	Jun 01, 2038		U-3602		
>A>	8440715	Jun 11, 2031		U-2548		
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP	U-3520		
	11648232	Jun 01, 2038		U-3602		
>A>	8440715	Jun 11, 2031		U-2548		
<u>SOTAGLIFLOZIN - INPEFA</u>						
N 216203 001	>A> 7781577	May 04, 2028	DS DP	U-3628		
	>A> 8217156	Oct 07, 2030	DS DP			
	>A> 8476413	May 29, 2028	DS DP	U-3628		
<u>SOTAGLIFLOZIN - INPEFA</u>						
N 216203 002	>A> 7781577	May 04, 2028	DS DP	U-3628		
	>A> 8217156	Oct 07, 2030	DS DP			
	>A> 8476413	May 29, 2028	DS DP	U-3628		
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 18, 2038	U-2769			
	10512620	Aug 18, 2038	U-3547			
	10799138	Apr 05, 2039	U-3125			
	10799138	Apr 05, 2039	U-3549			
	11583216	Aug 21, 2039	U-3549			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	11426404	Sep 15, 2040	U-3306			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP	U-3306	ODE-352	May 28, 2028
	11426404	Sep 15, 2040		U-3306		
<u>SPARENTEAN - FILSPARTI</u>						
N 216403 001	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
					ODE-389	Feb 17, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SPARSENTAN - FILSPARI</u>						
N 216403 002	9993461	Mar 29, 2030	U-3269		NCE ODE-389	Feb 17, 2028 Feb 17, 2030
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 001					ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 002					ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 001					ODE-403	Jul 14, 2029
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					M-291	Jan 22, 2024
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					M-291	Jan 22, 2024
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	11571531	Feb 23, 2026	U-1809			
<u>TADALAFIL - TADLIQ</u>						
N 214522 001 >A>	11666576	Dec 24, 2038	DP U-3397			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	11590088	Nov 13, 2039	U-2625			
	11597692	Nov 13, 2038	DS DP			
	11612573	May 19, 2036	U-2625			
	11617724	May 19, 2036	DP			
	11622945	May 19, 2036	DP			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033	U-2149			
	11633377	Jan 25, 2033	U-3003			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033	U-3003			
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001 >A>	11679116	Jun 06, 2036	DP			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	8410088	Jan 23, 2034	DS DP			
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601 002					PC	Sep 08, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209613 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209613 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209638 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209638 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209663 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209663 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209668 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209668 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209690 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209690 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209700 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209700 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209710 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209710 002					PC	Sep 08, 2023
<u>TERLIPRESSIN ACETATE - TERLIVAZ</u> N 022231 001					ODE-406	Sep 14, 2029
<u>TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE</u> N 216318 001	11642355	Mar 25, 2039		DP		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u> N 206089 001	11564933	Apr 12, 2039		U-1103		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u> N 206089 002	11564933	Apr 12, 2039		U-1103		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u> N 206089 003	11564933	Apr 12, 2039		U-1103		
<u>TESTOSTERONE UNDECANOATE - TLANDO</u> N 208088 001	11559530	Nov 28, 2037		U-1500		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 001	11590146 11617758	Dec 31, 2030 Mar 15, 2033	DP DP U-2506			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 002	11590146 11617758	Dec 31, 2030 Mar 15, 2033	DP DP U-2506			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 003	11590146 11617758	Dec 31, 2030 Mar 15, 2033	DP DP U-2506			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2024	DS DP U-3100			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2024	DS DP U-3100			
<u>TOFERSEN - QALSODY</u>						
N 215887 001	10385341 10669546 10968453	Apr 01, 2035 Apr 01, 2035 Apr 01, 2035	DS DP U-3575 U-3575		NCE ODE-432	Apr 25, 2028 Apr 25, 2030
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11633374	Aug 21, 2040	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	10869869 10869869*PED 7378423 7378423*PED 8580304 8580304*PED 8703781 8703781 8703781 8703781 8703781 8703781*PED 8835443 8835443 8835443 8835443 8835443 8835443 8835443*PED 8952018 8952018*PED 9155706 9155706*PED 9271941 9271941*PED 9399021 9399021*PED	Aug 30, 2033 Mar 02, 2034 May 29, 2027 Nov 29, 2027 Jan 28, 2032 Jul 28, 2032 Oct 15, 2030 Oct 15, 2030 Oct 15, 2030 Oct 15, 2030 Oct 15, 2030 Apr 15, 2031 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Dec 10, 2025 Oct 15, 2030 Apr 15, 2031 Jan 28, 2032 Jul 28, 2032 Jan 28, 2032 Jul 28, 2032 Jan 28, 2032 Jul 28, 2032	U-3184 DS DP DP DS DP U-1712 DS DP U-2020 DS DP U-2037 DS DP U-2302 DS DP U-2305 U-1581 U-1582 U-2020 U-2037 U-2302 U-2305 U-2020 DP		I-895 I-908 ODE-148 ODE-182 ODE-183 ODE-428 PED PED PED PED PED I-895 I-908 ODE-148 ODE-182 ODE-183 ODE-428 PED PED PED PED	Jun 22, 2025 Mar 16, 2026 Jun 22, 2024 Apr 30, 2025 May 04, 2025 Mar 16, 2030 Dec 22, 2024 Oct 30, 2025 Nov 04, 2025 Dec 22, 2025 Jun 22, 2025 Mar 16, 2026 Jun 22, 2024 Apr 30, 2025 May 04, 2025 Mar 16, 2030 Dec 22, 2024 Oct 30, 2025 Nov 04, 2025 Dec 22, 2025
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869 10869869*PED 7378423 7378423*PED 8580304 8580304*PED 8703781 8703781 8703781 8703781	Aug 30, 2033 Mar 02, 2034 May 29, 2027 Nov 29, 2027 Jan 28, 2032 Jul 28, 2032 Oct 15, 2030 Oct 15, 2030 Oct 15, 2030 Oct 15, 2030	U-3184 DS DP DP DS DP U-1712 DS DP U-2020 DS DP U-2037 DS DP U-2302		I-895 I-908 ODE-148 ODE-182 ODE-183 ODE-428 PED PED PED PED	Jun 22, 2025 Mar 16, 2026 Jun 22, 2024 Apr 30, 2025 May 04, 2025 Mar 16, 2030 Dec 22, 2024 Oct 30, 2025 Nov 04, 2025 Dec 22, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026
	8703781	Oct 15, 2030	DS DP U-3564		ODE-428	Mar 16, 2030
	8835443	Jun 10, 2025	U-3564			
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001					ODE-401	Apr 28, 2029
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	7807708	Jul 19, 2031	DS DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11529352	Jul 23, 2039	U-3504			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	9212204	Jan 27, 2032	U-3556		ODE-425	Mar 10, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3510		I-906 ODE-422	Jan 19, 2026 Jan 19, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3510		I-906 ODE-422	Jan 19, 2026 Jan 19, 2030
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11524964	Oct 17, 2036	U-3371			
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
>A>	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
>A>	11661425	Oct 17, 2036	DS DP			
>A>	8962629	Jan 15, 2031	DS	U-3255		
>A>	8962629	Jan 15, 2031	DS	U-3275		
>A>	8962629	Jan 15, 2031	DS	U-3341		
>A>	8962629	Jan 15, 2031	DS	U-3371		
>A>	8962629	Jan 15, 2031	DS	U-3624		
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	11535626	Oct 17, 2036	U-3298			
>A>	11661425	Oct 17, 2036	DS DP			
>A>	8962629	Jan 15, 2031	DS	U-3341		
>A>	8962629	Jan 15, 2031	DS	U-3624		
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	>A> 11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
>A>	11661425	Oct 17, 2036	DS DP			
>A>	8962629	Jan 15, 2031	DS	U-3341		
>A>	8962629	Jan 15, 2031	DS	U-3624		
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 215338 001					>A> CGT	Dec 20, 2023
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	11638692	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	11638692	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	11628200	Nov 06, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	11628200	Nov 06, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 006	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	11590128	Sep 06, 2033	U-3548			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	11590128	Sep 06, 2033	U-3548			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	11590128	Sep 06, 2033	U-3548			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	11622991	Dec 07, 2037	U-3056			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001				ODE-387	Nov 19, 2028	
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002				ODE-387	Nov 19, 2028	
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003				ODE-387	Nov 19, 2028	
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001				ODE-394	Dec 17, 2028	
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002				ODE-394	Dec 17, 2028	
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001				ODE-394	Dec 17, 2028	
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001				ODE-212	Jun 13, 2029	
<u>XENON XE-129 HYPERPOLARIZED - XENOVIEW</u>						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		ODE-274	Jan 19, 2030
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
<u>ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET</u>						
N 216386 001	7220862	Jan 21, 2024	DS DP		NCE	Mar 09, 2028
	7314883	Dec 05, 2023	U-3555			
	8481546	Oct 07, 2031	DS DP U-3555			
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216145 001					CGT	Aug 14, 2023

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 43rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm